lamotrigine has been researched along with Affective Psychosis, Bipolar in 484 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Topiramate, a structurally novel anticonvulsant, is being evaluated for other neurological conditions such as migraine, neuropathic pain, and essential tremor, and also for psychiatric conditions such as bipolar disorder, bulimia, post-traumatic stress disorder, and schizoaffective disorder, in addition to obesity." | 10.19 | The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder. ( Chengappa, KN; Gershon, S; Levine, J, 2001) |
| "Although not licensed for acute bipolar depression, lamotrigine has evidence for efficacy in trials and its use is recommended in guidelines." | 9.27 | Comparative economic evaluation of quetiapine plus lamotrigine combination vs quetiapine monotherapy (and folic acid vs placebo) in patients with bipolar depression (CEQUEL). ( Gardiner, A; Geddes, JR; Goodwin, GM; Mayer, S; Rendell, J; Simon, J, 2018) |
| "In the present study, an effort was made to investigate the effect of lamotrigine on cognitive function and serum inflammatory factors in patients with depression of recurrent bipolar disorder and to explore its possible mechanism." | 9.27 | Effect of lamotrigine on cognitive function and serum inflammatory factors in patients with depression of recurrent bipolar disorder. ( Li, L; Shi, S; Song, L; Wang, X, 2018) |
| "We conducted a double-blind crossover study of a low dose (15 mg, 'placebo') and an active dose (195 mg) of methylene blue in patients with bipolar disorder treated with lamotrigine." | 9.24 | Methylene blue treatment for residual symptoms of bipolar disorder: randomised crossover study. ( Alda, M; Blagdon, R; Dursun, S; Garnham, J; Hajek, T; MacLellan, S; MacQueen, G; McKinnon, M; Nair, C; O'Donovan, C, 2017) |
| " Lamotrigine, an anticonvulsant which decreases presynaptic glutamate release, has been shown to be effective in the depressive phase of bipolar disorder (BD-D); however, only 40-50% of patients have a full response." | 9.16 | Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trial. ( Anand, A; Barkay, G; Ghosh, S; Gunn, AD; Karne, HS; Mathew, SJ; Nurnberger, JI, 2012) |
| "To pilot the efficacy and safety data of lamotrigine adjunctive therapy to lithium and divalproex in patients with rapid-cycling bipolar disorder (RCBD) and a recent substance use disorder (SUD)." | 9.14 | Lamotrigine adjunctive therapy to lithium and divalproex in depressed patients with rapid cycling bipolar disorder and a recent substance use disorder: a 12-week, double-blind, placebo-controlled pilot study. ( Calabrese, JR; Chan, PK; Conroy, C; Fang, Y; Findling, RL; Ganocy, SJ; Gao, K; Kemp, DE; Serrano, MB; Wang, Z, 2010) |
| "The aim of the present randomized, single-blind, pilot study was to assess the efficacy of the addition of a second mood stabilizer, either olanzapine or lamotrigine, to lithium in patients with remitted bipolar disorder and comorbid anxiety disorder." | 9.13 | Olanzapine or lamotrigine addition to lithium in remitted bipolar disorder patients with anxiety disorder comorbidity: a randomized, single-blind, pilot study. ( Albert, U; Bogetto, F; Maina, G; Rosso, G, 2008) |
| "We used functional magnetic resonance imaging to examine changes in brain activation during a sad facial affect recognition task in 12 stable patients with bipolar disorder when medication-free compared with healthy controls and after 12 weeks of lamotrigine monotherapy." | 9.13 | Pilot investigation of the changes in cortical activation during facial affect recognition with lamotrigine monotherapy in bipolar disorder. ( Cobb, A; Frangou, S; Haldane, M; Jogia, J; Kumari, V, 2008) |
| "To assess lamotrigine effectiveness in bipolar disorder (BD) patients in a clinical setting." | 9.13 | Effectiveness of lamotrigine in bipolar disorder in a clinical setting. ( Bonner, JC; Brooks, JO; Champion, LM; Culver, JL; Hoblyn, JC; Ketter, TA; Marsh, WK; Nam, JY, 2008) |
| "To assess the efficacy and tolerability of lamotrigine in the maintenance treatment of bipolar disorder." | 9.12 | Lamotrigine in the maintenance treatment of bipolar disorder. ( Fujiwara, T; Hashimoto, Y; Kotake, K; Sakamoto, S; Watanabe, N, 2021) |
| "The effect of lamotrigine maintenance therapy on body weight was assessed retrospectively in analyses of data from two double-blind, placebo- and lithium-controlled, 18-month studies in patients with bipolar I disorder (n = 227 for lamotrigine, 190 for placebo, 166 for lithium)." | 9.12 | Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder. ( Bentley, B; Bowden, C; Calabrese, JR; Ketter, T; Sachs, G; Thompson, T; White, R, 2006) |
| "The effect of lamotrigine on the steady-state plasma concentrations of the atypical antipsychotics clozapine, olanzapine, and risperidone was investigated in patients with schizophrenia or bipolar disorder stabilized on chronic treatment with clozapine (200-500 mg/day; n = 11), risperidone (3-6 mg/day; n = 10) or olanzapine (10-20 mg/day; n = 14))." | 9.12 | Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. ( D'Amico, G; D'Arrigo, C; Micò, U; Migliardi, G; Muscatello, MR; Perucca, E; Santoro, V; Spina, E, 2006) |
| "To describe the frequency and correlates of lamotrigine therapy among the first 500 patients enrolled into the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) study." | 9.11 | Lamotrigine treatment of bipolar disorder: data from the first 500 patients in STEP-BD. ( Bowden, CL; Calabrese, JR; Goldberg, JF; Ketter, TA; Marangell, LB; Martinez, JM; Miklowitz, DJ; Miyahara, S; Sachs, GS; Thase, ME, 2004) |
| "These findings suggest that lithium- and lamotrigine-responsive patients differ with respect to course of illness, comorbidity and family history and may represent distinct subtypes of bipolar disorder." | 9.10 | Phenotypic spectra of bipolar disorder in responders to lithium versus lamotrigine. ( Alda, M; Duffy, A; Garnham, J; MacDougall, M; Munro, A; Passmore, MJ; Slaney, C; Teehan, A, 2003) |
| "This preliminary report supports clinical improvement for both mood cycling and depression in patients with bipolar disorder treated with lamotrigine." | 9.09 | Lamotrigine for the treatment of bipolar disorder: a clinical case series. ( Altshuler, L; Brown, ES; Denicoff, KD; Frye, M; Keck, PE; Kupka, R; Leverich, GS; McElroy, SL; Nolen, W; Post, RM; Suppes, T, 1999) |
| "Patients with diagnoses of refractory bipolar disorder who were currently experiencing manic, mixed, depressive, or hypomanic episodes were treated with lamotrigine as add-on therapy (60 patients) or monotherapy (15 patients)." | 9.09 | The efficacy of lamotrigine in rapid cycling and non-rapid cycling patients with bipolar disorder. ( Anderson, J; Ascher, J; Bolden-Watson, C; Bowden, CL; Calabrese, JR; Cookson, J; Keck, PE; McElroy, SL; Monaghan, E; Rhodes, LJ; Zhou, J, 1999) |
| "These open-label data provide preliminary evidence that lamotrigine may be an effective treatment option for patients with refractory bipolar disorder; however, potential benefits must be weighed against potential side effects, including rash." | 9.09 | Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder. ( Andersen, J; Ascher, JA; Bolden-Watson, C; Bowden, CL; Calabrese, JR; Cookson, J; Keck, PE; McElroy, SL; Rhodes, L; Zhou, J, 1999) |
| "324 patients with rapid-cycling bipolar disorder (DSM-IV criteria) received open-label lamotrigine, and 182 patients were randomly assigned to the double-blind maintenance phase." | 9.09 | A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. ( Ascher, JA; Bowden, CL; Calabrese, JR; Earl, NL; Greene, PL; Kusumakar, V; McElroy, SL; Monaghan, ET; Sachs, GS; Suppes, T; Swann, AC, 2000) |
| "Whether patients with adult bipolar disorder (BD) who have been clinically stabilized with lithium or lamotrigine should continue this medication is not established fully." | 9.01 | Efficacy and safety of lithium and lamotrigine for the maintenance treatment of clinically stable patients with bipolar disorder: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials with an enrichment design. ( Esumi, S; Hashimoto, R; Hashimoto, Y; Hatano, M; Iwata, N; Kato, M; Kishi, T; Matsuda, Y; Matsui, Y; Mishima, K; Miyake, N; Nomura, I; Okuya, M; Oya, K; Sakuma, K; Watanabe, N, 2019) |
| "This paper reviewed the relevant literature on the effects of lamotrigine on pregnancy outcomes to provide useful information regarding lamotrigine use in pregnant women with bipolar disorder." | 8.98 | The risks associated with the use of lamotrigine during pregnancy. ( Gao, Z; Kong, L; Wang, B; Wang, C; Zhou, T, 2018) |
| "83 weeks) in patients with unipolar depression (studies=4, n=187; monotherapy vs lithium=1, augmentation of antidepressants vs placebo=3) or bipolar depression (studies=14, n=1965; monotherapy vs placebo=5, monotherapy vs lithium or olanzapine+fluoxetine=2, augmentation of antidepressants vs placebo=1, augmentation of mood stabilizers vs placebo=3, augmentation of mood stabilizers vs trancylpromine, citalopram, or inositol=3) were meta-analyzed." | 8.93 | Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials. ( Anghelescu, IG; Correll, CU; Gao, K; Normann, C; Reis, C; Schaffer, A; Solmi, M; van der Loos, ML; Veronese, N; Zaninotto, L, 2016) |
| "We suggest that the early trials evaluating lamotrigine for acute bipolar disorder depression focused on a suboptimal clinical target, and in so doing, ensured less lamotrigine efficacy compared with trials of bipolar disorder preventative treatment." | 8.91 | The 'disconnect' between initial judgments of lamotrigine vs. its real-world effectiveness in managing bipolar disorder. A tale with wider ramifications. ( McCraw, S; Parker, G, 2015) |
| "Over the past decade the use of lamotrigine in bipolar disorder has increased." | 8.88 | Lamotrigine (Lamictal IR) for the treatment of bipolar disorder. ( Bowden, CL; Singh, V, 2012) |
| "Recent published data and treatment guidelines have created uncertainty about the use of lamotrigine in affective disorders, especially in acute bipolar depression." | 8.87 | Lamotrigine: when and where does it act in affective disorders? A systematic review. ( Amann, B; Born, C; Crespo, JM; McKenna, P; Pomarol-Clotet, E, 2011) |
| " We review the clinical literature which suggests that tolerance can develop to most treatment approaches in bipolar illness and present an animal model of tolerance development to anticonvulsant effects of carbamazepine or lamotrigine on amgydala-kindled seizures." | 8.87 | Tolerance to the prophylactic effects of carbamazepine and related mood stabilizers in the treatment of bipolar disorders. ( Post, RM; Weiss, SR, 2011) |
| "The mood stabilizers lithium, valproate and lamotrigine are traditionally used to treat bipolar disorder." | 8.87 | Beneficial effects of mood stabilizers lithium, valproate and lamotrigine in experimental stroke models. ( Chuang, DM; Fessler, EB; Wang, ZF, 2011) |
| " We present three cases of women exposed to lamotrigine during pregnancy and breastfeeding, with follow up of their infants until 15-18 months of development." | 8.85 | Neonatal outcomes with the use of lamotrigine for bipolar disorder in pregnancy and breastfeeding: a case series and review of the literature. ( Epperson, CN; Gonzalez, J; Kim, DR; O'Reardon, JP; Wakil, L, 2009) |
| "To provide an overview of the available literature concerning the prevention of congenital malformations following the use of lamotrigine (LMT) during pregnancy." | 8.85 | [Teratogenic effects of lamotrigine in women with bipolar disorder]. ( Berwaerts, K; De Fruyt, J; Sienaert, P, 2009) |
| "Lamotrigine is being prescribed increasingly for the treatment of bipolar disorder." | 8.84 | [Lamotrigine in the treatment of bipolar disorder, a review]. ( Knoppert-van der Klein, EA; Kölling, P; Nolen, WA; van der Loos, ML, 2007) |
| " Controlled trials in elderly patients with epilepsy demonstrate efficacy and tolerability comparable to gabapentin." | 8.84 | Lamotrigine therapy in elderly patients with epilepsy, bipolar disorder or dementia. ( Nanry, K; Ramsay, E; Sajatovic, M; Thompson, T, 2007) |
| "This paper briefly reviews and comments on the development of lamotrigine as a treatment for bipolar disorder." | 8.84 | Discovery and development of lamotrigine for bipolar disorder: a story of serendipity, clinical observations, risk taking, and persistence. ( Ascher, JA; Bowden, CL; Calabrese, JR; DeVeaugh-Geiss, J; Evoniuk, G; Weisler, RH, 2008) |
| "Lamotrigine (Lamictal, GlaxoSmithKline) is a recently developed anticonvulsant which has been investigated for efficacy in bipolar disorder." | 8.82 | Lamotrigine for bipolar disorder: translating research into clinical practice. ( Fung, J; Mok, H; Yatham, LN, 2004) |
| "Lamotrigine is a novel anticonvulsant agent that has recently been introduced as a long-term treatment in bipolar disorder." | 8.82 | Lamotrigine in the treatment of bipolar disorder. ( Bhagwagar, Z; Goodwin, GM, 2005) |
| "Lamotrigine has undergone a remarkable series of systematic studies since 1994 that now establish it as an efficacious, well-tolerated treatment in bipolar disorder." | 8.81 | Lamotrigine in the treatment of bipolar disorder. ( Bowden, CL, 2002) |
| "This article reviews published studies on the use of lamotrigine in the treatment of bipolar disorder (BD)." | 8.81 | Lamotrigine: a review of clinical studies in bipolar disorders. ( Tabarsi, E; Zerjav-Lacombe, S, 2001) |
| "To provide a qualitative, systematic update and review of the pharmacology, pharmacokinetics, efficacy in mood disorders, adverse effects, and costs of lamotrigine." | 8.81 | Lamotrigine update and its use in mood disorders. ( Hurley, SC, 2002) |
| "The utility of gabapentin and lamotrigine for the treatment of bipolar disorder is reviewed." | 8.80 | Gabapentin and lamotrigine in bipolar disorder. ( Botts, SR; Raskind, J, 1999) |
| "To describe the available data regarding the clinical efficacy of lamotrigine for the treatment of bipolar disorder." | 8.80 | Lamotrigine for the treatment of bipolar disorder. ( Engle, PM; Heck, AM, 2000) |
| "Bipolar disorder and treatment with lithium, antipsychotics, valproate, and lamotrigine." | 8.12 | Association of Lithium Treatment With the Risk of Osteoporosis in Patients With Bipolar Disorder. ( Köhler-Forsberg, O; Nierenberg, AA; Rohde, C; Østergaard, SD, 2022) |
| "In a nation-wide population-based longitudinal register linkage study for the first time 1) to investigate long-term response to lithium in patients with bipolar disorder with and without comorbid epilepsy, and 2) within patients with bipolar disorder and comorbid epilepsy to compare differences in responses between lithium, valproate and lamotrigine." | 8.12 | Response to lithium and anticonvulsants among patients with bipolar disorder with and without comorbid epilepsy - A nation-wide population-based longitudinal study. ( Budtz-Jørgensen, E; Gerds, T; Kessing, LV; Ziersen, SC, 2022) |
| "Lamotrigine is used to treat bipolar depression despite inconsistent evidence." | 8.02 | Lamotrigine for acute bipolar depression: An exploratory item-level analysis. ( Balbuena, L; Li, H; Lodhi, RJ; Peters, EM; Zhang, Y, 2021) |
| "Although mood stabilizers such as lithium (LIT), valproate (VAL), and lamotrigine (LMT) appear to be efficacious treatments for bipolar disorder (BD) in research settings, the long-term response to these mood stabilizers in clinical practice is highly variable among individuals." | 7.96 | Clinical correlates associated with the long-term response of bipolar disorder patients to lithium, valproate or lamotrigine: A retrospective study. ( Bahk, WM; Jung, YE; Kim, MD; Kwon, YJ; Lee, J; Lee, JG; Lee, K; Nam, B; Seo, JS; Song, JH; Wang, SM; Woo, YS; Yoon, BH, 2020) |
| "IntroductionLamotrigine is a commonly used drug in the treatment of bipolar disorder." | 7.91 | Lamotrigine-induced obsessive-compulsive disorder in patients with bipolar disorder. ( Doobay, M; Sharma, V, 2019) |
| " However, there were no associations between NAA/Cr, Glu/Cr, or Gln/Cr and either depression severity or lamotrigine treatment." | 7.91 | Lamotrigine Therapy and Biomarkers of Cerebral Energy Metabolism in Older Age Bipolar Depression. ( Forester, BP; Harper, DG; Jensen, E; Mellen, EJ; Ravichandran, C; Silveri, M, 2019) |
| "Although lamotrigine may be useful for treating patients with treatment-resistant bipolar disorder, some lamotrigine-associated adverse effects, including mild to moderate skin rash, may prevent the continuation of treatment." | 7.88 | Lamotrigine Rechallenge in Treatment-Resistant Bipolar Disorder. ( Inaba, T; Kato, TA; Kunitake, Y; Mizoguchi, Y; Monji, A; Sogawa, R; Tateishi, H, 2018) |
| " Among all mood stabilizers, lithium has the largest evidence base for efficacy in the peripartum period, but lamotrigine is increasingly prescribed for bipolar spectrum disorders during pregnancy." | 7.85 | Risk of postpartum episodes in women with bipolar disorder after lamotrigine or lithium use during pregnancy: A population-based cohort study. ( Bergink, V; Clark, CT; Kushner, SA; Liu, X; Munk-Olsen, T; Wesseloo, R, 2017) |
| "Here, we present the outcomes in the subset of six women who were treated with lamotrigine 100-400 mg/day for the entire pregnancy." | 7.83 | Maternal and Fetal Outcomes After Lamotrigine Use in Pregnancy: A Retrospective Analysis from an Urban Maternal Mental Health Centre in New Zealand. ( Hatters-Friedman, S; Moller-Olsen, C; North, A; Prakash, C, 2016) |
| "To examine the occurrence of menstrually-entrained mood cycling in women with treated bipolar disorder as compared to healthy controls, and to explore whether there is a specific effect of lamotrigine in dampening menstrually-entrained cyclicity of mood." | 7.81 | Lamotrigine and GABAA receptor modulators interact with menstrual cycle phase and oral contraceptives to regulate mood in women with bipolar disorder. ( Holtzman, J; Kenna, HA; Rasgon, NL; Reynolds-May, MF; Robakis, TK; Stemmle, PG, 2015) |
| "Lamotrigine is licensed for treatment of epilepsy and prevention or at least delay of depressive episodes in bipolar disorder." | 7.81 | Retrospective analysis of therapeutic drug monitoring data for treatment of bipolar disorder with lamotrigine. ( Haen, E; Unholzer, S, 2015) |
| "Little information is available on the need for dosage changes for lamotrigine in pregnant women with bipolar disorder." | 7.79 | Lamotrigine dosing for pregnant patients with bipolar disorder. ( Clark, CT; Helsel, J; Klein, AM; Perel, JM; Wisner, KL, 2013) |
| "It is not clear whether the effectiveness of lamotrigine versus lithium differs for patients with bipolar disorder treated in clinical practice." | 7.78 | An observational nationwide register based cohort study on lamotrigine versus lithium in bipolar disorder. ( Andersen, PK; Hellmund, G; Kessing, LV, 2012) |
| "Assess quetiapine plus lamotrigine (QTP+LTG) combination maintenance therapy effectiveness in challenging bipolar disorder (BD)." | 7.78 | Effectiveness of quetiapine plus lamotrigine maintenance therapy in challenging bipolar disorder patients. ( Brooks, JO; Childers, ME; Hoblyn, JC; Ittasakul, P; Johnson, KR; Ketter, TA; Srivastava, S, 2012) |
| "The purpose of this case series is to characterize a recently identified association of the antiepileptic drug (AED) lamotrigine with aseptic meningitis based on cases reported to the Food and Drug Administration (FDA)'s Adverse Event Reporting System (AERS) database." | 7.78 | Lamotrigine and aseptic meningitis. ( Avigan, M; Kortepeter, C; Simms, KM, 2012) |
| " Although there are rare reports of lamotrigine-associated aseptic meningitis, this is only the second confirmed by re-exposure to the medication." | 7.76 | Lamotrigine: an unusual etiology for aseptic meningitis. ( Edelson, DP; Lam, GM; Whelan, CT, 2010) |
| "To examine the treatment impact of lamotrigine on the neurocognitive profile of patients with pediatric bipolar disorder (PBD)." | 7.76 | Enhanced working and verbal memory after lamotrigine treatment in pediatric bipolar disorder. ( Carbray, JA; Mohammed, T; Passarotti, AM; Pavuluri, MN; Sweeney, JA, 2010) |
| "This was a 12-week, open-label, prospective trial of lamotrigine monotherapy to assess the effectiveness and tolerability of this compound in treating pediatric bipolar disorder." | 7.76 | A prospective open-label trial of lamotrigine monotherapy in children and adolescents with bipolar disorder. ( Biederman, J; Doyle, R; Georgiopoulos, A; Hammerness, P; Joshi, G; Kotarski, M; Mick, E; Williams, C; Wozniak, J, 2010) |
| "A bipolar disorder patient stabilized on lamotrigine 200 mg total daily dose was admitted to the hospital with end-stage renal disease." | 7.76 | Lamotrigine and hemodialysis in bipolar disorder: case analysis of dosing strategy with literature review. ( Kaufman, KR, 2010) |
| "The aim of this study was to test the effectiveness and safety of lamotrigine in maintenance of manic and depressive symptom control in pediatric bipolar disorder (PBD)." | 7.75 | Effectiveness of lamotrigine in maintaining symptom control in pediatric bipolar disorder. ( Carbray, JA; Henry, DB; Mohammed, T; Moss, M; Pavuluri, MN; Sweeney, JA, 2009) |
| "Aseptic meningitis could be a rare side effect of lamotrigine." | 7.75 | Lamotrigine-induced aseptic meningitis: a case report. ( Abraham, MN; Egbert, M; Green, MA; Horn, AJ; Sharma, A; Yates, TE, 2009) |
| "Using a retrospective chart review, we identified six patients with epilepsy who reported transient emergent psychological symptoms during stable, chronic lamotrigine monotherapy." | 7.75 | End-of-dose emergent psychopathology in ambulatory patients with epilepsy on stable-dose lamotrigine monotherapy: a case series of six patients. ( Frey, LC; Shrestha, A; Spitz, MC; Strom, LA, 2009) |
| " In this paper, we review the case of studies with lamotrigine in bipolar disorder, describing evidence of lack of efficacy in multiple mood states outside of the primary area of efficacy (prophylaxis of mood episodes)." | 7.74 | Publication bias and the pharmaceutical industry: the case of lamotrigine in bipolar disorder. ( Filkowski, M; Nassir Ghaemi, S; Shirzadi, AA, 2008) |
| "To report two cases of mouth ulcers in lamotrigine patients after oxcarbazepine withdrawal." | 7.74 | Two case reports of oral ulcers with lamotrigine several weeks after oxcarbazepine withdrawal. ( de Leon, J; O'Neill, A, 2007) |
| "Chronic lamotrigine, which is effective in the depressive phase or rapid cycling bipolar disorder does not alter brain arachidonic acid turnover in the unanesthetized rat." | 7.74 | Chronic lamotrigine does not alter the turnover of arachidonic acid within brain phospholipids of the unanesthetized rat: implications for the treatment of bipolar disorder. ( Bazinet, RP; Chang, L; Lee, HJ; Rao, JS; Rapoport, SI, 2007) |
| "The charts of 587 adult outpatients with a primary diagnosis of bipolar disorder who received treatment with lamotrigine in a private practice setting between July 1998 and May 2004 were reviewed retrospectively." | 7.73 | Efficacy and safety of lamotrigine for adults with bipolar disorder in a private practice setting. ( Ginsberg, LD, 2006) |
| "Our aim was to evaluate the effectiveness, safety, and tolerability of adjunctive lamotrigine in the treatment of adolescents with bipolar disorder." | 7.73 | Adjunctive lamotrigine treatment for adolescents with bipolar disorder: retrospective report of five cases. ( Díez-Suárez, A; Figueroa-Quintana, A; Soutullo, CA, 2006) |
| "To obtain pilot data in an observational setting on the use of lamotrigine plus lithium in the long-term treatment of patients with bipolar disorder, 87% of whom had failed to respond to at least one previous mood stabilizer." | 7.73 | Long-term lamotrigine plus lithium for bipolar disorder: One year outcome. ( Berv, DA; Ghaemi, SN; Goodwin, FK; Klugman, J; Pardo, TB; Schrauwen, E; Shirzadi, AA, 2006) |
| "To assess the efficacy of lamotrigine combined with either divalproex or lithium for the treatment of bipolar disorder." | 7.73 | Lamotrigine combined with divalproex or lithium for bipolar disorder: a case series. ( Bowden, CL; Jamison, KL; Redmond, JR, 2006) |
| "Recent reports suggesting lamotrigine as an effective treatment in bipolar disorder, and perhaps borderline personality disorder, a common comorbid personality disorder in bipolar patients, led us to retrospectively examine patients from two bipolar studies to investigate this pattern of comorbidity, and to determine whether lamotrigine effected the dimensions of borderline personality." | 7.72 | Borderline personality disorder in patients with bipolar disorder and response to lamotrigine. ( Hedges, DW; Marchant, BK; Preston, GA; Reimherr, FW; Strong, RE, 2004) |
| "This case suggests the potential utility of lamotrigine in treatment-resistant menstrually-related rapid cycling bipolar disorder, and raises the possibility that lamotrigine might be able to treat pathological entrainment of mood with the menstrual cycle." | 7.72 | Lamotrigine therapy in treatment-resistant menstrually-related rapid cycling bipolar disorder: a case report. ( Becker, OV; Glenn, T; Ketter, TA; Marsh, WK; Rasgon, NL, 2004) |
| "We present the case of a 17-year-old woman with a history of bipolar disorder, who developed a clinical syndrome manifested by fever, lymphadenopathy, skin rash, diarrhea, and acute renal failure requiring dialysis after the use of lamotrigine." | 7.70 | Acute granulomatous interstitial nephritis and colitis in anticonvulsant hypersensitivity syndrome associated with lamotrigine treatment. ( Fervenza, FC; Gibney, R; Kanakiriya, S; Kunau, RT; Lager, DJ, 2000) |
| "Aripiprazole is an atypical antipsychotic compound that is approved by the U." | 6.73 | Aripiprazole therapy in 20 older adults with bipolar disorder: a 12-week, open-label trial. ( Blow, FC; Cassidy, KA; Coconcea, N; Hays, RW; Ignacio, RV; Meyer, WJ; Sajatovic, M, 2008) |
| "The high risk of bipolar depression during pregnancy encourages consideration of lamotrigine (LTG)." | 6.73 | Lamotrigine in bipolar disorder: efficacy during pregnancy. ( Baldessarini, RJ; Calamaras, MR; Juric, S; Knight, B; Newport, DJ; Pennell, PB; Stowe, ZN; Viguera, AC, 2008) |
| "Lamotrigine treatment was well tolerated in this sample and associated with statistically significant improvement in mood and drug cravings but not drug use." | 6.71 | Lamotrigine in patients with bipolar disorder and cocaine dependence. ( Bobadilla, L; Brown, ES; Nejtek, VA; Orsulak, PJ; Perantie, DC, 2003) |
| "Lamotrigine was used at a mean +/- SD dose of 185." | 6.68 | Lamotrigine in rapid-cycling bipolar disorder. ( Calabrese, JR; Fatemi, SH; Rapport, DJ; Thuras, P, 1997) |
| " In the present paper, I review studies in unanaesthetized rats using a neuropharmacological approach, combined with kinetic, biochemical and molecular biology techniques, demonstrating that chronic administration of three commonly used mood stabilizers (lithium, valproic acid and carbamazepine), at therapeutically relevant doses, selectively target the brain arachidonic acid cascade." | 6.45 | Is the brain arachidonic acid cascade a common target of drugs used to manage bipolar disorder? ( Bazinet, RP, 2009) |
| "Lamotrigine was primarily effective against depression and lithium was primarily effective against mania." | 6.42 | Latest maintenance data on lamotrigine in bipolar disorder. ( Calabrese, JR; Shelton, MD; Vieta, E, 2003) |
| "Lamotrigine was generally well tolerated in maintenance studies with the most common adverse events being headache, nausea, infection and insomnia." | 6.42 | Lamotrigine: a review of its use in bipolar disorder. ( Goldsmith, DR; Ibbotson, T; Perry, CM; Wagstaff, AJ, 2003) |
| "Lamotrigine has a variable profile in kindling and contingent tolerance experiments and does not appear to have robust gamma-aminobutyric acid or monoaminergic actions." | 6.42 | Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders. ( Ketter, TA; Manji, HK; Post, RM, 2003) |
| " The most common adverse event with lamotrigine was headache." | 6.42 | Safety and tolerability of lamotrigine for bipolar disorder. ( Asnis, GM; Bentley, B; Bowden, CL; Ginsberg, LD; Leadbetter, R; White, R, 2004) |
| "Lamotrigine has emerged as a first line treatment for bipolar depression, which is an area of weakness for other mood stabilizers." | 6.42 | Separate and concomitant use of lamotrigine, lithium, and divalproex in bipolar disorders. ( Goodwin, FK; Lieberman, DZ, 2004) |
| "Lamotrigine has been found to have acute efficacy in treating episodes of bipolar depression without increasing cycling or provoking a switch into mania, as well as a long-term role in delaying relapse and recurrence of depressive episodes." | 6.41 | Long-term treatment of bipolar disorder with lamotrigine. ( Calabrese, JR; Elhaj, O; Kimmel, SE; Rapport, DJ; Shelton, MD, 2002) |
| " In an attempt to replicate and extend these preliminary open-label prospective findings, a series of multicenter, double-blind, placebo-controlled studies evaluating the efficacy and dose-response relationships of lamotrigine in the various phases of the illness, including both acute and maintenance designs in both bipolar I and II disorder, is ongoing." | 6.40 | Clinical studies on the use of lamotrigine in bipolar disorder. ( Calabrese, JR; Kimmel, SE; Kujawa, M; Rapport, DJ; Shelton, MD, 1998) |
| " Open reports suggest usefulness of gabapentin as an adjunct in bipolar disorder, but double-blind trials failed to confirm efficacy in acute mania and treatment-resistant rapid-cycling bipolar disorder." | 6.20 | Third generation anticonvulsants in bipolar disorder: a review of efficacy and summary of clinical recommendations. ( Calabrese, JR; Kroeker, G; Kusumakar, V; Rao, R; Scarrow, G; Yatham, LN, 2002) |
| "Topiramate, a structurally novel anticonvulsant, is being evaluated for other neurological conditions such as migraine, neuropathic pain, and essential tremor, and also for psychiatric conditions such as bipolar disorder, bulimia, post-traumatic stress disorder, and schizoaffective disorder, in addition to obesity." | 6.19 | The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder. ( Chengappa, KN; Gershon, S; Levine, J, 2001) |
| "Lamotrigine treatment was associated with significant improvements in mood, drug craving, and drug use." | 5.33 | Lamotrigine for bipolar disorder and comorbid cocaine dependence: a replication and extension study. ( Beard, L; Brown, ES; Dhanani, N; Orsulak, P; Perantie, DC; Rush, AJ, 2006) |
| "Lamotrigine was added to existing medication regimens." | 5.33 | Effects of lamotrigine in patients with bipolar disorder and alcohol dependence. ( Alamo, C; López-Muñoz, F; Rubio, G, 2006) |
| "Lamotrigine was generally well tolerated in maintenance studies with the most common adverse events being headache, nausea, infection and insomnia." | 5.32 | Spotlight on lamotrigine in bipolar disorder. ( Goldsmith, DR; Ibbotson, T; Perry, CM; Wagstaff, AJ, 2004) |
| "Although not licensed for acute bipolar depression, lamotrigine has evidence for efficacy in trials and its use is recommended in guidelines." | 5.27 | Comparative economic evaluation of quetiapine plus lamotrigine combination vs quetiapine monotherapy (and folic acid vs placebo) in patients with bipolar depression (CEQUEL). ( Gardiner, A; Geddes, JR; Goodwin, GM; Mayer, S; Rendell, J; Simon, J, 2018) |
| "In the present study, an effort was made to investigate the effect of lamotrigine on cognitive function and serum inflammatory factors in patients with depression of recurrent bipolar disorder and to explore its possible mechanism." | 5.27 | Effect of lamotrigine on cognitive function and serum inflammatory factors in patients with depression of recurrent bipolar disorder. ( Li, L; Shi, S; Song, L; Wang, X, 2018) |
| "Lamotrigine has acute antidepressant effects in patients with bipolar disorder." | 5.24 | Correlation between the Efficacy of Lamotrigine and the Serum Lamotrigine Level during the Remission Phase of Acute Bipolar II Depression: A Naturalistic and Unblinded Prospective Pilot Study. ( Aiba, T; Hiraki, K; Kikkawa, A; Kitamura, Y; Sendo, T, 2017) |
| "We conducted a double-blind crossover study of a low dose (15 mg, 'placebo') and an active dose (195 mg) of methylene blue in patients with bipolar disorder treated with lamotrigine." | 5.24 | Methylene blue treatment for residual symptoms of bipolar disorder: randomised crossover study. ( Alda, M; Blagdon, R; Dursun, S; Garnham, J; Hajek, T; MacLellan, S; MacQueen, G; McKinnon, M; Nair, C; O'Donovan, C, 2017) |
| " Evidence supporting the use of aripiprazole, olanzapine, quetiapine, valproate and lamotrigine for treatment of rapid cycling bipolar disorder was found." | 5.22 | Evidence-based treatment strategies for rapid cycling bipolar disorder, a systematic review. ( Roosen, L; Sienaert, P, 2022) |
| "This study aimed to compare the efficacy of lamotrigine versus placebo in 10- to 17-year-olds with bipolar I disorder (BP-I) who were receiving conventional bipolar disorder treatment." | 5.20 | Adjunctive Maintenance Lamotrigine for Pediatric Bipolar I Disorder: A Placebo-Controlled, Randomized Withdrawal Study. ( Chang, K; DelBello, M; Findling, RL; Foster, VJ; Horrigan, J; Kraus, JE; Krishen, A; Robb, A; Wamil, A, 2015) |
| "Patients with bipolar disorder in a euthymic state (Young's Mania Rating Scale (YMRS) score <12, and 21-item Hamilton Depression Rating Scale (HAM-D) score <7) for at least two months, having already received either olanzapine or lamotrigine as the maintenance treatment were recruited." | 5.19 | Olanzapine is superior to lamotrigine in the prevention of bipolar depression: a naturalistic observational study. ( Lee, MS; Lo, MC; Pan, PY; Yang, EL; Yeh, CB, 2014) |
| " This study aimed to identify and compare factors of a 31-item version of the HDRS (HDRS-31) in large samples of patients with bipolar depression and Major Depressive Disorder (MDD), then examine the responsiveness of such factors to lamotrigine compared with placebo in the bipolar depressed sample." | 5.17 | A factor analytic study in bipolar depression, and response to lamotrigine. ( Bowden, CL; Calabrese, JR; Evoniuk, G; Hadzi-Pavlovic, D; Mitchell, PB, 2013) |
| "Aripiprazole plus a mood stabilizer has minimal impact on metabolic changes in predominantly overweight/obese BPD patients over a 52-week period." | 5.17 | Investigation into the long-term metabolic effects of aripiprazole adjunctive to lithium, valproate, or lamotrigine. ( Baker, RA; Carlson, BX; De Hert, M; Eudicone, JM; Fyans, P; Kemp, DE; Marler, SV; Rahman, Z, 2013) |
| " Lamotrigine, an anticonvulsant which decreases presynaptic glutamate release, has been shown to be effective in the depressive phase of bipolar disorder (BD-D); however, only 40-50% of patients have a full response." | 5.16 | Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trial. ( Anand, A; Barkay, G; Ghosh, S; Gunn, AD; Karne, HS; Mathew, SJ; Nurnberger, JI, 2012) |
| "To identify baseline clinical factors associated with acute treatment response in depressed older adults with bipolar disorder (BD) receiving lamotrigine." | 5.16 | Correlates of treatment response in depressed older adults with bipolar disorder. ( Al Jurdi, RK; Bialko, C; Cassidy, KA; Gildengers, A; Gyulai, L; Mulsant, BH; Sajatovic, M; Tatsuoka, C; Young, RC, 2012) |
| "To compare the maintenance efficacy of lamotrigine (Lam) to combination therapy of Lam+divalproex ER (Div) in recently depressed patients with bipolar disorder (BD)." | 5.16 | Lamotrigine vs. lamotrigine plus divalproex in randomized, placebo-controlled maintenance treatment for bipolar depression. ( Bowden, CL; Chang, X; Mintz, J; Quinones, M; Singh, V; Thompson, P; Weisler, R, 2012) |
| "Treatment with SGAs followed by lamotrigine monotherapy enhanced prefrontal and temporal lobe activity during a Response Inhibition Task demonstrating the reversal of disorder-relevant neural circuitry dysfunction in patients with adolescent bipolar disorder." | 5.14 | Enhanced prefrontal function with pharmacotherapy on a response inhibition task in adolescent bipolar disorder. ( Harral, EM; Passarotti, AM; Pavuluri, MN; Sweeney, JA, 2010) |
| "To pilot the efficacy and safety data of lamotrigine adjunctive therapy to lithium and divalproex in patients with rapid-cycling bipolar disorder (RCBD) and a recent substance use disorder (SUD)." | 5.14 | Lamotrigine adjunctive therapy to lithium and divalproex in depressed patients with rapid cycling bipolar disorder and a recent substance use disorder: a 12-week, double-blind, placebo-controlled pilot study. ( Calabrese, JR; Chan, PK; Conroy, C; Fang, Y; Findling, RL; Ganocy, SJ; Gao, K; Kemp, DE; Serrano, MB; Wang, Z, 2010) |
| "The efficacy of lamotrigine as maintenance treatment for bipolar disorder (BD), particularly for delaying depressive episodes, is well established, but its efficacy in the acute treatment of bipolar depression is less clear." | 5.13 | Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. ( Ascher, JA; Calabrese, JR; Edwards, S; Huffman, RF; Leadbetter, RA; Monaghan, ET; Thompson, TR; White, RL, 2008) |
| "The aim of the present randomized, single-blind, pilot study was to assess the efficacy of the addition of a second mood stabilizer, either olanzapine or lamotrigine, to lithium in patients with remitted bipolar disorder and comorbid anxiety disorder." | 5.13 | Olanzapine or lamotrigine addition to lithium in remitted bipolar disorder patients with anxiety disorder comorbidity: a randomized, single-blind, pilot study. ( Albert, U; Bogetto, F; Maina, G; Rosso, G, 2008) |
| "We used functional magnetic resonance imaging to examine changes in brain activation during a sad facial affect recognition task in 12 stable patients with bipolar disorder when medication-free compared with healthy controls and after 12 weeks of lamotrigine monotherapy." | 5.13 | Pilot investigation of the changes in cortical activation during facial affect recognition with lamotrigine monotherapy in bipolar disorder. ( Cobb, A; Frangou, S; Haldane, M; Jogia, J; Kumari, V, 2008) |
| "To assess lamotrigine effectiveness in bipolar disorder (BD) patients in a clinical setting." | 5.13 | Effectiveness of lamotrigine in bipolar disorder in a clinical setting. ( Bonner, JC; Brooks, JO; Champion, LM; Culver, JL; Hoblyn, JC; Ketter, TA; Marsh, WK; Nam, JY, 2008) |
| "To assess the efficacy and tolerability of lamotrigine in the maintenance treatment of bipolar disorder." | 5.12 | Lamotrigine in the maintenance treatment of bipolar disorder. ( Fujiwara, T; Hashimoto, Y; Kotake, K; Sakamoto, S; Watanabe, N, 2021) |
| " The authors wished to prospectively study the efficacy of lamotrigine as adjunctive or monotherapy in adolescents with bipolar disorder who were experiencing a depressive episode." | 5.12 | An open-label study of lamotrigine adjunct or monotherapy for the treatment of adolescents with bipolar depression. ( Chang, K; Howe, M; Saxena, K, 2006) |
| "The effect of lamotrigine maintenance therapy on body weight was assessed retrospectively in analyses of data from two double-blind, placebo- and lithium-controlled, 18-month studies in patients with bipolar I disorder (n = 227 for lamotrigine, 190 for placebo, 166 for lithium)." | 5.12 | Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder. ( Bentley, B; Bowden, C; Calabrese, JR; Ketter, T; Sachs, G; Thompson, T; White, R, 2006) |
| "Despite the increasing use of lamotrigine (LTG) in bipolar disorder, little is known about its impact on cognition in bipolar patients." | 5.12 | Cognitive functioning in bipolar patients receiving lamotrigine: preliminary results. ( Benabarre, A; Colom, F; Comes, M; Daban, C; Goikolea, JM; Martínez-Arán, A; Sánchez-Moreno, J; Torrent, C; Vieta, E, 2006) |
| "A post hoc analysis was conducted to assess the effects of lamotrigine, lithium, and placebo administration on body weight in obese and nonobese patients with bipolar disorder from two double-blind, placebo-controlled, 18-month studies." | 5.12 | Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar I disorder. ( Bowden, CL; Calabrese, JR; Ketter, TA; Sachs, GS; Thompson, TR; White, RL, 2006) |
| "The effect of lamotrigine on the steady-state plasma concentrations of the atypical antipsychotics clozapine, olanzapine, and risperidone was investigated in patients with schizophrenia or bipolar disorder stabilized on chronic treatment with clozapine (200-500 mg/day; n = 11), risperidone (3-6 mg/day; n = 10) or olanzapine (10-20 mg/day; n = 14))." | 5.12 | Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. ( D'Amico, G; D'Arrigo, C; Micò, U; Migliardi, G; Muscatello, MR; Perucca, E; Santoro, V; Spina, E, 2006) |
| "Lamotrigine was effective and well tolerated and appeared to have no effect on body weight when given as monotherapy or as adjunctive therapy with valproate, antipsychotics, lithium, or antidepressants to outpatients with bipolar I disorder in a 12-week open-label study." | 5.12 | Effectiveness and weight effects of open-label lamotrigine with and without concomitant psychotropic medications in patients with bipolar I disorder. ( Graham, J; Nanry, K; Roberts, J; Thompson, T; Zarzar, MN, 2007) |
| "An original method based on the use of high-performance liquid chromatography with both coulometric and diode array detection has been developed for the therapeutic drug monitoring of patients with bipolar disorders being treated with olanzapine and lamotrigine." | 5.12 | Simultaneous high-performance liquid chromatographic determination of olanzapine and lamotrigine in plasma of bipolar patients. ( Amore, M; Koukopoulos, A; Raggi, MA; Sani, G; Saracino, MA, 2007) |
| "To describe the frequency and correlates of lamotrigine therapy among the first 500 patients enrolled into the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) study." | 5.11 | Lamotrigine treatment of bipolar disorder: data from the first 500 patients in STEP-BD. ( Bowden, CL; Calabrese, JR; Goldberg, JF; Ketter, TA; Marangell, LB; Martinez, JM; Miklowitz, DJ; Miyahara, S; Sachs, GS; Thase, ME, 2004) |
| "We assessed rash incidence in 100 patients with DSM-IV bipolar disorder instructed, for their first 3 months taking lamotrigine, to avoid other new medicines and new foods, cosmetics, conditioners, deodorants, detergents, and fabric softeners, as well as sunburn and exposure to poison ivy/oak." | 5.11 | Dermatology precautions and slower titration yield low incidence of lamotrigine treatment-emergent rash. ( Alarcon, AM; Becker, OV; Chandler, RA; Ketter, TA; Nowakowska, C; O'Keeffe, CM; Schumacher, MR; Wang, PW, 2005) |
| "The anticonvulsant lamotrigine has been reported to be efficacious and well tolerated as monotherapy in the treatment of bipolar patients as well as in treatment-refractory bipolar disorder." | 5.10 | Lamotrigine as an augmentation agent in treatment-resistant depression. ( Barbee, JG; Jamhour, NJ, 2002) |
| "These findings suggest that lithium- and lamotrigine-responsive patients differ with respect to course of illness, comorbidity and family history and may represent distinct subtypes of bipolar disorder." | 5.10 | Phenotypic spectra of bipolar disorder in responders to lithium versus lamotrigine. ( Alda, M; Duffy, A; Garnham, J; MacDougall, M; Munro, A; Passmore, MJ; Slaney, C; Teehan, A, 2003) |
| " Preliminary data suggest that lamotrigine, an established antiepileptic drug, may be effective for both the depression and mania associated with bipolar disorder." | 5.09 | A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. ( Ascher, JA; Bowden, CL; Calabrese, JR; Monaghan, E; Rudd, GD; Sachs, GS, 1999) |
| "This preliminary report supports clinical improvement for both mood cycling and depression in patients with bipolar disorder treated with lamotrigine." | 5.09 | Lamotrigine for the treatment of bipolar disorder: a clinical case series. ( Altshuler, L; Brown, ES; Denicoff, KD; Frye, M; Keck, PE; Kupka, R; Leverich, GS; McElroy, SL; Nolen, W; Post, RM; Suppes, T, 1999) |
| "Patients with diagnoses of refractory bipolar disorder who were currently experiencing manic, mixed, depressive, or hypomanic episodes were treated with lamotrigine as add-on therapy (60 patients) or monotherapy (15 patients)." | 5.09 | The efficacy of lamotrigine in rapid cycling and non-rapid cycling patients with bipolar disorder. ( Anderson, J; Ascher, J; Bolden-Watson, C; Bowden, CL; Calabrese, JR; Cookson, J; Keck, PE; McElroy, SL; Monaghan, E; Rhodes, LJ; Zhou, J, 1999) |
| "These open-label data provide preliminary evidence that lamotrigine may be an effective treatment option for patients with refractory bipolar disorder; however, potential benefits must be weighed against potential side effects, including rash." | 5.09 | Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder. ( Andersen, J; Ascher, JA; Bolden-Watson, C; Bowden, CL; Calabrese, JR; Cookson, J; Keck, PE; McElroy, SL; Rhodes, L; Zhou, J, 1999) |
| "Preliminary data from case reports and small open trials suggest a role for lamotrigine in the treatment of bipolar disorder, although controlled data for the manic phase are lacking." | 5.09 | Lamotrigine compared with lithium in mania: a double-blind randomized controlled trial. ( Berk, M; Brook, S; Ichim, L, 2000) |
| "324 patients with rapid-cycling bipolar disorder (DSM-IV criteria) received open-label lamotrigine, and 182 patients were randomly assigned to the double-blind maintenance phase." | 5.09 | A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. ( Ascher, JA; Bowden, CL; Calabrese, JR; Earl, NL; Greene, PL; Kusumakar, V; McElroy, SL; Monaghan, ET; Sachs, GS; Suppes, T; Swann, AC, 2000) |
| "In an open longitudinal investigation, 14 patients with rapid cycling bipolar disorder were treated for 1 year with either lithium or lamotrigine as mood stabilizer." | 5.09 | An open longitudinal study of patients with bipolar rapid cycling treated with lithium or lamotrigine for mood stabilization. ( Grunze, H; Schaerer, L; Schloesser, S; Walden, J, 2000) |
| "Lamotrigine (LTG) is a well-established anticonvulsant that is also approved for the prevention of mood relapses in bipolar disorder." | 5.01 | Lamotrigine as a mood stabilizer: insights from the pre-clinical evidence. ( Miranda, AS; Teixeira, AL, 2019) |
| "Whether patients with adult bipolar disorder (BD) who have been clinically stabilized with lithium or lamotrigine should continue this medication is not established fully." | 5.01 | Efficacy and safety of lithium and lamotrigine for the maintenance treatment of clinically stable patients with bipolar disorder: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials with an enrichment design. ( Esumi, S; Hashimoto, R; Hashimoto, Y; Hatano, M; Iwata, N; Kato, M; Kishi, T; Matsuda, Y; Matsui, Y; Mishima, K; Miyake, N; Nomura, I; Okuya, M; Oya, K; Sakuma, K; Watanabe, N, 2019) |
| "This paper reviewed the relevant literature on the effects of lamotrigine on pregnancy outcomes to provide useful information regarding lamotrigine use in pregnant women with bipolar disorder." | 4.98 | The risks associated with the use of lamotrigine during pregnancy. ( Gao, Z; Kong, L; Wang, B; Wang, C; Zhou, T, 2018) |
| "83 weeks) in patients with unipolar depression (studies=4, n=187; monotherapy vs lithium=1, augmentation of antidepressants vs placebo=3) or bipolar depression (studies=14, n=1965; monotherapy vs placebo=5, monotherapy vs lithium or olanzapine+fluoxetine=2, augmentation of antidepressants vs placebo=1, augmentation of mood stabilizers vs placebo=3, augmentation of mood stabilizers vs trancylpromine, citalopram, or inositol=3) were meta-analyzed." | 4.93 | Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials. ( Anghelescu, IG; Correll, CU; Gao, K; Normann, C; Reis, C; Schaffer, A; Solmi, M; van der Loos, ML; Veronese, N; Zaninotto, L, 2016) |
| "We suggest that the early trials evaluating lamotrigine for acute bipolar disorder depression focused on a suboptimal clinical target, and in so doing, ensured less lamotrigine efficacy compared with trials of bipolar disorder preventative treatment." | 4.91 | The 'disconnect' between initial judgments of lamotrigine vs. its real-world effectiveness in managing bipolar disorder. A tale with wider ramifications. ( McCraw, S; Parker, G, 2015) |
| " Several treatments [monoamine oxidase inhibitors (MAOIs), ziprasidone, aripiprazole and risperidone] have limited or no therapeutic activity in bipolar depression." | 4.90 | Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis. ( Cornelius, V; Smith, L; Taylor, DM; Young, AH, 2014) |
| "The 2 older FDA-approved treatments for bipolar depression, olanzapine-fluoxetine combination (OFC) and quetiapine (QTP) monotherapy, were efficacious (response NNT=4 for OFC, NNT=6 for QTP), but similarly likely to yield harms (OFC weight gain NNH=6; QTP sedation/somnolence NNH=5)." | 4.90 | Balancing benefits and harms of treatments for acute bipolar depression. ( Calabrese, JR; Citrome, L; Dell'Osso, B; Frye, MA; Ketter, TA; Miller, S, 2014) |
| "Over the past decade the use of lamotrigine in bipolar disorder has increased." | 4.88 | Lamotrigine (Lamictal IR) for the treatment of bipolar disorder. ( Bowden, CL; Singh, V, 2012) |
| "Recent published data and treatment guidelines have created uncertainty about the use of lamotrigine in affective disorders, especially in acute bipolar depression." | 4.87 | Lamotrigine: when and where does it act in affective disorders? A systematic review. ( Amann, B; Born, C; Crespo, JM; McKenna, P; Pomarol-Clotet, E, 2011) |
| " We review the clinical literature which suggests that tolerance can develop to most treatment approaches in bipolar illness and present an animal model of tolerance development to anticonvulsant effects of carbamazepine or lamotrigine on amgydala-kindled seizures." | 4.87 | Tolerance to the prophylactic effects of carbamazepine and related mood stabilizers in the treatment of bipolar disorders. ( Post, RM; Weiss, SR, 2011) |
| "The mood stabilizers lithium, valproate and lamotrigine are traditionally used to treat bipolar disorder." | 4.87 | Beneficial effects of mood stabilizers lithium, valproate and lamotrigine in experimental stroke models. ( Chuang, DM; Fessler, EB; Wang, ZF, 2011) |
| "A systematic search was carried out of electronic databases, reference books and other sources for original research studies which examined the effects of commonly used mood stabilizers (sodium valproate, carbamazepine, lamotrigine and lithium carbonate) on pregnancy outcomes." | 4.86 | Mood stabilizers in pregnancy: a systematic review. ( Buist, A; Galbally, M; Roberts, M, 2010) |
| " We describe a case of AHS with fulminant hepatitis that occurred two weeks after introduction of lamotrigine in a 40-year-old female patient with a recently diagnosed bipolar disorder, no pre-existent systemic organ involvement, and no other medication." | 4.85 | Fulminant hepatitis induced by lamotrigine. ( Marleau, D; Ouellet, G; Tremblay, L, 2009) |
| "There is consistent evidence that lamotrigine has a beneficial effect on depressive symptoms in the depressed phase of bipolar disorder." | 4.85 | Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. ( Calabrese, JR; Geddes, JR; Goodwin, GM, 2009) |
| " We present three cases of women exposed to lamotrigine during pregnancy and breastfeeding, with follow up of their infants until 15-18 months of development." | 4.85 | Neonatal outcomes with the use of lamotrigine for bipolar disorder in pregnancy and breastfeeding: a case series and review of the literature. ( Epperson, CN; Gonzalez, J; Kim, DR; O'Reardon, JP; Wakil, L, 2009) |
| "To provide an overview of the available literature concerning the prevention of congenital malformations following the use of lamotrigine (LMT) during pregnancy." | 4.85 | [Teratogenic effects of lamotrigine in women with bipolar disorder]. ( Berwaerts, K; De Fruyt, J; Sienaert, P, 2009) |
| "Lamotrigine is being prescribed increasingly for the treatment of bipolar disorder." | 4.84 | [Lamotrigine in the treatment of bipolar disorder, a review]. ( Knoppert-van der Klein, EA; Kölling, P; Nolen, WA; van der Loos, ML, 2007) |
| " Controlled trials in elderly patients with epilepsy demonstrate efficacy and tolerability comparable to gabapentin." | 4.84 | Lamotrigine therapy in elderly patients with epilepsy, bipolar disorder or dementia. ( Nanry, K; Ramsay, E; Sajatovic, M; Thompson, T, 2007) |
| "Starting with carbamazepine and valproate in the eighties, several anticonvulsant have been established as a treatment option in bipolar disorder." | 4.84 | [Anticonvulsants in the treatment of bipolar disorder]. ( Grunze, H, 2007) |
| "Lithium, valproate, lamotrigine and olanzapine are effective as maintenance therapy for the prevention of relapse in bipolar disorder." | 4.84 | A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder. ( Barbieri, M; Beynon, S; Bravo Vergel, Y; Duffy, S; Dunn, G; Geddes, J; Gilbody, S; Palmer, S; Soares-Weiser, K; Woolacott, N, 2007) |
| "This paper briefly reviews and comments on the development of lamotrigine as a treatment for bipolar disorder." | 4.84 | Discovery and development of lamotrigine for bipolar disorder: a story of serendipity, clinical observations, risk taking, and persistence. ( Ascher, JA; Bowden, CL; Calabrese, JR; DeVeaugh-Geiss, J; Evoniuk, G; Weisler, RH, 2008) |
| "Valproate, lamotrigine and carbamazepine have a valuable place in the management of bipolar disorder." | 4.83 | Anticonvulsants in bipolar disorder. ( Bowden, CL; Karren, NU, 2006) |
| " Weight gain and pharmacokinetic interaction with lamotrigine are perhaps the most consistent problems in use." | 4.82 | Valproate. ( Bowden, CL, 2003) |
| "The role of lithium carbonate in the maintenance treatment of bipolar disorder is well established." | 4.82 | Alternatives to lithium and divalproex in the maintenance treatment of bipolar disorder. ( Freeman, MP; Gelenberg, AJ; Gnanadesikan, M, 2003) |
| " The anticonvulsant lamotrigine, recently approved as maintenance therapy for bipolar depression, has undergone evaluation as acute and maintenance therapy for bipolar disorder in several controlled clinical trials." | 4.82 | Lamotrigine: a depression mood stabiliser. ( Herman, E, 2004) |
| "To examine whether lamotrigine has a unique role in the treatment of bipolar disorder, we evaluated the results of recent clinical trials and molecular and cell biological studies on lamotrigine." | 4.82 | The current understanding of lamotrigine as a mood stabilizer. ( Baldassano, CF; Gyulai, L; Hahn, CG; Lenox, RH, 2004) |
| "Following the introduction of lamotrigine in 1994 as a treatment for epilepsy in the United States, the drug has seen progressively greater application in psychiatry, particularly as a treatment for bipolar disorder." | 4.82 | Lamotrigine in psychiatry: pharmacology and therapeutics. ( Jefferson, JW, 2005) |
| "Lamotrigine (Lamictal, GlaxoSmithKline) is a recently developed anticonvulsant which has been investigated for efficacy in bipolar disorder." | 4.82 | Lamotrigine for bipolar disorder: translating research into clinical practice. ( Fung, J; Mok, H; Yatham, LN, 2004) |
| "Lamotrigine is a novel anticonvulsant agent that has recently been introduced as a long-term treatment in bipolar disorder." | 4.82 | Lamotrigine in the treatment of bipolar disorder. ( Bhagwagar, Z; Goodwin, GM, 2005) |
| "In the 1970s, several randomized controlled trials demonstrated significant antimanic and antidepressant properties of lithium in the prophylactic treatment of bipolar disorder." | 4.82 | Is the prophylactic antidepressant efficacy of lithium in bipolar I disorder dependent on study design and lithium level? ( Frangou, S; Grunze, H; Kleindienst, N; Moeller, HJ; Severus, WE, 2005) |
| "Lamotrigine has undergone a remarkable series of systematic studies since 1994 that now establish it as an efficacious, well-tolerated treatment in bipolar disorder." | 4.81 | Lamotrigine in the treatment of bipolar disorder. ( Bowden, CL, 2002) |
| "This article reviews published studies on the use of lamotrigine in the treatment of bipolar disorder (BD)." | 4.81 | Lamotrigine: a review of clinical studies in bipolar disorders. ( Tabarsi, E; Zerjav-Lacombe, S, 2001) |
| " Alternative and adjunctive treatments to lithium in bipolar disorder have been sought and the anticonvulsants carbamazepine and valproate show promise." | 4.81 | Developments in mood stabilisers. ( Ferrier, IN, 2001) |
| "To provide a qualitative, systematic update and review of the pharmacology, pharmacokinetics, efficacy in mood disorders, adverse effects, and costs of lamotrigine." | 4.81 | Lamotrigine update and its use in mood disorders. ( Hurley, SC, 2002) |
| "The utility of gabapentin and lamotrigine for the treatment of bipolar disorder is reviewed." | 4.80 | Gabapentin and lamotrigine in bipolar disorder. ( Botts, SR; Raskind, J, 1999) |
| "To describe the available data regarding the clinical efficacy of lamotrigine for the treatment of bipolar disorder." | 4.80 | Lamotrigine for the treatment of bipolar disorder. ( Engle, PM; Heck, AM, 2000) |
| "Treatment with valproate and antipsychotics-but not with lithium and lamotrigine-was associated with increased risk of DM in a real-world cohort of patients with bipolar disorder." | 4.31 | Pharmacological treatment of bipolar disorder and risk of diabetes mellitus: A nationwide study of 30,451 patients. ( Köhler-Forsberg, O; Nierenberg, AA; Rohde, C; Østergaard, SD, 2023) |
| "Bipolar disorder and treatment with lithium, antipsychotics, valproate, and lamotrigine." | 4.12 | Association of Lithium Treatment With the Risk of Osteoporosis in Patients With Bipolar Disorder. ( Köhler-Forsberg, O; Nierenberg, AA; Rohde, C; Østergaard, SD, 2022) |
| "In a nation-wide population-based longitudinal register linkage study for the first time 1) to investigate long-term response to lithium in patients with bipolar disorder with and without comorbid epilepsy, and 2) within patients with bipolar disorder and comorbid epilepsy to compare differences in responses between lithium, valproate and lamotrigine." | 4.12 | Response to lithium and anticonvulsants among patients with bipolar disorder with and without comorbid epilepsy - A nation-wide population-based longitudinal study. ( Budtz-Jørgensen, E; Gerds, T; Kessing, LV; Ziersen, SC, 2022) |
| "The Food and Drug Administration (FDA) is advising health care practitioners that lamotrigine (Lamictal), used in managing seizures and bipolar disorder, may increase the risk of serious and potentially lethal arrythmias." | 4.02 | Lamotrigine may Increase Risk of Arrythmias. ( Aschenbrenner, DS, 2021) |
| "Lamotrigine is used to treat bipolar depression despite inconsistent evidence." | 4.02 | Lamotrigine for acute bipolar depression: An exploratory item-level analysis. ( Balbuena, L; Li, H; Lodhi, RJ; Peters, EM; Zhang, Y, 2021) |
| "Although mood stabilizers such as lithium (LIT), valproate (VAL), and lamotrigine (LMT) appear to be efficacious treatments for bipolar disorder (BD) in research settings, the long-term response to these mood stabilizers in clinical practice is highly variable among individuals." | 3.96 | Clinical correlates associated with the long-term response of bipolar disorder patients to lithium, valproate or lamotrigine: A retrospective study. ( Bahk, WM; Jung, YE; Kim, MD; Kwon, YJ; Lee, J; Lee, JG; Lee, K; Nam, B; Seo, JS; Song, JH; Wang, SM; Woo, YS; Yoon, BH, 2020) |
| "IntroductionLamotrigine is a commonly used drug in the treatment of bipolar disorder." | 3.91 | Lamotrigine-induced obsessive-compulsive disorder in patients with bipolar disorder. ( Doobay, M; Sharma, V, 2019) |
| "Use of carbamazepine and valproic acid, but not lithium and lamotrigine, is associated with increased risk of stroke in patients with bipolar disorder." | 3.91 | Mood stabilisers and risk of stroke in bipolar disorder. ( Chang, CK; Chen, CC; Chen, PH; Kuo, CJ; Pan, CH; Su, SS; Tsai, SY, 2019) |
| " However, there were no associations between NAA/Cr, Glu/Cr, or Gln/Cr and either depression severity or lamotrigine treatment." | 3.91 | Lamotrigine Therapy and Biomarkers of Cerebral Energy Metabolism in Older Age Bipolar Depression. ( Forester, BP; Harper, DG; Jensen, E; Mellen, EJ; Ravichandran, C; Silveri, M, 2019) |
| "We found increased risks of cataract development in long-term users of lithium, lithium combined with other MS and valproic acid combined with other MS for more than two years among patients with BD and schizophrenia." | 3.88 | Associations between use of mood stabilizers and risk of cataract: A population-based nested case-control study. ( Chou, PH; Chu, CS; Lan, TH; Lin, CH, 2018) |
| " This limitation and high risks of neural tube and other major teratogenic effects, especially of valproate, indicate the need for great caution in the use of valproate and carbamazepine to treat bipolar disorder in women of child-bearing age." | 3.88 | Mood-Stabilizing Anticonvulsants, Spina Bifida, and Folate Supplementation: Commentary. ( Baldessarini, RJ; Patel, N; Viguera, AC, 2018) |
| "Although lamotrigine may be useful for treating patients with treatment-resistant bipolar disorder, some lamotrigine-associated adverse effects, including mild to moderate skin rash, may prevent the continuation of treatment." | 3.88 | Lamotrigine Rechallenge in Treatment-Resistant Bipolar Disorder. ( Inaba, T; Kato, TA; Kunitake, Y; Mizoguchi, Y; Monji, A; Sogawa, R; Tateishi, H, 2018) |
| " Among all mood stabilizers, lithium has the largest evidence base for efficacy in the peripartum period, but lamotrigine is increasingly prescribed for bipolar spectrum disorders during pregnancy." | 3.85 | Risk of postpartum episodes in women with bipolar disorder after lamotrigine or lithium use during pregnancy: A population-based cohort study. ( Bergink, V; Clark, CT; Kushner, SA; Liu, X; Munk-Olsen, T; Wesseloo, R, 2017) |
| "Here, we present the outcomes in the subset of six women who were treated with lamotrigine 100-400 mg/day for the entire pregnancy." | 3.83 | Maternal and Fetal Outcomes After Lamotrigine Use in Pregnancy: A Retrospective Analysis from an Urban Maternal Mental Health Centre in New Zealand. ( Hatters-Friedman, S; Moller-Olsen, C; North, A; Prakash, C, 2016) |
| "To examine the occurrence of menstrually-entrained mood cycling in women with treated bipolar disorder as compared to healthy controls, and to explore whether there is a specific effect of lamotrigine in dampening menstrually-entrained cyclicity of mood." | 3.81 | Lamotrigine and GABAA receptor modulators interact with menstrual cycle phase and oral contraceptives to regulate mood in women with bipolar disorder. ( Holtzman, J; Kenna, HA; Rasgon, NL; Reynolds-May, MF; Robakis, TK; Stemmle, PG, 2015) |
| "Lamotrigine is licensed for treatment of epilepsy and prevention or at least delay of depressive episodes in bipolar disorder." | 3.81 | Retrospective analysis of therapeutic drug monitoring data for treatment of bipolar disorder with lamotrigine. ( Haen, E; Unholzer, S, 2015) |
| "Lamotrigine and lithium were superior to placebo for time to intervention for any mood episode (median survival: placebo, 86 days [95% CI = 58 to 121]; lithium, 184 days [95% CI = 119 to not calculable]; lamotrigine, 197 days [95% CI = 144 to 388])." | 3.81 | A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. ( Bowden, CL; Calabrese, JR; Goodwin, GM; Greene, P; Grunze, H; Kasper, S; Leadbetter, R; White, R, 2004) |
| "The objective of the current study was to assess, in a naturalistic treatment setting, the clinical benefits of lamotrigine add-on therapy for patients with bipolar disorder." | 3.80 | Observational study to evaluate the clinical benefit of lamotrigine add-on therapy in bipolar patients in a naturalistic treatment setting. ( Bahk, WM; Jeong, JH; Jon, DI; Kim, MD; Koo, BH; Lee, JG; Pae, CU; Woo, YS, 2014) |
| "Results are encouraging in identifying a generally positive acceptance of a diagnosis of bipolar disorder, improved outcome following the introduction of diagnostic-specific management components, and a distinctive contribution of lamotrigine to improved three-month outcome." | 3.80 | The impact of being newly diagnosed with a bipolar disorder and the short-term outcome of disorder-specific management. ( Fletcher, K; Friend, P; Futeran, SM; Graham, RK; Parker, GB, 2014) |
| "Lithium is a first line option in the maintenance treatment of bipolar disorder, but several alternative treatment regimens have been introduced in recent years, among them treatment with antiepileptic compounds and atypical antipsychotic drugs." | 3.80 | [Changes in prescription patterns to patients with bipolar syndromes. Increased use of lamotrigine and decreased use of lithium]. ( Karanti, A; Kardell, M; Landén, M; Lundberg, U, 2014) |
| "Little information is available on the need for dosage changes for lamotrigine in pregnant women with bipolar disorder." | 3.79 | Lamotrigine dosing for pregnant patients with bipolar disorder. ( Clark, CT; Helsel, J; Klein, AM; Perel, JM; Wisner, KL, 2013) |
| "Patients with major affective disorders are more likely to complete suicide than patients in any other medical group." | 3.79 | Anticonvulsant therapy and suicide risk in affective disorders. ( Goodwin, FK, 1999) |
| "Lamotrigine was superior to placebo after 3 weeks as assessed by changes in the Montgomery-Asberg Depression Rating Scale (MADRS)." | 3.79 | Lamotrigine in the treatment of bipolar depression. ( Bowden, CL; Mitchell, P; Suppes, T, 1999) |
| "It is not clear whether the effectiveness of lamotrigine versus lithium differs for patients with bipolar disorder treated in clinical practice." | 3.78 | An observational nationwide register based cohort study on lamotrigine versus lithium in bipolar disorder. ( Andersen, PK; Hellmund, G; Kessing, LV, 2012) |
| " The present study examines the hypothesis that the three antiepileptics approved for bipolar disorder (carbamazepine, lamotrigine, and valproate) are associated with an elevated risk of suicide attempts and suicides." | 3.78 | Antiepileptic drugs for bipolar disorder and the risk of suicidal behavior: a 30-year observational study. ( Coryell, WH; Endicott, J; Fiedorowicz, JG; Keller, MB; Leon, AC; Li, C; Solomon, DA, 2012) |
| "Assess quetiapine plus lamotrigine (QTP+LTG) combination maintenance therapy effectiveness in challenging bipolar disorder (BD)." | 3.78 | Effectiveness of quetiapine plus lamotrigine maintenance therapy in challenging bipolar disorder patients. ( Brooks, JO; Childers, ME; Hoblyn, JC; Ittasakul, P; Johnson, KR; Ketter, TA; Srivastava, S, 2012) |
| "The purpose of this case series is to characterize a recently identified association of the antiepileptic drug (AED) lamotrigine with aseptic meningitis based on cases reported to the Food and Drug Administration (FDA)'s Adverse Event Reporting System (AERS) database." | 3.78 | Lamotrigine and aseptic meningitis. ( Avigan, M; Kortepeter, C; Simms, KM, 2012) |
| "The use of lamotrigine is a point of discrepancy among the diverse guidelines published on the management of bipolar disorder (BD)." | 3.78 | Clinical factors leading to lamotrigine prescription in bipolar outpatients: subanalysis of the SIN-DEPRES study. ( Balanzá-Martínez, V; Cobaleda, S; de Arce, R; Franch Valverde, JI; Grande, I; Iglesias Lorenzo, FG; Jiménez-Arriero, M; Vieta, E; Zaragoza, S, 2012) |
| "Lamotrigine and quetiapine are commonly used in bipolar disorder, but there are no published systematic studies of their use in combination for treatment-resistant bipolar depression." | 3.77 | Lamotrigine plus quetiapine combination therapy in treatment-resistant bipolar depression. ( Ahn, YM; Bonner, JC; Culver, JL; Ketter, TA; Marsh, WK; Nam, JY, 2011) |
| " Although there are rare reports of lamotrigine-associated aseptic meningitis, this is only the second confirmed by re-exposure to the medication." | 3.76 | Lamotrigine: an unusual etiology for aseptic meningitis. ( Edelson, DP; Lam, GM; Whelan, CT, 2010) |
| "To examine the treatment impact of lamotrigine on the neurocognitive profile of patients with pediatric bipolar disorder (PBD)." | 3.76 | Enhanced working and verbal memory after lamotrigine treatment in pediatric bipolar disorder. ( Carbray, JA; Mohammed, T; Passarotti, AM; Pavuluri, MN; Sweeney, JA, 2010) |
| "This was a 12-week, open-label, prospective trial of lamotrigine monotherapy to assess the effectiveness and tolerability of this compound in treating pediatric bipolar disorder." | 3.76 | A prospective open-label trial of lamotrigine monotherapy in children and adolescents with bipolar disorder. ( Biederman, J; Doyle, R; Georgiopoulos, A; Hammerness, P; Joshi, G; Kotarski, M; Mick, E; Williams, C; Wozniak, J, 2010) |
| "A bipolar disorder patient stabilized on lamotrigine 200 mg total daily dose was admitted to the hospital with end-stage renal disease." | 3.76 | Lamotrigine and hemodialysis in bipolar disorder: case analysis of dosing strategy with literature review. ( Kaufman, KR, 2010) |
| "Data were analyzed from two completed studies: an open-label trial of lamotrigine in patients with bipolar disorder (BPD) and cocaine-related disorder, and a placebo-controlled trial of quetiapine in patients with BPD and alcohol-related disorders." | 3.75 | Attrition factors in clinical trials of comorbid bipolar and substance-related disorders. ( Brown, ES; Nomamiukor, N, 2009) |
| "Overall there has been a slight increase in the use of lamotrigine in Norway during the last four years, most likely prescribed as a mood stabilizer in bipolar disorders." | 3.75 | The use of lithium, valproate or lamotrigine for psychiatric conditions in children and adolescents in Norway 2004-2007 - a prescription database study. ( Bramness, JG; Engeland, A; Furu, K; Grøholt, B, 2009) |
| "The aim of this study was to test the effectiveness and safety of lamotrigine in maintenance of manic and depressive symptom control in pediatric bipolar disorder (PBD)." | 3.75 | Effectiveness of lamotrigine in maintaining symptom control in pediatric bipolar disorder. ( Carbray, JA; Henry, DB; Mohammed, T; Moss, M; Pavuluri, MN; Sweeney, JA, 2009) |
| "Aseptic meningitis could be a rare side effect of lamotrigine." | 3.75 | Lamotrigine-induced aseptic meningitis: a case report. ( Abraham, MN; Egbert, M; Green, MA; Horn, AJ; Sharma, A; Yates, TE, 2009) |
| "Using a retrospective chart review, we identified six patients with epilepsy who reported transient emergent psychological symptoms during stable, chronic lamotrigine monotherapy." | 3.75 | End-of-dose emergent psychopathology in ambulatory patients with epilepsy on stable-dose lamotrigine monotherapy: a case series of six patients. ( Frey, LC; Shrestha, A; Spitz, MC; Strom, LA, 2009) |
| " The patient had bipolar disorder and was on lithium, lamotrigine, and ziprasidone." | 3.75 | Brugada syndrome unmasked by lithium. ( Chandra, AB; Chandra, PA, 2009) |
| " In this paper, we review the case of studies with lamotrigine in bipolar disorder, describing evidence of lack of efficacy in multiple mood states outside of the primary area of efficacy (prophylaxis of mood episodes)." | 3.74 | Publication bias and the pharmaceutical industry: the case of lamotrigine in bipolar disorder. ( Filkowski, M; Nassir Ghaemi, S; Shirzadi, AA, 2008) |
| "To report two cases of mouth ulcers in lamotrigine patients after oxcarbazepine withdrawal." | 3.74 | Two case reports of oral ulcers with lamotrigine several weeks after oxcarbazepine withdrawal. ( de Leon, J; O'Neill, A, 2007) |
| "Chronic lamotrigine, which is effective in the depressive phase or rapid cycling bipolar disorder does not alter brain arachidonic acid turnover in the unanesthetized rat." | 3.74 | Chronic lamotrigine does not alter the turnover of arachidonic acid within brain phospholipids of the unanesthetized rat: implications for the treatment of bipolar disorder. ( Bazinet, RP; Chang, L; Lee, HJ; Rao, JS; Rapoport, SI, 2007) |
| "Lamotrigine has been found to be efficacious in the acute management of bipolar depression and long-term management of bipolar disorder, especially in delaying depressive recurrence, either as monotherapy or as adjunctive therapy." | 3.74 | Antidepressant-like effect of lamotrigine is reversed by veratrine: a possible role of sodium channels in bipolar depression. ( Bourin, M; Hascoet, M; Prica, C, 2008) |
| " Lower doses of valproate and carbamazepine were required to prevent hyperactivity compared to doses required to block tonic-clonic seizures induced by pentylenetetrazole." | 3.73 | Evaluation of the effects of lamotrigine, valproate and carbamazepine in a rodent model of mania. ( Arban, R; Brackenborough, K; Gerrard, P; Large, C; Maraia, G; Wilson, A; Winyard, L, 2005) |
| "The charts of 587 adult outpatients with a primary diagnosis of bipolar disorder who received treatment with lamotrigine in a private practice setting between July 1998 and May 2004 were reviewed retrospectively." | 3.73 | Efficacy and safety of lamotrigine for adults with bipolar disorder in a private practice setting. ( Ginsberg, LD, 2006) |
| "Our aim was to evaluate the effectiveness, safety, and tolerability of adjunctive lamotrigine in the treatment of adolescents with bipolar disorder." | 3.73 | Adjunctive lamotrigine treatment for adolescents with bipolar disorder: retrospective report of five cases. ( Díez-Suárez, A; Figueroa-Quintana, A; Soutullo, CA, 2006) |
| "To obtain pilot data in an observational setting on the use of lamotrigine plus lithium in the long-term treatment of patients with bipolar disorder, 87% of whom had failed to respond to at least one previous mood stabilizer." | 3.73 | Long-term lamotrigine plus lithium for bipolar disorder: One year outcome. ( Berv, DA; Ghaemi, SN; Goodwin, FK; Klugman, J; Pardo, TB; Schrauwen, E; Shirzadi, AA, 2006) |
| "To assess the efficacy of lamotrigine combined with either divalproex or lithium for the treatment of bipolar disorder." | 3.73 | Lamotrigine combined with divalproex or lithium for bipolar disorder: a case series. ( Bowden, CL; Jamison, KL; Redmond, JR, 2006) |
| "Recent reports suggesting lamotrigine as an effective treatment in bipolar disorder, and perhaps borderline personality disorder, a common comorbid personality disorder in bipolar patients, led us to retrospectively examine patients from two bipolar studies to investigate this pattern of comorbidity, and to determine whether lamotrigine effected the dimensions of borderline personality." | 3.72 | Borderline personality disorder in patients with bipolar disorder and response to lamotrigine. ( Hedges, DW; Marchant, BK; Preston, GA; Reimherr, FW; Strong, RE, 2004) |
| " As part of a large study on the use of lamotrigine in patients with bipolar disorder and cocaine dependence, the frequency and nature of drug dreams, triggers for dreams, and response to the dreams during study participation were assessed in 37 outpatients for as long as 36 weeks." | 3.72 | Drug dreams in outpatients with bipolar disorder and cocaine dependence. ( Brown, ES; Dhanani, N; Perantie, DC; Yee, T, 2004) |
| "This case suggests the potential utility of lamotrigine in treatment-resistant menstrually-related rapid cycling bipolar disorder, and raises the possibility that lamotrigine might be able to treat pathological entrainment of mood with the menstrual cycle." | 3.72 | Lamotrigine therapy in treatment-resistant menstrually-related rapid cycling bipolar disorder: a case report. ( Becker, OV; Glenn, T; Ketter, TA; Marsh, WK; Rasgon, NL, 2004) |
| "This study attempts to provide real-world evidence of the economic value of lamotrigine as a mood stabilizer for patients with bipolar disorder." | 3.72 | The economic value of lamotrigine as a mood stabilizer: a U.S. managed care perspective. ( Krishnan, AA; Simons, WR, 2004) |
| "To study the effectiveness of adding lamotrigine to the treatment of inpatient geriatric patients with bipolar disorder (BD) who were in the depressed phase and had been on lithium and valproate for at least 3 months." | 3.71 | Lamotrigine use in geriatric patients with bipolar depression. ( Conn, DK; Robillard, M, 2002) |
| "We present the case of a 17-year-old woman with a history of bipolar disorder, who developed a clinical syndrome manifested by fever, lymphadenopathy, skin rash, diarrhea, and acute renal failure requiring dialysis after the use of lamotrigine." | 3.70 | Acute granulomatous interstitial nephritis and colitis in anticonvulsant hypersensitivity syndrome associated with lamotrigine treatment. ( Fervenza, FC; Gibney, R; Kanakiriya, S; Kunau, RT; Lager, DJ, 2000) |
| " All the studies identified LAM as an effective and safe drug in PMDs especially, BDs." | 3.01 | Efficacy and safety of lamotrigine in pediatric mood disorders: A systematic review. ( Ahern, K; Athreya, AP; Croarkin, PE; Garzon, J; Hassett, LC; Kumar, R; Ozger, C; Oztosun, C; Saliba, M; Singh, B; Vande Voort, JL; Yuruk, D, 2023) |
| " The changes in the depressive rating scale, remission/response rates, nervous system adverse events (NSAEs), gastrointestinal adverse events (GIAEs), metabolic parameters, and prolactin were compared between medication and placebo or among medications with the Cohen's d or number needed to treat/harm." | 3.01 | Efficacy and safety profiles of mood stabilizers and antipsychotics for bipolar depression: a systematic review. ( Bai, Y; Cai, L; Chen, G; Yang, H, 2023) |
| "Lamotrigine was associated with higher odds of treatment response compared with placebo in the melancholic subgroup but not in the nonmelancholic subgroup." | 2.87 | Melancholic Symptoms in Bipolar II Depression and Responsiveness to Lamotrigine in an Exploratory Pilot Study. ( Balbuena, L; Bowen, R; Peters, EM, 2018) |
| "Lamotrigine levels were unaffected by FA and did not differ between those participants who achieved remission and those with persisting symptoms." | 2.84 | Biochemical and genetic predictors and correlates of response to lamotrigine and folic acid in bipolar depression: Analysis of the CEQUEL clinical trial. ( Attenburrow, MJ; Gardiner, A; Geddes, JR; Goodwin, GM; Harrison, PJ; Hinds, C; Rendell, JM; Tunbridge, EM, 2017) |
| "The diagnoses were major depressive disorder (n = 15), bipolar I disorder (n = 6), and bipolar II disorder (n = 16)." | 2.82 | Prediction of an Optimal Dose of Lamotrigine for Augmentation Therapy in Treatment-Resistant Depressive Disorder From Plasma Lamotrigine Concentration at Week 2. ( Kagawa, S; Kondo, T; Mihara, K; Nagai, G; Nakamura, A; Nemoto, K; Suzuki, T, 2016) |
| "In a pilot study, 29 outpatients with bipolar depression on a stable lamotrigine dose regimen received placebo or memantine pills daily (titrated up by 5 mg week⁻¹ to 20 mg) in a randomized, double-blind, parallel group, 8 week study." | 2.78 | Bayesian model of Hamilton Depression Rating Score (HDRS) with memantine augmentation in bipolar depression. ( Anand, A; Bies, RR; Shekhar, A; Stevens, J, 2013) |
| " Safety and tolerability results revealed no unexpected adverse events for ARI combination with LTG." | 2.77 | Aripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double-blind study (CN138-392). ( Carlson, BX; Ketter, TA; Marcus, R; McQuade, RD; Sanchez, R; Sun, W; Timko, K; Vester-Blokland, E, 2012) |
| "In patients with bipolar depression, despite continued use of lithium, addition of lamotrigine revealed a continued benefit compared to placebo throughout the entire study." | 2.76 | Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design. ( Blom, MB; Hartong, EG; Mulder, P; Nolen, WA; Timmermans, MA; van der Loos, ML; van Noorden, MS; Vergouwen, AC; Vieta, E, 2011) |
| "Lamotrigine was added to prior treatment in a naturalistic fashion." | 2.75 | Adjunctive lamotrigine therapy for patients with bipolar II depression partially responsive to mood stabilizers. ( Cha, B; Chang, JS; Ha, K; Moon, E, 2010) |
| "Lamotrigine was better tolerated than lithium, but apparently this did not influence the outcome." | 2.75 | Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). ( Bendz, H; Gram, LF; Licht, RW; Nielsen, JN; Vestergaard, P, 2010) |
| " Blood samples were collected on Days -1 and 14 for determination of lamotrigine steady-state pharmacokinetic parameters." | 2.74 | A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder. ( Balch, AH; Benson, J; Boulton, DW; Carlson, BX; Croop, R; Mallikaarjun, S; Schieber, FC, 2009) |
| "Lamotrigine was found effective and safe as add-on treatment to lithium in the acute treatment of bipolar depression." | 2.74 | Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. ( Blom, MB; de Keyzer, HJ; Hartong, EG; Luteijn, ML; Mulder, PG; Nolen, WA; Notten, PJ; Timmermans, MA; van der Loos, ML; Vergouwen, AC; Vieta, E, 2009) |
| "Lamotrigine was added to the current therapy regime for DSM-IV bipolar I patients on an open-label basis for 12 weeks." | 2.74 | Rash in adult patients receiving lamotrigine to treat bipolar I disorder in Korea: a multicenter, prospective, naturalistic, open-label trial. ( Ahn, YM; Bahk, WM; Chung, SK; Jon, DI; Joo, YH; Jung, SH; Kim, W; Kim, Y; Lee, YS; Min, KJ; Seo, JS; Seok, JH; Shin, YC; Won, SH; Woo, YS; Yoon, BH, 2009) |
| "lamotrigine in bipolar depression not responding to conventional antidepressants." | 2.73 | Tranylcypromine vs. lamotrigine in the treatment of refractory bipolar depression: a failed but clinically useful study. ( Altshuler, LL; Frye, MA; Grunze, H; Hellemann, G; Keck, PE; Kupka, RW; Leverich, GS; McElroy, S; Mintz, J; Nolen, WA; Post, RM; Suppes, T, 2007) |
| "Lamotrigine was given for 12 weeks, with a target dosage of 200 mg/d." | 2.73 | Effect of open-label lamotrigine as monotherapy and adjunctive therapy on the self-assessed cognitive function scores of patients with bipolar I disorder. ( Graham, J; Kaye, NS; Nanry, K; Roberts, J; Thompson, T, 2007) |
| "Aripiprazole is an atypical antipsychotic compound that is approved by the U." | 2.73 | Aripiprazole therapy in 20 older adults with bipolar disorder: a 12-week, open-label trial. ( Blow, FC; Cassidy, KA; Coconcea, N; Hays, RW; Ignacio, RV; Meyer, WJ; Sajatovic, M, 2008) |
| "Lamotrigine and lithium were effective monotherapy for BDII depression, with comparable response and remission rates." | 2.73 | A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. ( Al Jurdi, R; Bernstein, IH; Fischer, EG; Gonzalez, R; Kelly, DI; Marangell, LB; Martinez, M; Shivakumar, G; Snow, DE; Suppes, T; Sureddi, S; Zboyan, HA, 2008) |
| "The high risk of bipolar depression during pregnancy encourages consideration of lamotrigine (LTG)." | 2.73 | Lamotrigine in bipolar disorder: efficacy during pregnancy. ( Baldessarini, RJ; Calamaras, MR; Juric, S; Knight, B; Newport, DJ; Pennell, PB; Stowe, ZN; Viguera, AC, 2008) |
| "Lamotrigine treatment induced a decrease in total HAMD scores in bipolar depressed patients, which was not significantly correlated with reduction of platelet MAO-B activity." | 2.73 | The effect of lamotrigine on platelet monoamine oxidase type B activity in patients with bipolar depression. ( Babic, A; Jakovljevic, M; Mihaljevic Peles, A; Muck-Seler, D; Mustapic, M; Nedic, G; Pivac, N; Sagud, M, 2008) |
| "Both lamotrigine and lithium were more effective than placebo in delaying the time to intervention for any mood episode (depression, mania, hypomania, or mixed) when relapses that occurred in the first 90 days were excluded from the analyses (p = ." | 2.72 | Recurrence in bipolar I disorder: a post hoc analysis excluding relapses in two double-blind maintenance studies. ( Calabrese, JR; DeVeaugh-Geiss, A; Frye, M; Goldberg, JF; Ketter, TA; Suppes, T; Thompson, TR; White, R, 2006) |
| "Lamotrigine treatment was well tolerated in this sample and associated with statistically significant improvement in mood and drug cravings but not drug use." | 2.71 | Lamotrigine in patients with bipolar disorder and cocaine dependence. ( Bobadilla, L; Brown, ES; Nejtek, VA; Orsulak, PJ; Perantie, DC, 2003) |
| "Both lamotrigine and lithium were superior to placebo at prolonging the time to intervention for any mood episode (lamotrigine vs placebo, P =." | 2.71 | A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. ( Asghar, SA; Bowden, CL; Calabrese, JR; DeVeaugh-Geiss, J; Earl, N; Hompland, M; Montgomery, P; Sachs, G; Smoot, TM; Yatham, LN, 2003) |
| "Lamotrigine was statistically superior to placebo at prolonging the time to intervention for a depressive episode (p = ." | 2.71 | A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. ( Ascher, J; Behnke, K; Bowden, CL; Calabrese, JR; DeVeaugh-Geiss, J; Earl, N; Mehtonen, OP; Montgomery, P; Paska, W; Sachs, G; Yatham, LN, 2003) |
| "Lamotrigine has demonstrated efficacy for the acute treatment of depression in bipolar I patients in a placebo-controlled, monotherapy study." | 2.71 | A 52-week, open-label continuation study of lamotrigine in the treatment of bipolar depression. ( Ascher, J; Cookson, J; Greene, P; Huffman, RF; McElroy, SL; Suppes, T; Zarate, CA, 2004) |
| "While both unipolar and bipolar depression have serious detrimental effects on patient QOL, our results suggest that some aspects of QOL may be worse in bipolar depression." | 2.71 | Quality of life in patients with bipolar I depression: data from 920 patients. ( Davis, KH; Fieve, RR; Harris, SD; Krishnan, AA; Lecrubier, Y; Yatham, LN, 2004) |
| "Treatment with lamotrigine as monotherapy and as adjunctive therapy was associated with improved cognitive functioning and reduced neurocognitive side effects, regardless of index mood polarity." | 2.71 | Effect of lamotrigine on cognitive complaints in patients with bipolar I disorder. ( Adams, BE; Asnis, GM; Davis, KH; Ginsberg, LD; Goodwin, FK; Khan, A; Krishnan, AA, 2004) |
| "Lamotrigine is a new anticonvulsant with few side effects that may have mood-stabilizing and elevating effects." | 2.68 | The anticonvulsant lamotrigine in treatment-resistant manic-depressive illness. ( Sachs, G; Sporn, J, 1997) |
| "Lamotrigine was used at a mean +/- SD dose of 185." | 2.68 | Lamotrigine in rapid-cycling bipolar disorder. ( Calabrese, JR; Fatemi, SH; Rapport, DJ; Thuras, P, 1997) |
| "Although mania defines bipolar I disorder, depressive episodes and symptoms dominate the longitudinal course of, and disproportionately account for morbidity and mortality in, bipolar disorders." | 2.66 | Bipolar disorders. ( Berk, M; Brietzke, E; Goldstein, BI; Kessing, LV; López-Jaramillo, C; Majeed, A; Malhi, GS; Mansur, RB; McIntyre, RS; Nierenberg, AA; Rosenblat, JD; Vieta, E; Vinberg, M; Young, AH, 2020) |
| "Vocal tremor is a neurologic disorder with myriad etiologies (eg, Parkinson disease, medications, or essential tremor)." | 2.61 | An Unusual Etiology of Vocal Tremor in a Professional Singer. ( Francis, DO; Hopewell, BL; Paige, C, 2019) |
| " For optimal dosing in pregnancy, therapeutic drug monitoring may be required to maintain effective drug concentrations." | 2.58 | Treatment of Peripartum Bipolar Disorder. ( Clark, CT; Wisner, KL, 2018) |
| "The lamotrigine level was 78." | 2.52 | Evolving Electrocardiographic Changes in Lamotrigine Overdose: A Case Report and Literature Review. ( Casso Dominguez, A; Chavez, P; Herzog, E, 2015) |
| " This systematic review aimed to assess the prevalence of their adverse effects (AEs) and to provide recommendations on their clinical management." | 2.52 | Management of adverse effects of mood stabilizers. ( Hidalgo, D; León-Caballero, J; Murru, A; Pacchiarotti, I; Popovic, D; Vieta, E, 2015) |
| "Treatment options for bipolar depression have increased over the last decade, most notably with regulatory approval for olanzapine/fluoxetine combination, quetiapine, and lurasidone." | 2.50 | Current landscape, unmet needs, and future directions for treatment of bipolar depression. ( Alarcon, RD; Biernacka, JM; Bobo, WV; Choi, DS; Frye, MA; Kung, S; Moore, KM; Prieto, ML; Tye, SJ; Veldic, M, 2014) |
| "Lamotrigine was considered to have mixed support." | 2.47 | Pharmacotherapy for the treatment of acute bipolar II depression: current evidence. ( Swartz, HA; Thase, ME, 2011) |
| "In the pharmacotherapy for bipolar depression, quetiapine (300 mg/day), lithium (more than 0." | 2.47 | [Evidence of treatment for depressive episodes of bipolar disorder]. ( Yamada, K, 2011) |
| "Their efficacy in bipolar depression has not always been confirmed in more recent and methodologically more reliable studies." | 2.47 | [Lithium and anticonvulsants in bipolar depression]. ( Llorca, PM; Nourry, A; Samalin, L, 2011) |
| "Lamotrigine has been shown to be useful in the long-term prophylaxis of depressive episodes in BD." | 2.45 | Lamotrigine-associated rash: to rechallenge or not to rechallenge? ( Bhagwagar, Z; Lorberg, B; Youssef, NA, 2009) |
| " In the present paper, I review studies in unanaesthetized rats using a neuropharmacological approach, combined with kinetic, biochemical and molecular biology techniques, demonstrating that chronic administration of three commonly used mood stabilizers (lithium, valproic acid and carbamazepine), at therapeutically relevant doses, selectively target the brain arachidonic acid cascade." | 2.45 | Is the brain arachidonic acid cascade a common target of drugs used to manage bipolar disorder? ( Bazinet, RP, 2009) |
| "A major challenge in the treatment of bipolar depression is the tendency for antidepressant medications, particularly tricyclic antidepressants, to precipitate episodes of mania, or to increase cycle frequency or symptom intensity." | 2.44 | The role of mood stabilisers in the treatment of the depressive facet of bipolar disorders. ( Bourin, M; Prica, C, 2007) |
| "Lamotrigine has obtained approval in several countries for the indication of preventing bipolar depressive episodes, which raises the question of differential efficacy of other antiepileptic drugs as mood stabilizers in the prevention of either depressive or hypo-/manic episodes." | 2.44 | Antiepileptic drugs and mood stability. ( Amann, B; Grunze, H; Trimble, M; Vieta, E, 2007) |
| "The diagnosis and management of bipolar depression are challenging, and many patients are undiagnosed or misdiagnosed due to symptom similarities with unipolar depression or other illnesses and/or comorbidities." | 2.43 | Challenges in the management of bipolar depression. ( Kelly, DI; Perla, JM; Suppes, T, 2005) |
| " Also discussed are findings concerning the continuation of acute treatments, including antidepressants, into the maintenance phase; dosage adjustments for maintenance treatment; the rationale for combination treatments; and implications of comorbid substance abuse and strategies for its management." | 2.43 | Maintenance treatment of bipolar disorder: Applying research to clinical practice. ( Chou, JC; Fazzio, L, 2006) |
| "However, the treatment of bipolar depression is hampered by the limited number and varying quality of available studies of pharmacologic treatments to guide clinical decision making." | 2.43 | The evidence for antidepressant use in bipolar depression. ( Ostacher, MJ, 2006) |
| "Lamotrigine was primarily effective against depression and lithium was primarily effective against mania." | 2.42 | Latest maintenance data on lamotrigine in bipolar disorder. ( Calabrese, JR; Shelton, MD; Vieta, E, 2003) |
| "Lamotrigine was generally well tolerated in maintenance studies with the most common adverse events being headache, nausea, infection and insomnia." | 2.42 | Lamotrigine: a review of its use in bipolar disorder. ( Goldsmith, DR; Ibbotson, T; Perry, CM; Wagstaff, AJ, 2003) |
| "Lamotrigine has a variable profile in kindling and contingent tolerance experiments and does not appear to have robust gamma-aminobutyric acid or monoaminergic actions." | 2.42 | Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders. ( Ketter, TA; Manji, HK; Post, RM, 2003) |
| " The most common adverse event with lamotrigine was headache." | 2.42 | Safety and tolerability of lamotrigine for bipolar disorder. ( Asnis, GM; Bentley, B; Bowden, CL; Ginsberg, LD; Leadbetter, R; White, R, 2004) |
| "Lamotrigine has a side-effect profile compatible with treatment adherence and is well tolerated in combination therapy." | 2.42 | Depression mood stabilisation: novel concepts and clinical management. ( Calabrese, JR, 2004) |
| "Lamotrigine has demonstrated efficacy in delaying time to depressive relapse." | 2.42 | Rethinking the treatment paradigm for bipolar depression: the importance of long-term management. ( Baldassano, CF; Ballas, CA; O'Reardon, JP, 2004) |
| "Lamotrigine has also demonstrated significant efficacy in recent studies and has been approved by the FDA." | 2.42 | Bipolar depression: an overview. ( Oral, ET; Vahip, S, 2004) |
| "Lamotrigine has emerged as a first line treatment for bipolar depression, which is an area of weakness for other mood stabilizers." | 2.42 | Separate and concomitant use of lamotrigine, lithium, and divalproex in bipolar disorders. ( Goodwin, FK; Lieberman, DZ, 2004) |
| "Lamotrigine has been found to have acute efficacy in treating episodes of bipolar depression without increasing cycling or provoking a switch into mania, as well as a long-term role in delaying relapse and recurrence of depressive episodes." | 2.41 | Long-term treatment of bipolar disorder with lamotrigine. ( Calabrese, JR; Elhaj, O; Kimmel, SE; Rapport, DJ; Shelton, MD, 2002) |
| "Serious drug eruptions associated with lamotrigine were rare." | 2.41 | Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. ( Bowden, CL; Calabrese, JR; Frye, MA; Goldberg, JF; Goodwin, FK; Kusumakar, V; Sachs, GS; Shelton, MD; Sullivan, JR; Suppes, T, 2002) |
| "Lamotrigine has demonstrated efficacy in both acute bipolar depression and maintenance efficacy in rapid cycling bipolar patients, especially those patients with bipolar II disorder, which is principally manifested as depression." | 2.41 | Novel treatments for bipolar disorder. ( Bowden, CL, 2001) |
| "Topiramate has shown encouraging results in both depressed and manic bipolar patients, and it may also promote weight loss." | 2.41 | Bipolar disorders and the effectiveness of novel anticonvulsants. ( Calabrese, JR; Kimmel, SE; Rapport, DJ; Shelton, MD, 2002) |
| " In an attempt to replicate and extend these preliminary open-label prospective findings, a series of multicenter, double-blind, placebo-controlled studies evaluating the efficacy and dose-response relationships of lamotrigine in the various phases of the illness, including both acute and maintenance designs in both bipolar I and II disorder, is ongoing." | 2.40 | Clinical studies on the use of lamotrigine in bipolar disorder. ( Calabrese, JR; Kimmel, SE; Kujawa, M; Rapport, DJ; Shelton, MD, 1998) |
| "Prescribed drugs for the treatment of bipolar disorder, including mood stabilizers (i." | 1.72 | Prescribing changes for bipolar patients discharged from two public psychiatric hospitals in Taiwan, 2006-2019. ( Chan, HY; Chen, CC; Chou, FH; Lin, CH, 2022) |
| "Lithium carbonate was associated with increased risks of rash (PT), drug interaction (PT), and tubulointerstitial diseases (SMQ)." | 1.72 | Analysis of adverse drug events in patients with bipolar disorders using the Japanese Adverse Drug Event Report database. ( Nabekura, T; Uwai, Y, 2022) |
| "Lamotrigine is a useful treatment in bipolar depression but requires several weeks of dose titration before its clinical effects can be assessed." | 1.51 | Changes in brain Glx in depressed bipolar patients treated with lamotrigine: A proton MRS study. ( Bargiotas, T; Cowen, PJ; Emir, UE; Godlewska, BR; Masaki, C, 2019) |
| "The dosage and frequency of lamotrigine administration for each patient must be prescribed carefully according to the disease, age, concomitant medications, and administration period." | 1.48 | A Standard Intervention Practice to Promote Appropriate Lamotrigine Therapy by Pharmacists. ( Itabe, H; Okada, N; Sasaki, T; Shimamura, H; Tanaka, K; Uchikura, T; Yamada, H, 2018) |
| "The diagnoses were major depressive disorder (n = 19), bipolar I disorder (n = 6), and bipolar II disorder (n = 22)." | 1.46 | Both Serum Brain-Derived Neurotrophic Factor and Interleukin-6 Levels Are Not Associated with Therapeutic Response to Lamotrigine Augmentation Therapy in Treatment-Resistant Depressive Disorder. ( Kagawa, S; Kondo, T; Mihara, K; Nagai, G; Nakamura, A; Nemoto, K; Suzuki, T, 2017) |
| "Lamotrigine (LTG) was less successful in those with a parental history of mood disorders or in BP-I compared to BP-II disorder." | 1.43 | Clinical correlates of sustained response to individual drugs used in naturalistic treatment of patients with bipolar disorder. ( Altshuler, LL; Frye, MA; Grunze, H; Keck, PE; Kupka, R; Leverich, GS; McElroy, SL; Nolen, WA; Post, RM; Rowe, M; Suppes, T, 2016) |
| "Treatment with lamotrigine improved the patient's condition." | 1.43 | [Psychogenic non-epileptic seizures: issues of comorbidity in the diagnosis and treatment]. ( Nikolaev, EL; Rezvy, G; SÖrlie, T, 2016) |
| " The objective of the study was to identify pharmacokinetic interactions of different mood stabilizers on the metabolism of risperidone (RIS) under natural conditions." | 1.43 | Pharmacokinetic Drug-Drug Interactions of Mood Stabilizers and Risperidone in Patients Under Combined Treatment. ( Gründer, G; Haen, E; Hiemke, C; Lammertz, SE; Paulzen, M; Schoretsanitis, G; Schruers, KR; Stegmann, B, 2016) |
| "Patients with bipolar depression underwent two-dimensional proton magnetic resonance spectroscopy of the anterior cingulate at baseline (n = 15) and after 12 weeks of lamotrigine treatment (n = 10)." | 1.42 | N-acetylaspartate normalization in bipolar depression after lamotrigine treatment. ( Abulseoud, OA; Baruth, JM; Choi, DS; Croarkin, PE; Frye, MA; Port, JD; Thomas, MA, 2015) |
| "Lamotrigine is an anticonvulsant that appears to have a mainly antidepressant effect and is indicated for the maintenance treatment of bipolar depression." | 1.35 | Lamotrigine-induced obsessional symptoms in a patient with bipolar II disorder: a case report. ( Caykoylu, A; Ekinci, O; Kuloglu, M; Yilmaz, E, 2009) |
| "Pretreatment with lamotrigine significantly attenuated AMPH/CDP-induced effects, but also reduced motility when tested in the presence of CDP-alone." | 1.35 | Effects of neuronal Kv7 potassium channel activators on hyperactivity in a rodent model of mania. ( Nielsen, AN; Redrobe, JP, 2009) |
| "The development of a skin rash is often associated with a rapid escalation of lamotrigine dose." | 1.35 | Feasibility of a slower lamotrigine titration schedule for bipolar depression: a naturalistic study. ( Chang, JS; Ha, K; Ha, TH; Joe, SH; Rim, HD; Won, S, 2009) |
| "Two trials were conducted for bipolar depression (N=410 and 833), and two for manic or mixed episodes (N=136 and 110)." | 1.35 | The empirical redefinition of the psychometric criteria for remission in bipolar disorder. ( Berk, M; Calabrese, JR; Malhi, GS; Mitchell, PB; Ng, F; Tohen, M; Wang, WV, 2008) |
| "These data suggest that non-melancholic bipolar depression is characterized by increased glutamate coupled with increased energy expenditure." | 1.34 | Increased anterior cingulate/medial prefrontal cortical glutamate and creatine in bipolar depression. ( Banakar, S; Chirichigno, JW; Davanzo, P; Elman, S; Fischer, J; Frye, MA; Mintz, J; O'Neill, J; Thomas, MA; Tsuang, J; Ventura, J; Walot, I; Watzl, J, 2007) |
| "Unfortunately, therapy appropriate for unipolar depression can increase the risk of manic switch or cycle acceleration in bipolar disorder, especially in those with a family history of bipolarity and suicide, although some antidepressants may be useful in some bipolar patients." | 1.33 | A different depression: clinical distinctions between bipolar and unipolar depression. ( Bowden, CL, 2005) |
| "Lamotrigine has been shown in randomized controlled studies to be efficacious in preventing bipolar depression and rapid cycling states." | 1.33 | Sustained remission with lamotrigine augmentation or monotherapy in female resistant depressives with mixed cyclothymic-dysthymic temperament. ( Connor, PD; Cunningham, PD; Haykal, RF; Jackson, WC; Long, S; Manning, JS, 2005) |
| "Lamotrigine was well-tolerated and only two patients discontinued due to side effects." | 1.33 | Lamotrigine for the treatment of bipolar spectrum disorder: a chart review. ( Asiel, A; Lahera, G; Montes, JM; Saiz-Ruiz, J, 2005) |
| "Lamotrigine treatment was associated with significant improvements in mood, drug craving, and drug use." | 1.33 | Lamotrigine for bipolar disorder and comorbid cocaine dependence: a replication and extension study. ( Beard, L; Brown, ES; Dhanani, N; Orsulak, P; Perantie, DC; Rush, AJ, 2006) |
| "Lamotrigine is an anticonvulsant and a mood stabiliser that is more effective at preventing depressive relapses than most other mood stabilising drugs." | 1.33 | PHARMAC and treatment of bipolar depression--the limits of utilitarianism. ( Ellis, P; Mulder, R; Porter, R, 2006) |
| " Therefore, the authors summarise adverse events of greatest prevalence and/or greatest severity based on data derived predominately from studies of geriatric patients with epilepsy and/or other non-psychiatric indications." | 1.33 | Safety and tolerability of mood-stabilising anticonvulsants in the elderly. ( Alldredge, B; Fenn, HH; Ketter, TA; Sommer, BR, 2006) |
| "Lamotrigine was added to existing medication regimens." | 1.33 | Effects of lamotrigine in patients with bipolar disorder and alcohol dependence. ( Alamo, C; López-Muñoz, F; Rubio, G, 2006) |
| "Nine patients with acute bipolar depression were simultaneously treated with a course of ECT while titrating lamotrigine for maintenance therapy." | 1.33 | Combined use of lamotrigine and electroconvulsive therapy in bipolar depression: a case series. ( Ostroff, RB; Penland, HR, 2006) |
| "For the management of bipolar depression, new data support quetiapine monotherapy as a first-line option." | 1.33 | Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. ( Beaulieu, S; Kennedy, SH; MacQueen, G; McIntyre, RS; O'Donovan, C; Parikh, SV; Sharma, V; Yatham, LN, 2006) |
| "Lamotrigine was generally well tolerated in maintenance studies with the most common adverse events being headache, nausea, infection and insomnia." | 1.32 | Spotlight on lamotrigine in bipolar disorder. ( Goldsmith, DR; Ibbotson, T; Perry, CM; Wagstaff, AJ, 2004) |
| "Lamotrigine is an anticonvulsant with an efficacy profile in psychiatric disorders different from those of valproate, carbamazepine and gabapentine." | 1.31 | [Lamotrigine in the treatment of mental disorders]. ( Fladvad, T; Malt, UF, 2001) |
| "Psychopharmacology research aims to expand the therapeutic ratio between efficacy, on the one hand, and adverse events and safety, on the other." | 1.31 | Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited. ( McIntyre, RS, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 36 (7.44) | 18.2507 |
| 2000's | 257 (53.10) | 29.6817 |
| 2010's | 159 (32.85) | 24.3611 |
| 2020's | 32 (6.61) | 2.80 |
| Authors | Studies |
|---|---|
| Ho, AM | 2 |
| Weinshilboum, RM | 2 |
| Frye, MA | 17 |
| Biernacka, JM | 3 |
| Hashimoto, Y | 2 |
| Kotake, K | 1 |
| Watanabe, N | 2 |
| Fujiwara, T | 1 |
| Sakamoto, S | 1 |
| Gomes, FA | 1 |
| Cerqueira, RO | 1 |
| Lee, Y | 1 |
| Mansur, RB | 3 |
| Kapczinski, F | 2 |
| McIntyre, RS | 6 |
| Yatham, LN | 15 |
| Berk, M | 8 |
| Milev, R | 2 |
| Brietzke, E | 2 |
| Aschenbrenner, DS | 1 |
| Fico, G | 2 |
| Anmella, G | 2 |
| Sagué-Villavella, M | 1 |
| Gomez-Ramiro, M | 2 |
| Hidalgo-Mazzei, D | 2 |
| Vieta, E | 21 |
| Murru, A | 4 |
| Köhler-Forsberg, O | 2 |
| Rohde, C | 2 |
| Nierenberg, AA | 5 |
| Østergaard, SD | 2 |
| Truong, TT | 1 |
| Bortolasci, CC | 2 |
| Kidnapillai, S | 2 |
| Spolding, B | 2 |
| Panizzutti, B | 2 |
| Liu, ZS | 1 |
| Watmuff, B | 1 |
| Kim, JH | 1 |
| Dean, OM | 2 |
| Richardson, M | 1 |
| Walder, K | 2 |
| Kessing, LV | 3 |
| Ziersen, SC | 1 |
| Gerds, T | 1 |
| Budtz-Jørgensen, E | 1 |
| Roosen, L | 1 |
| Sienaert, P | 2 |
| Strawbridge, R | 1 |
| Kurana, S | 1 |
| Kerr-Gaffney, J | 1 |
| Jauhar, S | 1 |
| Kaufman, KR | 2 |
| Yalin, N | 1 |
| Young, AH | 5 |
| Mills, J | 1 |
| Zhuo, C | 1 |
| Zhou, C | 1 |
| Tian, H | 1 |
| Li, Q | 1 |
| Chen, J | 1 |
| Yang, L | 1 |
| Zhang, Q | 1 |
| Li, R | 1 |
| Ma, X | 1 |
| Cai, Z | 1 |
| Chen, G | 2 |
| Xu, Y | 1 |
| Song, X | 1 |
| Kumar, R | 1 |
| Garzon, J | 1 |
| Yuruk, D | 1 |
| Hassett, LC | 1 |
| Saliba, M | 1 |
| Ozger, C | 1 |
| Oztosun, C | 1 |
| Ahern, K | 1 |
| Athreya, AP | 1 |
| Singh, B | 2 |
| Croarkin, PE | 2 |
| Vande Voort, JL | 1 |
| Lin, CH | 2 |
| Chan, HY | 1 |
| Chen, CC | 2 |
| Chou, FH | 1 |
| Salisbury-Afshar, E | 1 |
| Uwai, Y | 1 |
| Nabekura, T | 1 |
| Cai, L | 1 |
| Yang, H | 1 |
| Bai, Y | 2 |
| Chmiel, I | 1 |
| Yildiz, A | 1 |
| Siafis, S | 1 |
| Mavridis, D | 1 |
| Leucht, S | 1 |
| Woo, YS | 4 |
| Yoon, BH | 2 |
| Song, JH | 1 |
| Seo, JS | 2 |
| Nam, B | 1 |
| Lee, K | 1 |
| Lee, J | 1 |
| Jung, YE | 1 |
| Kim, MD | 2 |
| Lee, JG | 3 |
| Wang, SM | 1 |
| Kwon, YJ | 1 |
| Bahk, WM | 4 |
| Clark, CT | 4 |
| Sprague, J | 1 |
| Wisner, KL | 4 |
| Bogen, DL | 1 |
| Gao, K | 8 |
| Arnold, JG | 1 |
| Prihoda, TJ | 1 |
| Quinones, M | 2 |
| Singh, V | 4 |
| Schinagle, M | 1 |
| Conroy, C | 3 |
| D'Arcangelo, N | 1 |
| Calabrese, JR | 52 |
| Bowden, CL | 32 |
| Coombes, BJ | 1 |
| Nguyen, TTL | 1 |
| Liu, D | 1 |
| McElroy, SL | 12 |
| Nassan, M | 1 |
| Colby, CL | 1 |
| Larrabee, BR | 1 |
| Usui, K | 1 |
| Yamada, K | 2 |
| Okada, K | 1 |
| Ouchi, R | 1 |
| Nibuya, M | 1 |
| Takahashi, A | 1 |
| Shito, Y | 1 |
| Watanabe, Y | 1 |
| Saeki, H | 1 |
| Suzuki, E | 1 |
| Goldstein, BI | 2 |
| López-Jaramillo, C | 1 |
| Malhi, GS | 3 |
| Rosenblat, JD | 1 |
| Majeed, A | 1 |
| Vinberg, M | 1 |
| Vandevelde, A | 1 |
| Benbrika, S | 1 |
| Madigand, J | 1 |
| Dollfus, S | 1 |
| Parker, G | 4 |
| Ricciardi, T | 1 |
| Tavella, G | 2 |
| Spoelma, MJ | 1 |
| Peters, EM | 2 |
| Lodhi, RJ | 1 |
| Zhang, Y | 2 |
| Li, H | 2 |
| Balbuena, L | 2 |
| de Miquel, C | 1 |
| Manchia, M | 1 |
| Alda, M | 7 |
| Gonzalez-Pinto, A | 1 |
| Carvalho, AF | 1 |
| Kikkawa, A | 1 |
| Kitamura, Y | 1 |
| Aiba, T | 1 |
| Hiraki, K | 1 |
| Sendo, T | 1 |
| Wesseloo, R | 1 |
| Liu, X | 3 |
| Kushner, SA | 1 |
| Munk-Olsen, T | 1 |
| Bergink, V | 1 |
| Patorno, E | 1 |
| Huybrechts, KF | 1 |
| Bateman, BT | 1 |
| Cohen, JM | 1 |
| Desai, RJ | 1 |
| Mogun, H | 1 |
| Cohen, LS | 1 |
| Hernandez-Diaz, S | 1 |
| Oriolo, G | 1 |
| Brugués, A | 1 |
| Pintor, L | 1 |
| Goikolea, JM | 2 |
| Kong, L | 1 |
| Zhou, T | 1 |
| Wang, B | 1 |
| Gao, Z | 1 |
| Wang, C | 1 |
| Tunbridge, EM | 1 |
| Attenburrow, MJ | 2 |
| Gardiner, A | 3 |
| Rendell, JM | 2 |
| Hinds, C | 2 |
| Goodwin, GM | 7 |
| Harrison, PJ | 2 |
| Geddes, JR | 4 |
| Chu, CS | 1 |
| Lan, TH | 1 |
| Chou, PH | 1 |
| Patel, N | 1 |
| Viguera, AC | 2 |
| Baldessarini, RJ | 3 |
| Graham, RK | 2 |
| Parker, GB | 2 |
| Hashizume, H | 1 |
| Kageyama, R | 1 |
| Kaneko, Y | 1 |
| Kagawa, S | 2 |
| Mihara, K | 2 |
| Suzuki, T | 2 |
| Nagai, G | 2 |
| Nakamura, A | 3 |
| Nemoto, K | 2 |
| Kondo, T | 2 |
| Kennedy, SH | 3 |
| Parikh, SV | 3 |
| Schaffer, A | 4 |
| Bond, DJ | 1 |
| Frey, BN | 1 |
| Sharma, V | 6 |
| Rej, S | 1 |
| Beaulieu, S | 3 |
| MacQueen, G | 4 |
| Milev, RV | 1 |
| Ravindran, A | 2 |
| O'Donovan, C | 6 |
| McIntosh, D | 1 |
| Lam, RW | 1 |
| Vazquez, G | 1 |
| Kozicky, J | 1 |
| Kanba, S | 1 |
| Lafer, B | 1 |
| Suppes, T | 20 |
| Malhi, G | 1 |
| Post, RM | 10 |
| Shimamura, H | 1 |
| Yamada, H | 1 |
| Okada, N | 1 |
| Uchikura, T | 1 |
| Tanaka, K | 1 |
| Sasaki, T | 1 |
| Itabe, H | 1 |
| Inaba, T | 1 |
| Sogawa, R | 1 |
| Mizoguchi, Y | 1 |
| Tateishi, H | 1 |
| Kunitake, Y | 1 |
| Kato, TA | 1 |
| Monji, A | 1 |
| Dream, A | 1 |
| Holmgren, H | 1 |
| Merrill, R | 1 |
| Simon, EL | 1 |
| Hopewell, BL | 1 |
| Paige, C | 1 |
| Francis, DO | 1 |
| Bauer, IE | 1 |
| Suchting, R | 1 |
| Cazala, F | 1 |
| Alpak, G | 1 |
| Sanches, M | 1 |
| Nery, FG | 1 |
| Zunta-Soares, GB | 1 |
| Soares, JC | 1 |
| Udawela, M | 1 |
| Connor, T | 1 |
| Sanigorski, A | 1 |
| Crowley, T | 1 |
| Jamain, S | 1 |
| Gray, L | 1 |
| Scarr, E | 1 |
| Leboyer, M | 1 |
| Dean, B | 1 |
| Chang, CF | 1 |
| Chung, KH | 1 |
| Doobay, M | 1 |
| Bowen, R | 1 |
| Gonda, X | 4 |
| Rihmer, Z | 3 |
| Chen, PH | 1 |
| Tsai, SY | 1 |
| Pan, CH | 1 |
| Chang, CK | 1 |
| Su, SS | 1 |
| Kuo, CJ | 1 |
| Simon, J | 2 |
| Rendell, J | 2 |
| Mayer, S | 1 |
| Miranda, AS | 2 |
| Teixeira, AL | 2 |
| Razzouk, D | 1 |
| Godlewska, BR | 1 |
| Emir, UE | 1 |
| Masaki, C | 1 |
| Bargiotas, T | 1 |
| Cowen, PJ | 1 |
| Shi, S | 1 |
| Li, L | 1 |
| Song, L | 1 |
| Wang, X | 2 |
| Silva Lima, AFBD | 1 |
| Cohen, M | 1 |
| Miguel, S | 1 |
| Cruz, L | 1 |
| Kugimiya, T | 1 |
| Kohno, K | 1 |
| Ishii, N | 2 |
| Terao, T | 3 |
| Mellen, EJ | 1 |
| Harper, DG | 1 |
| Ravichandran, C | 1 |
| Jensen, E | 1 |
| Silveri, M | 1 |
| Forester, BP | 1 |
| Oya, K | 1 |
| Sakuma, K | 1 |
| Esumi, S | 1 |
| Hatano, M | 1 |
| Matsuda, Y | 1 |
| Matsui, Y | 1 |
| Miyake, N | 1 |
| Nomura, I | 1 |
| Okuya, M | 1 |
| Iwata, N | 1 |
| Kato, M | 1 |
| Hashimoto, R | 1 |
| Mishima, K | 1 |
| Kishi, T | 1 |
| Coles, AS | 1 |
| Sasiadek, J | 1 |
| George, TP | 1 |
| Agrawal, A | 1 |
| Nogar, JN | 1 |
| Koenig, S | 1 |
| Wimpelmann, J | 1 |
| Høvik, H | 1 |
| Riedel, B | 1 |
| Slørdal, L | 1 |
| Segmiller, FM | 1 |
| Hermisson, I | 1 |
| Riedel, M | 1 |
| Seemüller, F | 3 |
| Volkamer, T | 1 |
| Laux, G | 1 |
| Möller, HJ | 3 |
| Brunnauer, A | 1 |
| Rezvy, G | 2 |
| Sørlie, T | 1 |
| Mitchell, PB | 3 |
| Hadzi-Pavlovic, D | 1 |
| Evoniuk, G | 5 |
| Abe, Y | 1 |
| Yasugawa, S | 1 |
| Miyamoto, K | 1 |
| Baek, JH | 2 |
| Bernstein, EE | 1 |
| Pae, CU | 3 |
| Jeong, JH | 1 |
| Koo, BH | 1 |
| Jon, DI | 2 |
| Lu, D | 1 |
| Lin, X | 1 |
| Su, L | 1 |
| Klein, AM | 1 |
| Perel, JM | 1 |
| Helsel, J | 1 |
| Cha, DS | 1 |
| Kim, RD | 1 |
| Fletcher, K | 1 |
| Futeran, SM | 1 |
| Friend, P | 1 |
| Hooshmand, F | 1 |
| Miller, S | 2 |
| Dore, J | 1 |
| Wang, PW | 2 |
| Hill, SJ | 1 |
| Portillo, N | 1 |
| Ketter, TA | 20 |
| Chou, YC | 1 |
| Chao, FH | 1 |
| Chou, YH | 1 |
| Jakobsson, J | 1 |
| Bjerke, M | 1 |
| Ekman, CJ | 1 |
| Sellgren, C | 1 |
| Johansson, AG | 1 |
| Zetterberg, H | 1 |
| Blennow, K | 1 |
| Landén, M | 3 |
| Shon, SH | 1 |
| Joo, Y | 1 |
| Lee, JS | 1 |
| Kim, HW | 1 |
| Pan, PY | 1 |
| Lee, MS | 1 |
| Lo, MC | 1 |
| Yang, EL | 1 |
| Yeh, CB | 2 |
| Mauer, S | 1 |
| Alahmari, R | 1 |
| Vöhringer, PA | 1 |
| Vergne, DE | 1 |
| Lövdahl, H | 1 |
| Correa, E | 1 |
| Patkar, A | 1 |
| Pae, C | 1 |
| Strejilevich, S | 1 |
| Dalley, S | 1 |
| Ghaemi, SN | 4 |
| Fagan, CS | 1 |
| Carmody, TJ | 2 |
| McClintock, SM | 1 |
| Suris, A | 1 |
| Jeon-Slaughter, H | 1 |
| Lo, A | 1 |
| Brown, ES | 7 |
| Taylor, DM | 1 |
| Cornelius, V | 1 |
| Smith, L | 1 |
| Park, SW | 1 |
| Seo, MK | 1 |
| Cho, HY | 1 |
| Lee, CH | 1 |
| Lee, JH | 1 |
| Lee, BJ | 1 |
| Seol, W | 1 |
| Kim, YH | 1 |
| Volkert, J | 1 |
| Zierhut, KC | 1 |
| Schiele, MA | 1 |
| Wenzel, M | 1 |
| Kopf, J | 1 |
| Kittel-Schneider, S | 1 |
| Reif, A | 1 |
| Chavez, P | 1 |
| Casso Dominguez, A | 1 |
| Herzog, E | 1 |
| Oh, HK | 1 |
| Tibrewal, P | 1 |
| Dhillon, R | 2 |
| Pavuluri, M | 1 |
| Thomas, MA | 2 |
| Port, JD | 1 |
| Baruth, JM | 1 |
| Choi, DS | 2 |
| Abulseoud, OA | 1 |
| Karanti, A | 2 |
| Kardell, M | 2 |
| Lundberg, U | 1 |
| Bobeck, C | 1 |
| Osterman, M | 1 |
| Tidemalm, D | 1 |
| Runeson, B | 1 |
| Lichtenstein, P | 1 |
| Prieto, ML | 1 |
| Bobo, WV | 1 |
| Kung, S | 1 |
| Veldic, M | 1 |
| Alarcon, RD | 1 |
| Moore, KM | 1 |
| Tye, SJ | 1 |
| Dell'Osso, B | 2 |
| Citrome, L | 1 |
| Robakis, TK | 1 |
| Holtzman, J | 1 |
| Stemmle, PG | 1 |
| Reynolds-May, MF | 1 |
| Kenna, HA | 1 |
| Rasgon, NL | 2 |
| Lau, C | 1 |
| Watson, H | 1 |
| Cheong, J | 1 |
| Mintz, J | 6 |
| Tohen, M | 5 |
| McCraw, S | 2 |
| Kálmán, J | 4 |
| Popovic, D | 1 |
| Pacchiarotti, I | 4 |
| Hidalgo, D | 1 |
| León-Caballero, J | 1 |
| Unholzer, S | 1 |
| Haen, E | 2 |
| Findling, RL | 4 |
| Chang, K | 2 |
| Robb, A | 1 |
| Foster, VJ | 1 |
| Horrigan, J | 1 |
| Krishen, A | 1 |
| Wamil, A | 1 |
| Kraus, JE | 1 |
| DelBello, M | 1 |
| Voysey, M | 1 |
| Tunbridge, E | 1 |
| Yu, LM | 1 |
| Hainsworth, J | 1 |
| Khan, SJ | 1 |
| Fersh, ME | 1 |
| Ernst, C | 1 |
| Klipstein, K | 1 |
| Albertini, ES | 1 |
| Lusskin, SI | 1 |
| Laurito, LD | 1 |
| Fontenelle, LF | 1 |
| Kahn, DA | 1 |
| Leverich, GS | 5 |
| Kupka, R | 2 |
| Keck, PE | 11 |
| Altshuler, LL | 4 |
| Rowe, M | 1 |
| Grunze, H | 16 |
| Nolen, WA | 8 |
| Dome, P | 1 |
| Aebischer, B | 1 |
| Elsig, S | 1 |
| Taeymans, J | 1 |
| Pomp, S | 1 |
| Kuhness, D | 1 |
| Barcaro, G | 1 |
| Sementa, L | 1 |
| Mankad, V | 1 |
| Fortunelli, A | 1 |
| Sterrer, M | 1 |
| Netzer, FP | 1 |
| Surnev, S | 1 |
| Schmieder, AH | 1 |
| Caruthers, SD | 1 |
| Keupp, J | 1 |
| Wickline, SA | 1 |
| Lanza, GM | 1 |
| Lowe, J | 1 |
| Wodarcyk, AJ | 1 |
| Floyd, KT | 1 |
| Rastogi, N | 1 |
| Schultz, EJ | 1 |
| Swager, SA | 1 |
| Chadwick, JA | 1 |
| Tran, T | 1 |
| Raman, SV | 1 |
| Janssen, PM | 1 |
| Rafael-Fortney, JA | 1 |
| Alcalay, RN | 1 |
| Levy, OA | 1 |
| Wolf, P | 1 |
| Oliva, P | 1 |
| Zhang, XK | 1 |
| Waters, CH | 1 |
| Fahn, S | 1 |
| Kang, U | 1 |
| Liong, C | 1 |
| Ford, B | 1 |
| Mazzoni, P | 1 |
| Kuo, S | 1 |
| Johnson, A | 1 |
| Xiong, L | 1 |
| Rouleau, GA | 1 |
| Chung, W | 1 |
| Marder, KS | 1 |
| Gan-Or, Z | 1 |
| Kamei, K | 1 |
| Katayama, Y | 1 |
| Hatano, K | 1 |
| Kodama, K | 1 |
| Shirahama, M | 1 |
| Sakai, A | 1 |
| Hirakawa, H | 1 |
| Mizokami, Y | 1 |
| Shiotsuki, I | 1 |
| Inoue, Y | 1 |
| Akboga, MK | 1 |
| Yayla, C | 1 |
| Balci, KG | 1 |
| Ozeke, O | 1 |
| Maden, O | 1 |
| Kisacik, H | 1 |
| Temizhan, A | 1 |
| Aydogdu, S | 1 |
| Zhu, J | 2 |
| Ying, SH | 1 |
| Feng, MG | 1 |
| Zhang, XG | 1 |
| Wang, L | 1 |
| Hao, YY | 1 |
| Liang, GD | 1 |
| Ma, YH | 1 |
| Yang, GS | 1 |
| Hu, JH | 1 |
| Pfeifer, L | 1 |
| Goertz, RS | 1 |
| Neurath, MF | 1 |
| Strobel, D | 1 |
| Wildner, D | 1 |
| Lin, JT | 1 |
| Yang, XN | 1 |
| Zhong, WZ | 1 |
| Liao, RQ | 1 |
| Dong, S | 1 |
| Nie, Q | 1 |
| Weng, SX | 1 |
| Fang, XJ | 1 |
| Zheng, JY | 1 |
| Wu, YL | 1 |
| Řezanka, T | 1 |
| Kaineder, K | 1 |
| Mezricky, D | 1 |
| Řezanka, M | 1 |
| Bišová, K | 1 |
| Zachleder, V | 1 |
| Vítová, M | 1 |
| Rinker, JA | 1 |
| Marshall, SA | 1 |
| Mazzone, CM | 1 |
| Lowery-Gionta, EG | 1 |
| Gulati, V | 1 |
| Pleil, KE | 1 |
| Kash, TL | 1 |
| Navarro, M | 1 |
| Thiele, TE | 1 |
| Huang, Y | 1 |
| Jin, Z | 1 |
| Li, X | 2 |
| Li, B | 1 |
| Xu, P | 1 |
| Huang, P | 1 |
| Liu, C | 1 |
| Fokdal, L | 1 |
| Sturdza, A | 1 |
| Mazeron, R | 1 |
| Haie-Meder, C | 1 |
| Tan, LT | 1 |
| Gillham, C | 1 |
| Šegedin, B | 1 |
| Jürgenliemk-Schultz, I | 1 |
| Kirisits, C | 1 |
| Hoskin, P | 1 |
| Pötter, R | 1 |
| Lindegaard, JC | 1 |
| Tanderup, K | 1 |
| Levin, DE | 1 |
| Schmitz, AJ | 1 |
| Hines, SM | 1 |
| Hines, KJ | 1 |
| Tucker, MJ | 1 |
| Brewer, SH | 1 |
| Fenlon, EE | 1 |
| Álvarez-Pérez, S | 1 |
| Blanco, JL | 1 |
| Peláez, T | 1 |
| Martínez-Nevado, E | 1 |
| García, ME | 1 |
| Puckerin, AA | 1 |
| Chang, DD | 1 |
| Subramanyam, P | 1 |
| Colecraft, HM | 1 |
| Dogan, H | 1 |
| Coteli, E | 1 |
| Karatas, F | 1 |
| Ceylan, O | 1 |
| Sahin, MD | 1 |
| Akdamar, G | 1 |
| Kryczyk, A | 1 |
| Żmudzki, P | 1 |
| Hubicka, U | 1 |
| Giovannelli, D | 1 |
| Chung, M | 1 |
| Staley, J | 1 |
| Starovoytov, V | 1 |
| Le Bris, N | 1 |
| Vetriani, C | 1 |
| Chen, W | 1 |
| Wu, L | 1 |
| Shen, Y | 1 |
| Liang, Y | 1 |
| Tan, H | 1 |
| Yang, Y | 1 |
| Liu, Q | 1 |
| Wang, M | 1 |
| Liu, L | 1 |
| Liu, B | 1 |
| Liu, GH | 1 |
| Zhu, YJ | 1 |
| Wang, JP | 1 |
| Che, JM | 1 |
| Chen, QQ | 1 |
| Chen, Z | 1 |
| Maucksch, U | 1 |
| Runge, R | 1 |
| Wunderlich, G | 1 |
| Freudenberg, R | 1 |
| Naumann, A | 1 |
| Kotzerke, J | 1 |
| Nikolaev, EL | 1 |
| SÖrlie, T | 1 |
| Alonso-Navarro, H | 1 |
| Montes, JM | 2 |
| Plaza-Nieto, JF | 1 |
| Jiménez-Jiménez, FJ | 1 |
| McKinnon, M | 1 |
| Blagdon, R | 1 |
| Garnham, J | 3 |
| MacLellan, S | 1 |
| Hajek, T | 1 |
| Nair, C | 1 |
| Dursun, S | 1 |
| van den Ameele, S | 1 |
| van Diermen, L | 1 |
| Staels, W | 1 |
| Coppens, V | 1 |
| Dumont, G | 1 |
| Sabbe, B | 1 |
| Morrens, M | 1 |
| Mischoulon, D | 1 |
| Zajecka, J | 1 |
| Freeman, MP | 2 |
| Fava, M | 1 |
| Solmi, M | 1 |
| Veronese, N | 1 |
| Zaninotto, L | 1 |
| van der Loos, ML | 4 |
| Reis, C | 1 |
| Normann, C | 1 |
| Anghelescu, IG | 1 |
| Correll, CU | 1 |
| Prakash, C | 1 |
| Hatters-Friedman, S | 1 |
| Moller-Olsen, C | 1 |
| North, A | 1 |
| Levesque, S | 1 |
| Riley, C | 1 |
| Schoretsanitis, G | 1 |
| Gründer, G | 1 |
| Stegmann, B | 1 |
| Schruers, KR | 1 |
| Hiemke, C | 1 |
| Lammertz, SE | 1 |
| Paulzen, M | 1 |
| Tessitore, E | 1 |
| Ramlawi, M | 1 |
| Tobler, O | 1 |
| Sunthorn, H | 1 |
| Sommerdyk, C | 1 |
| Sawagashira, R | 1 |
| Fujii, Y | 1 |
| Kusumi, I | 1 |
| Nomamiukor, N | 1 |
| Schwartz, R | 1 |
| Avello, E | 1 |
| Palisson, F | 1 |
| Kuloglu, M | 1 |
| Caykoylu, A | 1 |
| Ekinci, O | 1 |
| Yilmaz, E | 1 |
| Sümegi, A | 2 |
| Born, C | 2 |
| Bernhard, B | 1 |
| Dittmann, S | 2 |
| Ukaegbu, C | 1 |
| Banks, JB | 1 |
| Carter, NJ | 1 |
| Goldman, LS | 1 |
| Rybakowski, F | 1 |
| Kaminska, K | 1 |
| Lorberg, B | 1 |
| Youssef, NA | 1 |
| Bhagwagar, Z | 2 |
| Nassir Ghaemi, S | 1 |
| Shirzadi, AA | 2 |
| Filkowski, M | 1 |
| Ouellet, G | 1 |
| Tremblay, L | 1 |
| Marleau, D | 1 |
| Brown, E | 1 |
| Dunner, DL | 1 |
| Adams, DH | 3 |
| Degenhardt, E | 1 |
| Houston, JP | 2 |
| Schieber, FC | 1 |
| Boulton, DW | 1 |
| Balch, AH | 1 |
| Croop, R | 1 |
| Mallikaarjun, S | 1 |
| Benson, J | 1 |
| Carlson, BX | 4 |
| Bisol, LW | 1 |
| Lara, DR | 1 |
| Redrobe, JP | 1 |
| Nielsen, AN | 1 |
| Mendhekar, DN | 1 |
| Gupta, N | 1 |
| Yatham, L | 1 |
| Goldberg, J | 1 |
| Bourne, E | 1 |
| Bahn, RS | 1 |
| Adams, B | 1 |
| Bramness, JG | 1 |
| Grøholt, B | 1 |
| Engeland, A | 1 |
| Furu, K | 1 |
| Joe, SH | 1 |
| Chang, JS | 2 |
| Won, S | 1 |
| Rim, HD | 1 |
| Ha, TH | 1 |
| Ha, K | 2 |
| Mulder, PG | 1 |
| Hartong, EG | 2 |
| Blom, MB | 2 |
| Vergouwen, AC | 2 |
| de Keyzer, HJ | 1 |
| Notten, PJ | 1 |
| Luteijn, ML | 1 |
| Timmermans, MA | 2 |
| Moretti, M | 1 |
| Pavuluri, MN | 6 |
| Henry, DB | 1 |
| Moss, M | 1 |
| Mohammed, T | 2 |
| Carbray, JA | 2 |
| Sweeney, JA | 5 |
| Green, MA | 1 |
| Abraham, MN | 1 |
| Horn, AJ | 1 |
| Yates, TE | 1 |
| Egbert, M | 1 |
| Sharma, A | 1 |
| Taillia, H | 1 |
| Alla, P | 1 |
| Fournier, B | 1 |
| Bounolleau, P | 1 |
| Ouologem, M | 1 |
| Ricard, D | 1 |
| Sallansonnet-Froment, M | 1 |
| de Greslan, T | 1 |
| Renard, JL | 1 |
| Arvilommi, P | 1 |
| Suominen, K | 1 |
| Mantere, O | 1 |
| Leppämäki, S | 1 |
| Valtonen, HM | 1 |
| Isometsä, E | 1 |
| Bonnín, CM | 1 |
| Martínez-Arán, A | 2 |
| Torrent, C | 2 |
| Rosa, AR | 2 |
| Franco, C | 1 |
| Sanchez-Moreno, J | 4 |
| Joo, YH | 1 |
| Kim, W | 1 |
| Ahn, YM | 2 |
| Chung, SK | 1 |
| Won, SH | 1 |
| Shin, YC | 1 |
| Jung, SH | 1 |
| Seok, JH | 1 |
| Lee, YS | 1 |
| Kim, Y | 1 |
| Min, KJ | 1 |
| Kemp, DE | 6 |
| Ganocy, SJ | 5 |
| Muzina, DJ | 3 |
| Xia, G | 1 |
| Frey, LC | 1 |
| Strom, LA | 1 |
| Shrestha, A | 1 |
| Spitz, MC | 1 |
| Salvadore, G | 1 |
| Drevets, WC | 1 |
| Henter, ID | 1 |
| Zarate, CA | 3 |
| Manji, HK | 2 |
| Goldberg, JF | 7 |
| Saville, BR | 1 |
| Goodwin, FK | 6 |
| Coskun, M | 1 |
| Bozkurt, H | 1 |
| Zoroglu, S | 1 |
| Wakil, L | 1 |
| Epperson, CN | 1 |
| Gonzalez, J | 1 |
| O'Reardon, JP | 2 |
| Kim, DR | 1 |
| Large, CH | 1 |
| Di Daniel, E | 1 |
| George, MS | 1 |
| Bazinet, RP | 2 |
| Berwaerts, K | 1 |
| De Fruyt, J | 1 |
| Rubner, P | 1 |
| Koppi, S | 1 |
| Conca, A | 1 |
| Egger, C | 1 |
| Muehlbacher, M | 1 |
| Grohmann, R | 1 |
| Stuppaeck, C | 1 |
| Fountoulakis, K | 1 |
| Siamouli, M | 1 |
| Chandra, PA | 1 |
| Chandra, AB | 1 |
| Perlis, RH | 1 |
| Fijal, B | 1 |
| Sutton, VK | 1 |
| Farmen, M | 1 |
| Breier, A | 1 |
| Lam, GM | 1 |
| Edelson, DP | 1 |
| Whelan, CT | 1 |
| Bastiampillai, TJ | 1 |
| Reid, CE | 1 |
| Bowden, C | 3 |
| Licht, RW | 5 |
| Kasper, S | 4 |
| Swann, AC | 2 |
| Mah, L | 1 |
| Conn, DK | 2 |
| Presecki, P | 1 |
| Grosić, V | 1 |
| Silić, A | 1 |
| Mihanović, M | 1 |
| Berner, JE | 1 |
| LeBlanc, SR | 1 |
| Ovanessian, MM | 1 |
| Passarotti, AM | 5 |
| Biederman, J | 1 |
| Joshi, G | 1 |
| Mick, E | 1 |
| Doyle, R | 1 |
| Georgiopoulos, A | 1 |
| Hammerness, P | 1 |
| Kotarski, M | 1 |
| Williams, C | 1 |
| Wozniak, J | 1 |
| Woodward, TC | 1 |
| Tafesse, E | 1 |
| Quon, P | 1 |
| Lazarus, A | 1 |
| Moon, E | 1 |
| Cha, B | 1 |
| El-Mallakh, RS | 1 |
| Elmaadawi, AZ | 1 |
| Loganathan, M | 1 |
| Lohano, K | 1 |
| Gao, Y | 1 |
| Nielsen, JN | 2 |
| Gram, LF | 1 |
| Vestergaard, P | 1 |
| Bendz, H | 1 |
| Locklear, J | 1 |
| Günther, O | 1 |
| Ekman, M | 1 |
| Miltenburger, C | 1 |
| Chatterton, ML | 1 |
| Aström, M | 1 |
| Paulsson, B | 1 |
| Swartz, HA | 1 |
| Thase, ME | 3 |
| Harral, EM | 1 |
| Amann, B | 4 |
| Crespo, JM | 1 |
| Pomarol-Clotet, E | 1 |
| McKenna, P | 2 |
| Halasz, S | 1 |
| Kliment, E | 1 |
| Parnes, SA | 1 |
| Fitzgerald, JM | 2 |
| Ventriglio, A | 1 |
| Vincenti, A | 1 |
| Centorrino, F | 1 |
| Talamo, A | 1 |
| Fitzmaurice, G | 1 |
| Galbally, M | 1 |
| Roberts, M | 1 |
| Buist, A | 1 |
| Brecher, M | 1 |
| Edwards, S | 3 |
| Eudicone, JM | 2 |
| Jansen, W | 1 |
| Leon, AC | 2 |
| Minkwitz, M | 1 |
| Pikalov, A | 1 |
| Stassen, HH | 1 |
| Szegedi, A | 1 |
| Van Willigenburg, AP | 1 |
| Weiss, SR | 1 |
| Wang, Z | 1 |
| Chan, PK | 2 |
| Serrano, MB | 1 |
| Fang, Y | 1 |
| Berle, JØ | 1 |
| Solberg, DK | 1 |
| Spigset, O | 1 |
| Nam, JY | 2 |
| Culver, JL | 2 |
| Marsh, WK | 3 |
| Bonner, JC | 2 |
| Mulder, P | 1 |
| van Noorden, MS | 1 |
| Sachs, GS | 8 |
| Ice, KS | 1 |
| Chappell, PB | 1 |
| Schwartz, JH | 1 |
| Gurtovaya, O | 1 |
| Vanderburg, DG | 1 |
| Kasuba, B | 1 |
| Sajatovic, M | 6 |
| Gildengers, A | 2 |
| Al Jurdi, RK | 2 |
| Gyulai, L | 4 |
| Cassidy, KA | 3 |
| Greenberg, RL | 1 |
| Bruce, ML | 1 |
| Mulsant, BH | 2 |
| Ten Have, T | 1 |
| Young, RC | 2 |
| Bürgy, M | 1 |
| Waldo, SW | 1 |
| Treit, K | 1 |
| Goldschlager, N | 1 |
| Hellmund, G | 1 |
| Andersen, PK | 1 |
| Wang, ZF | 1 |
| Fessler, EB | 1 |
| Chuang, DM | 1 |
| Solomon, DA | 1 |
| Li, C | 1 |
| Fiedorowicz, JG | 1 |
| Coryell, WH | 1 |
| Endicott, J | 1 |
| Keller, MB | 1 |
| Samalin, L | 1 |
| Nourry, A | 1 |
| Llorca, PM | 1 |
| Ortiz, A | 1 |
| Ittasakul, P | 1 |
| Johnson, KR | 1 |
| Srivastava, S | 1 |
| Childers, ME | 1 |
| Brooks, JO | 2 |
| Hoblyn, JC | 2 |
| Sun, W | 1 |
| Timko, K | 1 |
| McQuade, RD | 1 |
| Sanchez, R | 1 |
| Vester-Blokland, E | 1 |
| Marcus, R | 1 |
| Anand, A | 2 |
| Gunn, AD | 1 |
| Barkay, G | 1 |
| Karne, HS | 1 |
| Nurnberger, JI | 1 |
| Mathew, SJ | 1 |
| Ghosh, S | 1 |
| Simms, KM | 1 |
| Kortepeter, C | 1 |
| Avigan, M | 1 |
| Wada, K | 1 |
| Christensen, J | 1 |
| Sandgaard, AP | 1 |
| Sidenius, P | 1 |
| Linnet, K | 1 |
| Wegbreit, E | 1 |
| Ellis, JA | 1 |
| Nandam, A | 1 |
| Stevens, MC | 1 |
| Tatsuoka, C | 1 |
| Bialko, C | 1 |
| Sunderajan, P | 1 |
| Hu, LT | 1 |
| Sowell, SM | 1 |
| Weisler, R | 1 |
| Thompson, P | 1 |
| Chang, X | 1 |
| Motomura, E | 1 |
| Tanii, H | 1 |
| Usami, A | 1 |
| Ohoyama, K | 1 |
| Nakagawa, M | 1 |
| Okada, M | 1 |
| Grande, I | 1 |
| Balanzá-Martínez, V | 1 |
| Jiménez-Arriero, M | 1 |
| Iglesias Lorenzo, FG | 1 |
| Franch Valverde, JI | 1 |
| de Arce, R | 1 |
| Zaragoza, S | 1 |
| Cobaleda, S | 1 |
| Stevens, J | 1 |
| Bies, RR | 1 |
| Shekhar, A | 1 |
| Tensho, M | 1 |
| Chao, KC | 1 |
| Lu, ML | 1 |
| Shen, WW | 1 |
| Fein, EB | 1 |
| Obral, S | 1 |
| De Hert, M | 1 |
| Rahman, Z | 1 |
| Fyans, P | 1 |
| Marler, SV | 1 |
| Baker, RA | 1 |
| Diler, RS | 1 |
| Ladouceur, CD | 1 |
| Segreti, A | 1 |
| Almeida, JR | 1 |
| Birmaher, B | 1 |
| Axelson, DA | 1 |
| Phillips, ML | 1 |
| Pan, LA | 1 |
| Barbee, JG | 1 |
| Jamhour, NJ | 1 |
| Overstreet, K | 1 |
| Costanza, C | 1 |
| Behling, C | 1 |
| Hassanin, T | 1 |
| Masliah, E | 1 |
| Shelton, MD | 8 |
| Rapport, DJ | 9 |
| Kimmel, SE | 6 |
| Elhaj, O | 4 |
| Robillard, M | 1 |
| Sullivan, JR | 1 |
| Kusumakar, V | 5 |
| Labiner, DM | 1 |
| Goodwin, G | 1 |
| Baldwin, D | 1 |
| Licht, R | 1 |
| Margolese, HC | 1 |
| Beauclair, L | 1 |
| Szkrumelak, N | 1 |
| Chouinard, G | 1 |
| Nejtek, VA | 1 |
| Perantie, DC | 3 |
| Orsulak, PJ | 1 |
| Bobadilla, L | 1 |
| Ernst, CL | 1 |
| Shelton, RC | 1 |
| Passmore, MJ | 1 |
| Duffy, A | 2 |
| MacDougall, M | 2 |
| Munro, A | 2 |
| Slaney, C | 2 |
| Teehan, A | 2 |
| Sachs, G | 4 |
| Asghar, SA | 1 |
| Hompland, M | 1 |
| Montgomery, P | 2 |
| Earl, N | 2 |
| Smoot, TM | 1 |
| DeVeaugh-Geiss, J | 3 |
| Grof, P | 1 |
| Gnanadesikan, M | 1 |
| Gelenberg, AJ | 1 |
| Carandang, CG | 1 |
| Maxwell, DJ | 1 |
| Robbins, DR | 1 |
| Oesterheld, JR | 1 |
| Horiuchi, R | 1 |
| Takeuchi, J | 1 |
| Goldsmith, DR | 2 |
| Wagstaff, AJ | 2 |
| Ibbotson, T | 2 |
| Perry, CM | 2 |
| Behnke, K | 1 |
| Mehtonen, OP | 1 |
| Ascher, J | 3 |
| Paska, W | 1 |
| Kupka, RW | 3 |
| McElroy, S | 2 |
| Keck, P | 1 |
| Walden, J | 3 |
| Main, L | 1 |
| Singh, J | 1 |
| Krystal, AD | 1 |
| Benazzi, F | 1 |
| Asnis, GM | 2 |
| Ginsberg, LD | 4 |
| Bentley, B | 2 |
| Leadbetter, R | 2 |
| White, R | 6 |
| Hadjipavlou, G | 1 |
| Mok, H | 2 |
| Cookson, J | 3 |
| Huffman, RF | 2 |
| Greene, P | 2 |
| Marangell, LB | 3 |
| Martinez, JM | 1 |
| Miyahara, S | 2 |
| Miklowitz, DJ | 2 |
| Preston, GA | 1 |
| Marchant, BK | 1 |
| Reimherr, FW | 1 |
| Strong, RE | 1 |
| Hedges, DW | 1 |
| Yonkers, KA | 1 |
| Stowe, Z | 1 |
| Leibenluft, E | 2 |
| Cohen, L | 1 |
| Miller, L | 1 |
| Manber, R | 1 |
| Viguera, A | 1 |
| Altshuler, L | 2 |
| Yee, T | 1 |
| Dhanani, N | 2 |
| Johnson, G | 1 |
| Tajima, O | 1 |
| Herman, E | 1 |
| Lewis, FT | 1 |
| Kass, E | 1 |
| Klein, RM | 1 |
| Manfredi, G | 1 |
| Kotzalidis, GD | 1 |
| Ruberto, A | 1 |
| Girardi, P | 1 |
| Tatarelli, R | 1 |
| Pardo, TB | 2 |
| Hsu, DJ | 1 |
| Stahl, SM | 2 |
| Hahn, CG | 1 |
| Baldassano, CF | 2 |
| Lenox, RH | 1 |
| Ball, JR | 1 |
| Ballas, CA | 1 |
| Lecrubier, Y | 1 |
| Fieve, RR | 1 |
| Davis, KH | 2 |
| Harris, SD | 1 |
| Krishnan, AA | 3 |
| Becker, OV | 2 |
| Glenn, T | 1 |
| Oral, ET | 2 |
| Vahip, S | 1 |
| Lieberman, DZ | 1 |
| Mackin, P | 1 |
| Khan, A | 1 |
| Adams, BE | 2 |
| Schatzberg, AF | 1 |
| Fogh, K | 1 |
| Simons, WR | 1 |
| Arban, R | 1 |
| Maraia, G | 1 |
| Brackenborough, K | 1 |
| Winyard, L | 1 |
| Wilson, A | 1 |
| Gerrard, P | 1 |
| Large, C | 1 |
| Manning, JS | 2 |
| Haykal, RF | 1 |
| Connor, PD | 1 |
| Cunningham, PD | 1 |
| Jackson, WC | 1 |
| Long, S | 1 |
| Jefferson, JW | 2 |
| Curtis, V | 1 |
| Youngstrom, EA | 2 |
| Jackson, K | 1 |
| Bilali, S | 1 |
| Saiz-Ruiz, J | 1 |
| Lahera, G | 1 |
| Asiel, A | 1 |
| Gajwani, P | 3 |
| Thompson, TR | 7 |
| Wilson, BG | 1 |
| Fung, J | 1 |
| Rahman, M | 1 |
| Haider, N | 1 |
| Chandler, RA | 1 |
| Alarcon, AM | 1 |
| Nowakowska, C | 1 |
| O'Keeffe, CM | 1 |
| Schumacher, MR | 1 |
| LeDrew, K | 1 |
| Phillips, L | 1 |
| Hogan, M | 1 |
| MacCallum, A | 1 |
| Vajda, FJ | 1 |
| Solinas, C | 1 |
| Parikh, S | 1 |
| McIntyre, R | 1 |
| Silverstone, P | 2 |
| Baruch, P | 1 |
| Daigneault, A | 1 |
| Young, LT | 2 |
| Connolly, M | 1 |
| Gorman, CP | 1 |
| Forsthoff, A | 1 |
| Muzina, D | 1 |
| Thakur, A | 1 |
| Jagadheesan, K | 1 |
| Sinha, VK | 2 |
| Howland, RH | 1 |
| Kelly, DI | 3 |
| Perla, JM | 1 |
| Andrews, G | 1 |
| Page, AC | 1 |
| Severus, WE | 1 |
| Kleindienst, N | 1 |
| Frangou, S | 3 |
| Moeller, HJ | 1 |
| Selek, S | 5 |
| Haluk, SA | 1 |
| Farrelly, N | 1 |
| Dibben, C | 1 |
| Hunt, N | 1 |
| Chang, CC | 2 |
| Shiah, IS | 2 |
| Chang, HA | 2 |
| Huang, SY | 1 |
| Green, T | 1 |
| Shoval, G | 1 |
| Weizman, A | 1 |
| Raskin, S | 1 |
| Teitelbaum, A | 1 |
| Zislin, J | 1 |
| Durst, R | 1 |
| Dehning, S | 1 |
| Müller, N | 1 |
| Kugaya, A | 1 |
| Sanacora, G | 1 |
| Wang, TS | 1 |
| Ostacher, MJ | 2 |
| Bauer, MS | 1 |
| Wisniewski, SR | 1 |
| Antai-Otong, D | 1 |
| Beard, L | 1 |
| Orsulak, P | 1 |
| Rush, AJ | 1 |
| Saxena, K | 1 |
| Howe, M | 2 |
| Ketter, T | 1 |
| Thompson, T | 5 |
| Ellis, P | 1 |
| Mulder, R | 1 |
| Porter, R | 1 |
| Uher, R | 1 |
| Jones, HM | 1 |
| Fenn, HH | 1 |
| Sommer, BR | 1 |
| Alldredge, B | 1 |
| Daban, C | 2 |
| Benabarre, A | 1 |
| Comes, M | 2 |
| Colom, F | 2 |
| Greist, JH | 1 |
| Graham, JA | 1 |
| Roberts, JN | 1 |
| Nanry, KP | 1 |
| Karren, NU | 1 |
| Savas, HA | 4 |
| Bulbul, F | 1 |
| Kaya, MC | 2 |
| Savas, E | 2 |
| Rubio, G | 1 |
| López-Muñoz, F | 1 |
| Alamo, C | 1 |
| Varghese, SP | 1 |
| Haith, LR | 1 |
| Patton, ML | 1 |
| Guilday, RE | 1 |
| Ackerman, BH | 1 |
| Bildik, T | 1 |
| Tamar, M | 1 |
| Korkmaz, S | 1 |
| Gokcen, S | 1 |
| Ozbaran, B | 1 |
| Erermis, S | 1 |
| Aydin, C | 1 |
| Soutullo, CA | 1 |
| Díez-Suárez, A | 1 |
| Figueroa-Quintana, A | 1 |
| Frye, M | 2 |
| DeVeaugh-Geiss, A | 1 |
| Calvert, NW | 1 |
| Burch, SP | 1 |
| Fu, AZ | 1 |
| Reeves, P | 1 |
| Penland, HR | 1 |
| Ostroff, RB | 1 |
| White, RL | 2 |
| Zuker, P | 1 |
| Levitt, A | 1 |
| Desarkar, P | 1 |
| Hillemacher, T | 1 |
| Bleich, S | 1 |
| Kornhuber, J | 1 |
| Frieling, H | 1 |
| Brown, EB | 1 |
| Deldar, A | 1 |
| Williamson, DJ | 1 |
| Spaulding, T | 1 |
| Westlund, R | 1 |
| Thomason, C | 1 |
| Dann, R | 1 |
| Yumru, M | 1 |
| Kurt, E | 1 |
| Atagun, I | 1 |
| Chou, JC | 1 |
| Fazzio, L | 1 |
| Schrauwen, E | 1 |
| Klugman, J | 1 |
| Berv, DA | 1 |
| Spina, E | 1 |
| D'Arrigo, C | 1 |
| Migliardi, G | 1 |
| Santoro, V | 1 |
| Muscatello, MR | 1 |
| Micò, U | 1 |
| D'Amico, G | 1 |
| Perucca, E | 1 |
| Redmond, JR | 1 |
| Jamison, KL | 1 |
| Chae, JH | 1 |
| Jun, TY | 1 |
| Cruz, N | 2 |
| Gilmer, WS | 1 |
| Fleck, J | 1 |
| Dago, PL | 1 |
| Kölling, P | 1 |
| Knoppert-van der Klein, EA | 1 |
| Ramsay, E | 1 |
| Nanry, K | 3 |
| Colangelo, E | 1 |
| Mistler, LA | 1 |
| Brunette, MF | 1 |
| Rosenberg, SD | 1 |
| Vidaver, RM | 1 |
| Luckoor, R | 1 |
| Iber, M | 1 |
| Watzl, J | 1 |
| Banakar, S | 1 |
| O'Neill, J | 1 |
| Davanzo, P | 1 |
| Fischer, J | 1 |
| Chirichigno, JW | 1 |
| Ventura, J | 1 |
| Elman, S | 1 |
| Tsuang, J | 1 |
| Walot, I | 1 |
| O'Neill, A | 1 |
| de Leon, J | 1 |
| Hellemann, G | 1 |
| Freeman, SA | 1 |
| Passmore, M | 1 |
| Bourin, M | 2 |
| Prica, C | 2 |
| Matthews, AM | 1 |
| Fireman, M | 1 |
| Hauser, P | 1 |
| Lee, HJ | 1 |
| Rao, JS | 1 |
| Chang, L | 1 |
| Rapoport, SI | 1 |
| Trimble, M | 1 |
| Dann, RS | 1 |
| Dossett, EC | 1 |
| Land, AJ | 1 |
| Gitlin, MJ | 1 |
| Haldane, M | 2 |
| Jogia, J | 2 |
| Cobb, A | 2 |
| Kozuch, E | 1 |
| Kumari, V | 2 |
| da Rocha, FF | 1 |
| Soares, FM | 1 |
| Correa, H | 1 |
| Bilali, SR | 1 |
| Ng, F | 1 |
| Wang, WV | 1 |
| Kaye, NS | 1 |
| Graham, J | 2 |
| Roberts, J | 2 |
| Derry, S | 1 |
| Moore, RA | 1 |
| Soares-Weiser, K | 1 |
| Bravo Vergel, Y | 1 |
| Beynon, S | 1 |
| Dunn, G | 1 |
| Barbieri, M | 1 |
| Duffy, S | 1 |
| Geddes, J | 1 |
| Gilbody, S | 1 |
| Palmer, S | 1 |
| Woolacott, N | 1 |
| Luckenbaugh, DA | 1 |
| Zarzar, MN | 1 |
| Moor, S | 1 |
| Luty, S | 1 |
| Joyce, P | 1 |
| Weisler, RH | 1 |
| Ascher, JA | 5 |
| Saracino, MA | 1 |
| Koukopoulos, A | 1 |
| Sani, G | 1 |
| Amore, M | 1 |
| Raggi, MA | 1 |
| Han, C | 1 |
| Marks, DM | 1 |
| Patkar, AA | 1 |
| Dencker, D | 1 |
| Dias, R | 1 |
| Pedersen, ML | 1 |
| Husum, H | 1 |
| McMeekin, H | 1 |
| Sagud, M | 2 |
| Pivac, N | 2 |
| Mustapic, M | 2 |
| Nedic, G | 2 |
| Peles, AM | 1 |
| Kramaric, M | 1 |
| Jakovljevic, M | 2 |
| Muck-Seler, D | 2 |
| Haro, JM | 1 |
| Reed, C | 1 |
| Bertsch, J | 1 |
| Miller, MA | 1 |
| Levsky, ME | 1 |
| Monaghan, ET | 2 |
| Leadbetter, RA | 1 |
| Maina, G | 1 |
| Albert, U | 1 |
| Rosso, G | 1 |
| Bogetto, F | 1 |
| Coconcea, N | 1 |
| Ignacio, RV | 1 |
| Blow, FC | 1 |
| Hays, RW | 1 |
| Meyer, WJ | 1 |
| Khan, M | 1 |
| Corpse, C | 1 |
| Altamura, AC | 1 |
| Mundo, E | 1 |
| Tacchini, G | 1 |
| Buoli, M | 1 |
| Fernández Corcuera, P | 1 |
| Pomarol, E | 1 |
| Bernstein, IH | 1 |
| Fischer, EG | 1 |
| Zboyan, HA | 1 |
| Snow, DE | 1 |
| Martinez, M | 1 |
| Al Jurdi, R | 1 |
| Shivakumar, G | 1 |
| Sureddi, S | 1 |
| Gonzalez, R | 1 |
| Rocha, FF | 1 |
| Chang, KD | 1 |
| Wagner, C | 1 |
| Garrett, A | 1 |
| Reiss, A | 1 |
| Newport, DJ | 1 |
| Stowe, ZN | 1 |
| Calamaras, MR | 1 |
| Juric, S | 1 |
| Knight, B | 1 |
| Pennell, PB | 1 |
| Champion, LM | 1 |
| Babic, A | 1 |
| Mihaljevic Peles, A | 1 |
| Hascoet, M | 1 |
| Fatemi, SH | 2 |
| Woyshville, MJ | 1 |
| Hesslinger, B | 1 |
| van Calker, D | 1 |
| Berger, M | 1 |
| Sporn, J | 1 |
| Fogelson, DL | 1 |
| Sternbach, H | 1 |
| Labbate, LA | 1 |
| Rubey, RN | 1 |
| Thuras, P | 1 |
| Buzan, RD | 1 |
| Dubovsky, SL | 1 |
| Koek, RJ | 1 |
| Yerevanian, BI | 1 |
| Tueth, MJ | 1 |
| Murphy, TK | 1 |
| Evans, DL | 1 |
| Strakowski, SM | 1 |
| Blinder, BJ | 1 |
| Bhat, S | 1 |
| Sanathara, VA | 1 |
| Xie, X | 1 |
| Hagan, RM | 1 |
| Ferrier, IN | 2 |
| Kujawa, M | 2 |
| Erfurth, A | 1 |
| Monaghan, E | 2 |
| Rudd, GD | 1 |
| Pinto, OC | 1 |
| Akiskal, HS | 1 |
| Lovell, RW | 1 |
| Nolen, W | 1 |
| Denicoff, KD | 1 |
| Rhodes, LJ | 2 |
| Anderson, J | 1 |
| Bolden-Watson, C | 2 |
| Zhou, J | 2 |
| Andersen, J | 1 |
| Rhodes, L | 1 |
| Mitchell, P | 1 |
| Preda, A | 1 |
| Fazeli, A | 1 |
| McKay, BG | 1 |
| Bowers, MB | 1 |
| Mazure, CM | 1 |
| Rosenbaum, JF | 1 |
| Fredman, SJ | 1 |
| Botts, SR | 1 |
| Raskind, J | 1 |
| Bozikas, V | 1 |
| Vartzopoulos, D | 1 |
| Phocas, C | 1 |
| Karavatos, A | 1 |
| Kaprinis, G | 1 |
| Hamer, RM | 1 |
| Simpson, PM | 1 |
| Engle, PM | 1 |
| Heck, AM | 1 |
| Chaudron, LH | 1 |
| Ichim, L | 1 |
| Brook, S | 1 |
| Solvason, HB | 1 |
| Ballasiotes, AA | 1 |
| Skaer, TL | 1 |
| Fervenza, FC | 1 |
| Kanakiriya, S | 1 |
| Kunau, RT | 1 |
| Gibney, R | 1 |
| Lager, DJ | 1 |
| Damiani, JT | 1 |
| Christensen, RC | 1 |
| Earl, NL | 1 |
| Greene, PL | 1 |
| Janowsky, DS | 1 |
| Nemeroff, CB | 1 |
| Alao, AO | 1 |
| Dewan, MJ | 1 |
| Schaerer, L | 1 |
| Schloesser, S | 1 |
| Zerjav-Lacombe, S | 1 |
| Tabarsi, E | 1 |
| Malt, UF | 2 |
| Fladvad, T | 2 |
| Burdick, KE | 1 |
| Shirley, ER | 1 |
| Caban, SJ | 1 |
| Meland, E | 1 |
| Caban, S | 1 |
| Chengappa, KN | 1 |
| Gershon, S | 1 |
| Levine, J | 1 |
| Hurley, SC | 1 |
| Rao, R | 1 |
| Scarrow, G | 1 |
| Kroeker, G | 1 |
| Cosgrove, VE | 1 |
| Macdonald, KJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double Blind Placebo Controlled Study of Lamictal in Acute Bipolar Depression[NCT00056277] | Phase 3 | 150 participants (Actual) | Interventional | 2003-02-27 | Completed | ||
| Lamotrigine Versus Lithium in Subjects With Bipolar Affective Disorders - a Randomised Study of Prophylactic Effect[NCT00226135] | Phase 3 | 150 participants | Interventional | 2001-03-31 | Completed | ||
| A Multicenter, Double-Blind, Placebo-Controlled, Fixed-Dose, 8-Week Evaluation of the Efficacy and Safety of Lamotrigine in the Treatment of Depression in Patients With Type II Bipolar Disorder[NCT00274677] | Phase 3 | 221 participants (Actual) | Interventional | 2003-11-30 | Completed | ||
| Sequential Multiple Assignment Randomized Treatment (SMART) for Bipolar Disorder[NCT01588457] | Phase 4 | 112 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| Study SCA104779, an Evaluation of BW430C (Lamotrigine) Versus Placebo in the Prevention of Mood Episodes in Bipolar I Disorder Patients[NCT00550407] | Phase 3 | 215 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| Study by 1H NMR of the Variations of the Metabolome During the Course of Electroconvulsive Therapy in Patients With Major Depressive Episode[NCT05973643] | 50 participants (Anticipated) | Interventional | 2023-10-15 | Not yet recruiting | |||
| The BrainDrugs-Epilepsy Study: A Prospective Open-label Cohort Precision Medicine Study in Epilepsy[NCT05450822] | 550 participants (Anticipated) | Observational | 2022-02-18 | Recruiting | |||
| Clinical Evaluation of the Antidepressant Effect of the Use of Probiotics in Bipolar Disorder and Possible Mediating Effects of Systemic and Intestinal Inflammatory Markers in the Microbiota[NCT05762887] | 84 participants (Anticipated) | Interventional | 2023-01-09 | Recruiting | |||
| Music as a Potential Intervention to Improve Hemodynamic Tolerability of Repetitive Sub-Anesthetic IV Ketamine Infusions in Bipolar and Unipolar Depression: A Pilot Study[NCT04701866] | 32 participants (Actual) | Interventional | 2021-01-11 | Completed | |||
| A Collaborative Treatment Network for Youth With or at High Risk for Bipolar Disorder[NCT05427123] | 80 participants (Anticipated) | Observational | 2022-07-01 | Recruiting | |||
| PRIME Care (PRecision Medicine In MEntal Health Care)[NCT03170362] | 1,944 participants (Actual) | Interventional | 2017-06-15 | Completed | |||
| A Pilot Study of Prophylactic Management of Lamotrigine for Bipolar Disorder in Pregnant Women[NCT03774641] | 20 participants (Anticipated) | Observational | 2018-12-03 | Recruiting | |||
| Pharmacokinetics of Lamotrigine in Pregnant and Postpartum Women With Bipolar Disorder[NCT01996293] | 30 participants (Actual) | Observational | 2013-09-30 | Completed | |||
| Comparison of Olanzapine and Lamotrigine in the Prevention of Recurrence of Depressive Episode in the Patients With Bipolar Disorders[NCT01864551] | Phase 4 | 60 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| The Evaluation of Lamictal as an Add-on Treatment for Bipolar I Disorder in Children and Adolescents, 10 to 17 Years of Age[NCT00723450] | Phase 3 | 301 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| Double-Blind Trial of Methylene Blue for Cognitive Dysfunction in Bipolar Disorder[NCT00214877] | Phase 3 | 40 participants (Anticipated) | Interventional | 2003-11-30 | Completed | ||
| A Mulitcentre, Double-blind, Randomised, Fixed-dose Evaluation of the Safety and Efficacy of Lamictal (Lamotrigine) Compared to Placebo as an add-on Therapy to Lithium or Another Mood Stabiliser in the Treatment of Bipolar Depression, Followed by Long-ter[NCT00224510] | Phase 3 | 120 participants (Actual) | Interventional | 2002-08-31 | Completed | ||
| A Multi-centre, Observational Study to Evaluate the Incidence of Non-serious Rash in Korean Bipolar I Patients With Lamotrigine Therapy in Real World Setting[NCT00460226] | 238 participants (Actual) | Observational | 2007-03-31 | Completed | |||
| Open Trial of Lamotrigine Monotherapy in Pediatric Bipolar Disorder[NCT00176228] | Phase 2 | 48 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
| A Six-Week, Double-Blind, Multicenter, Placebo Controlled Study Evaluating The Efficacy And Safety Of Flexible Doses Of Oral Ziprasidone As Add-On, Adjunctive Therapy With Lithium, Valproate Or Lamotrigine In Bipolar I Depression[NCT00483548] | Phase 3 | 298 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Eight-Month Maintenance Treatment of Bipolar Depression With Lamotrigine or Lamotrigine Plus Divalproex Combination[NCT00183469] | Phase 4 | 86 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| Efficacy and Safety of Antidepressant Augmentation With Lamotrigine in Patients With Treatment-Resistant Depression[NCT00652171] | Phase 3 | 34 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| Orally-Disintegrating vs. Regular Olanzapine Tablets: Effects on Weight and GI Hormones[NCT00384332] | Phase 4 | 20 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| The Safety and Effectiveness of Probiotic Supplementation on Bipolar Depression: a Proof of Concept Randomized Controlled Trial[NCT02155972] | Phase 2 | 16 participants (Actual) | Interventional | 2013-05-31 | Terminated (stopped due to The trial was terminated because of inability to recruit the needed number of participants) | ||
| Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)[NCT00012558] | 5,000 participants | Interventional | 1998-09-30 | Completed | |||
| A Randomized, Double-blind, Double-dummy, Controlled Trial of Lithium Versus Paroxetine in Subjects With Major Depression Who Have a Family History of Bipolar Disorder or Completed Suicide - a Pilot Study[NCT00400088] | Phase 3 | 2 participants (Actual) | Interventional | 2007-06-30 | Terminated (stopped due to Recruitment difficulties) | ||
| Medication Safety and Contraceptive Counseling for Reproductive Aged Women With Psychiatric Conditions[NCT02292056] | 50 participants (Anticipated) | Interventional | 2013-09-30 | Recruiting | |||
| Light-Therapy in the Treatment of the Acute Phase of the Bipolar Type II Depression: Double-Blind, Placebo-Controlled Study to Establish Efficacy and Safety[NCT00590265] | 50 participants (Anticipated) | Interventional | 2008-01-31 | Active, not recruiting | |||
| Reducing Cardiovascular Risk in Adults With Serious Mental Illness Using an Electronic Medical Record-based Clinical Decision Support[NCT02451670] | 10,347 participants (Actual) | Interventional | 2016-01-20 | Completed | |||
| Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776] | Phase 2 | 54 participants (Actual) | Interventional | 2017-08-07 | Completed | ||
| Investigation of the Effects of in Vivo Lithium Treatment on Gene Expression Levels Using Lymphoblastoid Cell Lines From Human Healthy Subjects[NCT01565759] | Phase 1 | 20 participants (Anticipated) | Interventional | 2012-05-31 | Recruiting | ||
| The Effect of a Single Dose of Lamotrigine on Brain Function in Healthy Volunteers[NCT04396938] | 36 participants (Actual) | Interventional | 2017-05-10 | Completed | |||
| Aripiprazole in Late Life Bipolar Disorder[NCT00194038] | Phase 4 | 20 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| Acute Treatment of Bipolar II Depression[NCT00074776] | Phase 3 | 102 participants (Actual) | Interventional | 2003-05-31 | Completed | ||
| Pilot Evaluation of Levetiracetam (Keppra® (Registered Trademark)) in Bipolar Illness[NCT00015769] | Phase 2 | 30 participants | Interventional | 2001-04-30 | Completed | ||
| Understanding the Neurocognitive Effects of Fecal Microbiota Transplantation in Major Depressive Disorder Patients With and Without Irritable Bowel Syndrome[NCT05174273] | Phase 2/Phase 3 | 180 participants (Anticipated) | Interventional | 2022-04-06 | Recruiting | ||
| Study of Lamotrigine Treatment of Affective Instability in Borderline Personality Disorder[NCT00634062] | Phase 4 | 28 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percentages of Type I and Type II Bipolar Disorder included in Randomization groups (NCT01588457)
Timeframe: Baseline
| Intervention | percentage of participants (Number) |
|---|---|
| Bipolar Type 1 Divalproex Group | 70 |
| Bipolar Type II Divalproex Group | 74.1 |
| Bipolar Type 1 Lithium Group | 30 |
| Bipolar Type II Lithium Group | 25.9 |
"The BISS uses a structured interview to assess the full spectrum of symptoms associated with all primary clinical states in bipolar disorder, yielding a total severity, a depression, a mania, as well as dimensional scale scores. There are 42 items; each item is rated on a 0-4 scale. The BISS is a clinician-rated instrument. The Scale is rated as follows:~0 Not at all~Slight~Mild~Moderate~Severe Each of the 42 items is rated separately, with a score, based on the most recent 7 day period. The mean score is calculated from the total score, giving an overall score out of 4, where 0 is slight and 4 is the most severe symptoms. A negative score indicated an improvement from baseline to 26 weeks." (NCT01588457)
Timeframe: Change from Baseline to 26 weeks
| Intervention | calculated mean scale score (Mean) | ||||
|---|---|---|---|---|---|
| Mania | Depression | Irritability | Anxiety | Psychosis | |
| Divalproex After Randomization 1 | -0.31 | -0.71 | -0.50 | -0.49 | -0.14 |
| Divalproex or Lithium Monotherapy | 0.15 | -0.18 | -0.27 | 0.16 | -0.27 |
| Lithium After Randomization 1 | -0.41 | -0.20 | -0.39 | -0.51 | -0.25 |
| Lithium or Divalproex Plus Lamotrigine | -0.85 | -0.95 | -0.96 | -0.93 | -0.16 |
| Lithium or Divalproex Plus Quetiapine | -0.38 | -0.61 | -0.66 | -0.72 | -0.14 |
Baseline demographic percentages of subject randomized to either Divalproex or Lithium at the first randomization (NCT01588457)
Timeframe: Baseline
| Intervention | percentage of subjects (Number) | ||
|---|---|---|---|
| Single never married | Married | Disrupted Marriage | |
| Divalproex | 27.1 | 55.9 | 17.0 |
| Lithium | 33.3 | 37.0 | 29.6 |
"The Clinical Global Impression-Severity Scale (CGI-S) is used to assess global illness severity~The CGI-S score change is measured from baseline to 26 weeks and is rated on a 7-point scale. The scale is read as follows:~very much improved since the initiation of treatment~much improved~minimally improved~no change from baseline (the initiation of treatment)~minimally worse~much worse~very much worse since the initiation of treatment The score is calculated as a mean of all items, where 1 indicates improvement from inititation of visit, and 7 indicates the condition to be much worse since the inititation of treatment. A negative score indicates a change from worse to better." (NCT01588457)
Timeframe: Change from Baseline to 26 weeks
| Intervention | calculated mean scale score (Mean) | ||
|---|---|---|---|
| CGI-Depression | CGI-Mania | CGI-Overall | |
| Divalproex After Randomization 1 | -1.11 | -0.69 | -1.28 |
| Divalproex or Lithium Monotherapy | -0.09 | -0.19 | -0.11 |
| Lithium After Randomization 1 | -0.32 | -1.12 | -0.55 |
| Lithium or Divalproex Plus Lamotrigine | -1.24 | -1.81 | -1.64 |
| Lithium or Divalproex Plus Quetiapine | -0.99 | -0.71 | -0.99 |
The CGI-S is a 7-point scale that assessed the participant's severity of illness based on the total clinical experience of the Investigator with this particular population; 0=not assessed, 1= normal, not at all ill to 7= among the most extremely ill participants. Change from baseline was calculated as the Week 16/Withdrawal value minus the baseline value (at Week 0 of the Preliminary Phase). (NCT00550407)
Timeframe: Baseline and Week 16/Withdrawal
| Intervention | points on a scale (Mean) |
|---|---|
| Lamotrigine 25-200 mg | -0.7 |
The CGI-S is a 7-point scale that assessed the participant's severity of illness based on the total clinical experience of the Investigator with this particular population; 0=not assessed, 1= normal, not at all ill to 7= among the most extremely ill participants. Change from baseline was calculated as the Week 26/Withdrawal value minus the baseline value (at the time of randomization). (NCT00550407)
Timeframe: Baseline and Week 26/Withdrawal
| Intervention | points on a scale (Mean) |
|---|---|
| Placebo | 1.0 |
| Lamotrigine 200 mg | 0.4 |
The HAMD-17 is a 17-item questionnaire that detects change and measures illness severity. Individual items are rated on a scale of 0-4, and 0-2, with the total HAMD-17 score ranging from 0 (not ill) to 52 (severely ill). Change from baseline was calculated as the Week 16/Withdrawal value minus the baseline value (at Week 0 of the Preliminary Phase). (NCT00550407)
Timeframe: Baseline and Week 16/Withdrawal
| Intervention | points on a scale (Mean) |
|---|---|
| Lamotrigine 25-200 mg | -4.1 |
The HAMD-17 is a 17-item questionnaire that detects change and measures illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with the total HAMD-17 score ranging from 0 (not ill) to 52 (severely ill). Change from baseline was calculated as the Week 26/Withdrawal value minus the baseline value (at the time of randomization). (NCT00550407)
Timeframe: Baseline and Week 26/Withdrawal
| Intervention | points on a scale (Mean) |
|---|---|
| Placebo | 5.4 |
| Lamotrigine 200 mg | 2.7 |
The YMRS is an 11-item questionnaire that detects change and measures illness severity. Individual items are rated on a scale of 0-8 and 0-4, with the total YMRS score ranging from 0 (not ill) to 60 (severely ill). Change from baseline was calculated as the Week 16/Withdrawal value minus the baseline value (at Week 0 of the Preliminary Phase). (NCT00550407)
Timeframe: Baseline and Week 16/Withdrawal
| Intervention | points on a scale (Mean) |
|---|---|
| Lamotrigine 25-200 mg | 0.4 |
The YMRS is an 11-item questionnaire that detects change and measures illness severity. Individual items are rated on a scale of 0-8 and 0-4, with the total YMRS score ranging from 0 (not ill) to 60 (severely ill). Change from baseline was calculated as the Week 26/Withdrawal value minus the baseline value (at the time of randomization). (NCT00550407)
Timeframe: Baseline and Week 26/Withdrawal
| Intervention | points on a scale (Mean) |
|---|---|
| Placebo | 2.2 |
| Lamotrigine 200 mg | 1.0 |
The CGI-I is a 7-point scale that assessed the participant's global improvement compared to his/her condition at study entry whether or not, in the judgement of the Investigator, it was due entirely to drug treatment; 0=not assessed, 1= very much improved to 7= very much worse. (NCT00550407)
Timeframe: Week 16/Withdrawal
| Intervention | points on a scale (Mean) |
|---|---|
| Lamotrigine 25-200 mg | 3.1 |
The CGI-I is a 7-point scale that assessed the participant's global improvement compared to his/her condition at study entry whether or not, in the judgement of the Investigator, it was due entirely to drug treatment; 0=not assessed, 1= very much improved to 7= very much worse. (NCT00550407)
Timeframe: Week 26/Withdrawal
| Intervention | points on a scale (Mean) |
|---|---|
| Placebo | 3.5 |
| Lamotrigine 200 mg | 2.4 |
"The TIME was defined as the time from entry into the Randomized Phase to the time of the first prescription of any additional pharmacotherapy or electroconvulsive therapy (ECT) determined by the Investigator to be necessary for treatment of a relapse or recurrence of depression or the recurrence of a manic, hypomanic, or mixed episode, whichever occurred first. Categorization as a manic, hypomanic, or mixed episode was left to the Investigator's discretion. See the outcome measure entitled Number of Participants with Intervention for Any Mood Episode for data related to TIME." (NCT00550407)
Timeframe: Randomization to Study Withdrawal (up to Week 26)
| Intervention | days (Median) |
|---|---|
| Placebo | 109.0 |
"The time from randomization to the time at which the participant was withdrawn from the Double-Blind Phase of the study for any reason was measured. No data are reported for the Lamotrigine group because of an incalculable confidence interval. See the outcome measure entitled Number of Participants with a Withdrawal Event for data regarding the number of participants who withdrew from the study." (NCT00550407)
Timeframe: Randomization to Study Withdrawal (up to Week 26)
| Intervention | days (Median) |
|---|---|
| Placebo | 67.5 |
The number of participants who withdrew from the study was measured. This outcome measure was added post-hoc because no data are being reported for the Lamotrigine group regarding time to study withdrawal. See the primary outcome measure for time to study withdrawal data for the Placebo group. Data from participants who had not withdrawn were defined as censored. (NCT00550407)
Timeframe: Randomization to Study Withdrawal (up to Week 26)
| Intervention | participants (Number) | |
|---|---|---|
| Withdrawal Event | Censored | |
| Lamotrigine 200 mg | 24 | 21 |
| Placebo | 43 | 15 |
The number of participants with intervention for a manic, hypomanic, or mixed episode was measured. The necessity of the intervention was determined by the Investigator's discretion. This outcome measure was added post-hoc because no data are being reported for the Placebo or Lamotrigine groups regarding time to intervention for manic, hypomanic, or mixed episode (TIMan). Data from participants who had not met TIMan were defined as censored. (NCT00550407)
Timeframe: Randomization to Study Withdrawal (up to Week 26)
| Intervention | participants (Number) | |
|---|---|---|
| Intervention Event | Censored | |
| Lamotrigine 200 mg | 5 | 40 |
| Placebo | 10 | 48 |
The number of participants with intervention for any mood episode was measured. The necessity of the intervention was determined by the Investigator's discretion. This outcome measure was added post-hoc because no data are being reported for the Lamotrigine group regarding time to intervention for any mood episode (TIME). See the outcome measure for TIME for data for the Placebo group. Data from participants who had not met TIME were defined as censored. (NCT00550407)
Timeframe: Randomization to Study Withdrawal (up to Week 26)
| Intervention | participants (Number) | |
|---|---|---|
| Intervention Event | Censored | |
| Lamotrigine 200 mg | 20 | 25 |
| Placebo | 37 | 21 |
The number of participants with intervention for depressive episode was measured. The necessity of the intervention was determined by the Investigator's discretion. This outcome measure was added post-hoc because no data are being reported for the Placebo or Lamotrigine groups regarding time to intervention for depressive episode (TIDep). Data from participants who had not met TIDep were defined as censored. (NCT00550407)
Timeframe: Randomization to Study Withdrawal (up to Week 26)
| Intervention | participants (Number) | |
|---|---|---|
| Intervention Event | Censored | |
| Lamotrigine 200 mg | 15 | 30 |
| Placebo | 27 | 31 |
Severity of the bipolar illness was based on the CGI-BP(S) score which had a range from 1 (normal, not ill) to 7 (very severely ill). Analysis was performed using mixed model repeated measures. (NCT00723450)
Timeframe: Baseline and Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, and 18
| Intervention | Scores on a scale (Least Squares Mean) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 | Week 2 | Week 3 | Week 4 | Week 5 | Week 6 | Week 7 | Week 8 | Week 9 | Week 10 | Week 11 | Week 12 | Week 13 | Week 14 | Week 15 | Week 16 | Week 17 | Week 18 | |
| LTG: Open-Label Phase | -0.4 | -0.6 | -0.9 | -1.0 | -1.2 | -1.3 | -1.4 | -1.5 | -1.6 | -1.8 | -1.9 | -2.1 | -2.1 | -2.1 | -2.1 | -2.1 | -2.0 | -2.1 |
The CGI-P is a 10-item scale used to assess attention deficit hyperactivity disorder (ADHD) symptoms in children and adolescents aged 3-17 years of age. The scale is composed of two factors: restless-impulsive behavior and emotional lability. Each item was scored on a 0-3 scale. The range of scores for the CGI-P is 0 (best possible outcome) to 30 (worst possible outcome). The CGI-P was completed by the participant's custodial parent or legal guardian. Analysis was performed using mixed model repeated measures. (NCT00723450)
Timeframe: Baseline and Weeks 4, 8, 12, 16, and 18
| Intervention | Scores on a scale (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | Week 18 | |
| LTG: Open-Label Phase | -4.0 | -5.7 | -6.7 | -7.1 | -8.2 |
The P-YMRS was adapted from the YMRS for completion by parents of the pediatric participants with bipolar disorder in order to assess the severity of the manic symptoms. The P-YMRS consisted of 11 items and had a total score range of 0 (best possible outcome) to 60 (worst possible outcome). The P-YMRS was completed by the participant's custodial parent or legal guardian. Analysis was performed using mixed model repeated measures. (NCT00723450)
Timeframe: Baseline and Weeks 4, 8, 12, 16, and 18
| Intervention | Scores on a scale (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | Week 18 | |
| LTG: Open-Label Phase | -4.7 | -6.0 | -7.4 | -8.2 | -9.3 |
The QIDS-A17-C is a 17-item scale used to assess depression severity in adolescents according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) diagnostic criteria for a major depressive episode; it is a modified version of the Quick Inventory of Depressive Symptomatology (QIDS) used for adults. Each item is scored on a 0-3 scale, yielding 9 domain scores. The range of scores is 0 (best possible outcome) to 27 (worst possible outcome). Analysis was performed using mixed model repeated measures. (NCT00723450)
Timeframe: Baseline and Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, and 18
| Intervention | Scores on a Scale (Least Squares Mean) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 | Week 2 | Week 3 | Week 4 | Week 5 | Week 6 | Week 7 | Week 8 | Week 9 | Week 10 | Week 11 | Week 12 | Week 13 | Week 14 | Week 15 | Week 16 | Week 17 | Week 18 | |
| LTG: Open-Label Phase | -2.1 | -2.9 | -3.7 | -3.8 | -4.3 | -4.7 | -5.1 | -4.9 | -5.6 | -6.1 | -6.4 | -6.6 | -6.7 | -6.8 | -6.8 | -6.8 | -6.5 | -6.5 |
The QIDS-A17-SR is a 17-item scale used to assess depression severity in adolescents according to the DSM-IV-TR diagnostic criteria for a major depressive episode; it is a modified version of the Quick Inventory of Depressive Symptomatology (QIDS) used for adults. Each item is scored on a 0-3 scale, yielding 9 domain scores. The range of scores is 0 (best possible outcome) to 27 (worst possible outcome). The scale is completed by the participant. Analysis was performed using mixed model repeated measures. (NCT00723450)
Timeframe: Baseline and Weeks 4, 8, 12, 16, and 18
| Intervention | Scores on a scale (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | Week 18 | |
| LTG: Open-Label Phase | -2.7 | -3.3 | -4.3 | -4.5 | -5.0 |
The YMRS consists of 11 items and is based on the participant's report of their mania symptoms. It is clinician rated. Four items (irritability, speech, thought content, and disruptive/aggressive behavior) are rated on a scale of 0 to 8, while the other seven items (elevated mood, increased motor activity-energy, sexual interest, sleep, language, appearance, and insight) are rated on a scale of 0 to 4. The range of scores for the YMRS is 0 (best possible outcome) to 60 (worst possible outcome). The YMRS was completed by the investigator or their qualified designee. Analysis was performed using mixed model repeated measures. (NCT00723450)
Timeframe: Baseline and Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, and 18
| Intervention | Scores on a scale (Least Squares Mean) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 | Week 2 | Week 3 | Week 4 | Week 5 | Week 6 | Week 7 | Week 8 | Week 9 | Week 10 | Week 11 | Week 12 | Week 13 | Week 14 | Week 15 | Week 16 | Week 17 | Week 18 | |
| LTG: Open-Label Phase | -3.2 | -4.8 | -6.4 | -6.5 | -7.5 | -8.4 | -9.1 | -8.8 | -9.6 | -10.3 | -11.1 | -11.6 | -12.0 | -12.0 | -12.4 | -12.3 | -12.2 | -12.1 |
Severity of the bipolar illness was based on the CGI-BP(S) score which had a range from 1 (normal, not ill) to 7 (very severely ill). Analysis was performed using mixed model repeated measures. (NCT00723450)
Timeframe: Randomization and Weeks 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, and 36
| Intervention | Scores on a scale (Least Squares Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 | Week 2 | Week 3 | Week 4 | Week 6 | Week 8 | Week 10 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | |
| Lamotrigine | 0.0 | 0.2 | 0.2 | 0.3 | 0.4 | 0.4 | 0.6 | 0.4 | 0.6 | 0.8 | 0.6 | 0.5 | 0.5 | 0.3 |
| Placebo | 0.2 | 0.4 | 0.4 | 0.6 | 0.8 | 0.7 | 0.4 | 0.5 | 0.6 | 0.5 | 0.4 | 0.3 | 0.2 | 0.4 |
The CGI-P is a 10-item scale used to assess attention deficit hyperactivity disorder (ADHD) symptoms in children and adolescents aged 3-17 years of age. The scale is composed of two factors: restless-impulsive behavior and emotional lability. Each item was scored on a 0-3 scale. The range of scores for the CGI-P is 0 (best possible outcome) to 30 (worst possible outcome). The CGI-P was completed by the participant's custodial parent or legal guardian. Analysis was performed using mixed model repeated measures. (NCT00723450)
Timeframe: Randomization and Weeks 8, 16, 24, 32, and 36
| Intervention | Scores on a scale (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Week 8 | Week 16 | Week 24 | Week 32 | Week 36 | |
| Lamotrigine | 2.1 | 1.2 | 3.1 | 2.6 | 0.5 |
| Placebo | 3.1 | 3.4 | 2.4 | 2.7 | 1.5 |
The P-YMRS was adapted from the YMRS for completion by parents of the pediatric participants with bipolar disorder in order to assess the severity of the manic symptoms. The P-YMRS consisted of 11 items and had a total score range of 0 (best possible outcome) to 60 (worst possible outcome). The P-YMRS was completed by the participant's custodial parent or legal guardian. Analysis was performed using mixed model repeated measures. (NCT00723450)
Timeframe: Randomization and Weeks 8, 16, 24, 32, and 36
| Intervention | Scores on a scale (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Week 8 | Week 16 | Week 24 | Week 32 | Week 36 | |
| Lamotrigine | 4.3 | 2.6 | 5.7 | 6.0 | 4.5 |
| Placebo | 4.9 | 2.7 | 5.3 | 5.1 | 5.3 |
The QIDS-A17-C is a 17-item scale used to assess depression severity in adolescents according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) diagnostic criteria for a major depressive episode; it is a modified version of the Quick Inventory of Depressive Symptomatology (QIDS) used for adults. Each item is scored on a 0-3 scale, yielding 9 domain scores. The range of scores is 0 (best possible outcome) to 27 (worst possible outcome). Analysis was performed using mixed model repeated measures. (NCT00723450)
Timeframe: Randomization and Weeks 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, and 36
| Intervention | Scores on a scale (Least Squares Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 | Week 2 | Week 3 | Week 4 | Week 6 | Week 8 | Week 10 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | |
| Lamotrigine | 0.5 | 1.1 | 0.6 | 1.0 | 1.5 | 1.7 | 1.5 | 1.2 | 1.8 | 2.5 | 1.8 | 2.3 | 1.9 | 1.9 |
| Placebo | 0.8 | 1.5 | 1.3 | 1.2 | 1.9 | 1.9 | 1.4 | 1.4 | 2.2 | 1.5 | 1.7 | 1.6 | 1.0 | 2.3 |
The QIDS-A17-SR is a 17-item scale used to assess depression severity in adolescents according to the DSM-IV-TR diagnostic criteria for a major depressive episode; it is a modified version of the Quick Inventory of Depressive Symptomatology (QIDS) used for adults. Each item is scored on a 0-3 scale, yielding 9 domain scores. The range of scores is 0 (best possible outcome) to 27 (worst possible outcome). The scale is completed by the participant. Analysis was performed using mixed model repeated measures. (NCT00723450)
Timeframe: Randomization and Weeks 8, 16, 24, 32, and 36
| Intervention | Scores on a scale (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Week 8 | Week 16 | Week 24 | Week 32 | Week 36 | |
| Lamotrigine | 1.2 | 1.4 | 1.5 | 0.2 | 0.8 |
| Placebo | 1.6 | 1.6 | 1.0 | 0.6 | 0.9 |
The YMRS consists of 11 items and is based on the participant's report of their mania symptoms. It is clinician rated. Four items (irritability, speech, thought content, and disruptive/aggressive behavior) are rated on a scale of 0 to 8, while the other seven items (elevated mood, increased motor activity-energy, sexual interest, sleep, language, appearance, and insight) are rated on a scale of 0 to 4. The range of scores for the YMRS is 0 (best possible outcome) to 60 (worst possible outcome). The YMRS was completed by the investigator or their qualified designee. Analysis was performed using mixed model repeated measures. (NCT00723450)
Timeframe: Randomization and Weeks 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, and 36
| Intervention | Scores on a scale (Least Squares Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 | Week 2 | Week 3 | Week 4 | Week 6 | Week 8 | Week 10 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | |
| Lamotrigine | 0.4 | 2.1 | 1.3 | 2.0 | 2.3 | 3.5 | 2.9 | 1.6 | 3.0 | 4.5 | 2.9 | 3.7 | 2.6 | 1.2 |
| Placebo | 1.3 | 2.6 | 2.6 | 3.7 | 4.9 | 4.3 | 3.5 | 3.2 | 4.7 | 4.8 | 4.2 | 4.4 | 4.5 | 3.5 |
"The CGI-BP(I) asks the following question: Compared to the Baseline assessment in this trial, how much has the participant changed?. Scores on the CGI-I range from 1 (very much improved) to 7 (very much worse). The investigator or their designee rated improvement regardless of whether the improvement to be due to drug treatment. Improvement defined as CGI-BP(I)=1 (improved) or 2 (very much improved). Missing data imputed using last-observation carried forward (LOCF)." (NCT00723450)
Timeframe: Baseline and Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, and 18
| Intervention | Participants (Number) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1, n=297 | Week 2, n=297 | Week 3, n=297 | Week 4, n=297 | Week 5, n=297 | Week 6, n=297 | Week 7, n=297 | Week 8, n=297 | Week 9, n=297 | Week 10, n=297 | Week 11, n=297 | Week 12, n=297 | Week 13, n=297 | Week 14, n=297 | Week 15, n=297 | Week 16, n=297 | Week 17, n=297 | Week 18, n=297 | |
| LTG: Open-Label Phase | 27 | 46 | 72 | 86 | 113 | 124 | 138 | 140 | 159 | 176 | 182 | 195 | 205 | 211 | 210 | 209 | 208 | 206 |
"The CGI-BP(I) asks the following question: Compared to the Randomization assessment in this trial, how much has the participant changed?. Scores on the CGI-I range from 1 (very much improved) to 7 (very much worse). The investigator or their designee rated improvement regardless of whether the improvement to be due to drug treatment. Improvement defined as CGI-BP(I)=1 (improved) or 2 (very much improved). Missing data imputed using last-observation carried forward (LOCF)." (NCT00723450)
Timeframe: Randomization and Weeks 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, and 36
| Intervention | Participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 | Week 2 | Week 3 | Week 4 | Week 6 | Week 8 | Week 10 | Week 12 | Week 16 | Week 20 | Week 24 | Week 28 | Week 32 | Week 36 | |
| Lamotrigine | 31 | 22 | 21 | 19 | 23 | 19 | 12 | 17 | 16 | 14 | 15 | 15 | 15 | 13 |
| Placebo | 31 | 25 | 24 | 22 | 20 | 22 | 22 | 21 | 21 | 21 | 21 | 22 | 19 | 20 |
The number of participants requiring intervention to treat either the emergence of or a change in bipolar symptoms that is, experiencing a relapse/recurrence to depression, mania/hypomania, or mixed mood state were analyzed. (NCT00723450)
Timeframe: From randomization until a relapse/recurrence to depression, mania/hypomania, or mixed mood state (up to Week 36)
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Depression | Mania/hypomania | Mixed episode state | |
| Lamotrigine | 3 | 6 | 9 |
| Placebo | 5 | 16 | 10 |
The proportion of participants (par.) requiring intervention to treat either the emergence of or a change in bipolar symptoms, that is, experiencing a relapse/recurrence to depression, mania/hypomania, or mixed mood state at any time within the first 30, 90, and 180 days in the Randomized Phase were analyzed. (NCT00723450)
Timeframe: From randomization up to Week 36
| Intervention | Participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Mania/hypomania, 30 days, n=16, 6 | Mania/hypomania, 90 days, n=16, 6 | Mania/hypomania, 180 days, n=16, 6 | Depression, 30 days, n=5, 3 | Depression, 90 days, n=5, 3 | Depression, 180 days, n=5, 3 | Mixed mood state, 30 days, n= 10, 9 | Mixed mood state, 90 days, n= 10, 9 | Mixed mood state, 180 days, n= 10, 9 | |
| Lamotrigine | 2 | 4 | 5 | 1 | 2 | 3 | 2 | 6 | 8 |
| Placebo | 9 | 12 | 16 | 1 | 5 | 5 | 3 | 7 | 10 |
Improvement of bipolar illness was based on the CGI-BP (I) score which ranged from 1 (very much improved) to 7 (very much worse). Analysis was performed using mixed model repeated measures. (NCT00723450)
Timeframe: Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, and 18
| Intervention | Scores on a scale (Mean) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1, n=290 | Week 2, n=278 | Week 3, n=270 | Week 4, n=265 | Week 5, n=258 | Week 6, n=243 | Week 7, n=246 | Week 8, n=236 | Week 9, n=227 | Week 10, n=205 | Week 11, n=181 | Week 12, n=168 | Week 13, n=141 | Week 14, n=118 | Week 15, n=93 | Week 16, n=72 | Week 17, n=42 | Week 18, n=28 | |
| LTG: Open-Label Phase | 3.6 | 3.3 | 3.1 | 3.0 | 2.8 | 2.7 | 2.5 | 2.5 | 2.3 | 2.2 | 2.2 | 2.0 | 1.9 | 1.9 | 1.8 | 2.0 | 2.0 | 2.0 |
Improvement of bipolar illness was based on the CGI-BP(I) score which ranged from 1 (very much improved) to 7 (very much worse). Analysis was performed using mixed model repeated measures. (NCT00723450)
Timeframe: Randomization weeks 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32 and 36
| Intervention | Scores on a scale (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1, n=84, 85 | Week 2, n=82, 81 | Week 3, n=74, 75 | Week 4, n=65, 70 | Week 6, n=58, 64 | Week 8, n=51, 60 | Week 10, n=45, 55 | Week 12, n=45, 49 | Week 16, n=43, 50 | Week 20, n=37, 43 | Week 24, n=34, 36 | Week 28, n=29, 32 | Week 32, n=28, 27 | Week 36, n=27, 24 | |
| Lamotrigine | 3.3 | 3.6 | 3.6 | 3.6 | 3.4 | 3.6 | 3.8 | 3.4 | 3.5 | 3.8 | 3.4 | 3.5 | 3.5 | 3.6 |
| Placebo | 3.3 | 3.7 | 3.6 | 3.6 | 3.8 | 3.5 | 3.3 | 3.3 | 3.4 | 3.0 | 3.0 | 2.7 | 3.0 | 3.0 |
The time from randomization to the intervention for a mood episode (depression, mania/hypomania or mixed mood) was analyzed. TIME was calculated using the log rank test with stratification for index mood state (depression, mania/hypomania, mixed mood). (NCT00723450)
Timeframe: From randomization until intervention administered for a mood episode (up to Week 36)
| Intervention | Days (Mean) | ||
|---|---|---|---|
| Stratum: Depression, n=22, 21 | Stratum: Mania/Hypomania, n=36, 37 | Stratum: Mixed Mood, n=28, 29 | |
| Lamotrigine | 164 | 179 | 127 |
| Placebo | 62 | 129 | 120 |
The time from randomization to intervention for depression (TIDep), mania/hypomania (TIMan), or a mixed episode (TIMix) was analyzed. TIDep, TIMan, and TIMix were calculated using the log rank test with stratification for index mood state (depression, mania/hypomania, mixed mood). (NCT00723450)
Timeframe: From randomization until intervention administered for depression, mania/hypomania or a mixed episode (up to Week 36)
| Intervention | Days (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| TIDep: Depression, n=22, 21 | TIDep: Mania/Hypomania, n=36, 37 | TIDep: Mixed Mood, n=28, 29 | TIMan: Depression, n=22, 21 | TIMan: Mania/Hypomania, n=36, 37 | TIMan: Mixed Mood, n=28, 29 | TIMix: Depression, n=22, 21 | TIMix: Mania/Hypomania, n=36, 37 | TIMix: Mixed Mood, n=28, 29 | |
| Lamotrigine | 46 | NA | 159 | 182 | 61 | 148 | 158 | 194 | 57 |
| Placebo | 61 | NA | 59 | 74 | 139 | 105 | 37 | 135 | 160 |
TOBE was defined by the first prescription of any additional pharmacotherapy to treat bipolar symptoms, increasing the dose(s) of the participants conventional bipolar medication(s), treatment with electroconvulsive therapy, or moving the participant to a more restricted environment for observation, safety, or treatment; or participant withdrawal from the study due to a bipolar-related adverse event (AE) or serious adverse event (SAE); or participants withdrawal from the study due to lack of efficacy as defined by rating scale threshold scores. TOBE was calculated using a log rank test with stratification for index mood state (depression, mania/hypomania, mixed mood). (NCT00723450)
Timeframe: From randomization until Week 36
| Intervention | Days (Mean) | ||
|---|---|---|---|
| Stratum: Depression, n=22,21 | Stratum: Mania/Hypomania, n=36, 37 | Stratum: Mixed Mood, n=28, 29 | |
| Lamotrigine | 155 | 163 | 136 |
| Placebo | 50 | 120 | 107 |
The time from randomization to the withdrawal from study was analyzed. TTW was calculated using the log rank test with stratification for index mood state (depression, mania/hypomania, mixed mood). (NCT00723450)
Timeframe: From randomization until withdrawal from the study for any cause (up to Week 36)
| Intervention | Days (Mean) | ||
|---|---|---|---|
| Stratum: Depression, n=22, 21 | Stratum: Mania/Hypomania, n=36, 37 | Stratum: Mixed Mood, n=28, 29 | |
| Lamotrigine | 141 | 144 | 106 |
| Placebo | 113 | 138 | 101 |
Response for depressive symptoms was defined as a score less than 40 on the CDRS-R. Range is 18 to 120. Score 18 is normal and higher score signifies depression. The Children's Depression Rating Scale (CDRS) is a 16-item measure used to determine the severity of depression in children 6-18 years of age. Items are measured on 3-, 4-, 5-, and 6-point scales. The mean and standard deviation at week 0, 8 and 14 will indicate if there is a change in the scores with the treatment. (NCT00176228)
Timeframe: weekly at baseline and each week during osing (8 weeks) and dose stabilized phase (6 weeks)
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | 8 week point | 14 week point | |
| Lamotrigine | 52 | 31.39 | 26.10 |
This measure has 11 items. The purpose of each item is to rate the severity of that abnormality in the patient. A severity rating is assigned to each of the eleven items, based on the patient's subjective report of his or her condition over the previous forty-eight hours and the clinician's behavioral observations during the interview, with the emphasis on the latter. There are four items that are graded on a 0 to 8 scale (irritability, speech, thought content, and disruptive/aggressive behavior), while the remaining seven items are graded on a 0 to 4 scale. Total score of zero to 60 is possible, zero being normal and 60 being severe, 12 serving as a cut off point for illness if equal or above. There are several ways to show change in outcome. The mean and standard deviation at week 0, 8 and 14 will indicate if there is a change in the scores with the treatment. (NCT00176228)
Timeframe: Weekly during the 8 week lamotrigine dose titration and 6 week full dose phase.
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | 8 week point | 14 week point | |
| Lamotrigine Effectiveness on YMRS (Mania Measure) | 19.61 | 7.06 | 5.68 |
CGI-S is a single-item clinician rated scale used to assess global severity of bipolar illness based on an overall evaluation of symptoms of bipolar mania, associated behavioral symptoms, and condition of the subject. Scored from 1 (normal, not at all ill) to 7 (among the most severely ill subjects). Higher score = more affected. Change calculated as a difference between post-baseline observation and baseline CGI-S score values. (NCT00483548)
Timeframe: Baseline, Week 6
| Intervention | scores on scale (Mean) |
|---|---|
| Ziprasidone | -1.5 |
| Placebo | -1.5 |
MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts); rated on a 7-point Likert scale 0 (normal) to 6 (most abnormal); total score 0 to 44 (higher score indicates greater severity of symptoms). Change calculated as a difference between post-baseline observation and baseline MADRS score values. (NCT00483548)
Timeframe: Baseline, Week 6
| Intervention | scores on scale (Mean) |
|---|---|
| Ziprasidone | -14.7 |
| Placebo | -13.2 |
Number of subjects with improvement defined as CGI-I response of 1 (very much improved) or 2 (much improved). CGI-I is a single-item clinician rated scale used to assess global improvement in the subject's clinical state (bipolar mania) in response to study treatment and as compared to their status at pre-treatment baseline. Scores range from 1 (very much improved) to 4 (no change) to 7 (very much worse). Higher score = more affected. (NCT00483548)
Timeframe: Baseline, Week 6
| Intervention | participants (Number) |
|---|---|
| Ziprasidone | 66 |
| Placebo | 69 |
Number of subjects with MADRS total score ≤ 12 (indicates remission). MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts); rated on a 7-point Likert scale 0 (normal) to 6 (most abnormal); total score 0 to 44 (higher score indicates greater severity of symptoms). (NCT00483548)
Timeframe: Week 6
| Intervention | participants (Number) |
|---|---|
| Ziprasidone | 48 |
| Placebo | 54 |
Number of subjects with reduction of ≥50 percent (%) in MADRS total score (indicates response). MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts); rated on a 7-point Likert scale 0 (normal) to 6 (most abnormal); total score 0 to 44 (higher score indicates greater severity of symptoms). Reduction calculated as ([A-B]/B*100): A=value at observation; B=baseline value. (NCT00483548)
Timeframe: Week 6
| Intervention | participants (Number) |
|---|---|
| Ziprasidone | 62 |
| Placebo | 65 |
CGI-I is a single-item clinician rated scale used to assess global improvement in the subject's clinical state (bipolar mania) in response to study treatment and as compared to their status at pre-treatment baseline. Scores range from 1 (very much improved) to 4 (no change) to 7 (very much worse). Higher score = more affected. Week 6 is the primary timepoint. (NCT00483548)
Timeframe: Week 1, Week 2, Week 3, Week 4, Week 5, Week 6
| Intervention | scores on scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Week 1 (n=142, 141) | Week 2 (n=120, 138) | Week 3 (n=115, 130) | Week 4 (n=106, 122) | Week 5 (n=103, 112) | Week 6 (n=92, 108) | |
| Placebo | 3.4 | 3.1 | 2.9 | 2.8 | 2.6 | 2.4 |
| Ziprasidone | 3.2 | 2.9 | 2.7 | 2.6 | 2.5 | 2.4 |
AIMS is a clinician rated 12-item scale to rate 7 body areas and global judgments on the severity of abnormal movements, incapacitation and subject's awareness of abnormal movements. Items 1 to 10 scored 0 (none) to 4 (severe); items 11 to 14 are No or Yes response to dental status and sleep movements and are assessed separately. AIMS total score is sum of first 7 items. Change calculated as a difference between post-baseline observation and baseline AIMS score values. (NCT00483548)
Timeframe: Baseline, Week 2, Week 4, Week 6
| Intervention | scores on scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Total score: Week 2 (n=136, 142) | Total score: Week 4 (n=111, 127) | Total score: Week 6 (n=100, 111) | Global severity score: Week 2 (n=136, 142) | Global severity score: Week 4 (n=111, 127) | Global severity score: Week 6 (n=100, 111) | Incapacitation score: Week 2 (n=136, 142) | Incapacitation score: Week 4 (n=111, 127) | Incapacitation score: Week 6 (n=100, 111) | |
| Placebo | -0.1 | -0.0 | -0.0 | -0.0 | 0.0 | 0.0 | -0.0 | -0.0 | 0.0 |
| Ziprasidone | 0.1 | -0.0 | -0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
BARS is a clinician rated scale to evaluate akathisia associated with use of antipsychotic medications: objective motor restlessness, range 0 to 3; subjective complaints of restlessness and associated distress, range 0 to 3; global clinical assessment of akathisia, range 0 to 5. Higher scores indicate more affected. Change calculated as a difference between post-baseline observation and baseline BARS score values. (NCT00483548)
Timeframe: Baseline, Week 2, Week 4, Week 6
| Intervention | scores on scale (Mean) | ||
|---|---|---|---|
| Week 2 (n=135, 139) | Week 4 (n=111, 125) | Week 6 (n=100, 110) | |
| Placebo | -0.0 | 0.0 | -0.0 |
| Ziprasidone | 0.1 | 0.0 | 0.0 |
CGI-S is a single-item clinician rated scale used to assess global severity of bipolar illness based on an overall evaluation of symptoms of bipolar mania, associated behavioral symptoms, and condition of the subject. Scores range from 1 (normal, not at all ill) to 7 (among the most severely ill subjects). Higher score = more affected. Change calculated as a difference between post-baseline observation and baseline CGI-S score values. (NCT00483548)
Timeframe: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5
| Intervention | scores on scale (Mean) | ||||
|---|---|---|---|---|---|
| Week 1 (n=142, 141) | Week 2 (n=120, 139) | Week 3 (n=115, 130) | Week 4 (n=106, 122) | Week 5 (n=103, 112) | |
| Placebo | -0.4 | -0.7 | -0.9 | -1.1 | -1.3 |
| Ziprasidone | -0.5 | -0.9 | -0.9 | -1.1 | -1.3 |
GAF is a clinician rated scale to measure the severity of illness-related impairment in psychological, social, and occupational functioning using a 100-point scale (single score of 1 to 100) with 100 indicating a superior level of function. Change calculated as a difference between post-baseline observation and baseline GAF score values. (NCT00483548)
Timeframe: Baseline, Week 6
| Intervention | scores on scale (Mean) | |
|---|---|---|
| Week 6 (n=100, 110) | ET (n=34, 27) | |
| Placebo | 11.2 | 2.8 |
| Ziprasidone | 14.7 | 0.0 |
HAM-A is a clinician rated 14-item scale that rates the intensity of psychic anxiety (items 1 to 6 and item 14) and somatic anxiety (items 7 to 13) on a 5-point severity scale; scores range from 0 (not present) to 4 (very severe); lower score indicates less affected. Change calculated as a difference between post-baseline observation and baseline HAM-A score values. Week 6 is the primary timepoint. (NCT00483548)
Timeframe: Baseline, Week 2, Week 4, Week 6
| Intervention | scores on scale (Mean) | ||
|---|---|---|---|
| Week 2 (n=136, 141) | Week 4 (n=111, 127) | Week 6 (n=100, 111) | |
| Placebo | -5.9 | -7.4 | -8.6 |
| Ziprasidone | -5.6 | -7.1 | -8.5 |
MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts); rated on a 7-point Likert scale 0 (normal) to 6 (most abnormal); total score 0 to 44 (higher score indicates greater severity of symptoms). Change calculated as a difference between post-baseline observation and baseline MADRS score values. (NCT00483548)
Timeframe: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5
| Intervention | scores on scale (Mean) | ||||
|---|---|---|---|---|---|
| Week 1 (n=142, 141) | Week 2 (n=121, 139) | Week 3 (n=115, 130) | Week 4 (n=106, 122) | Week 5 (n=103, 112) | |
| Placebo | -6.1 | -9.0 | -11.0 | -11.8 | -13.3 |
| Ziprasidone | -8.1 | -11.7 | -13.0 | -14.1 | -14.9 |
Q-LES-Q is a 16-item subject rated scale to measure satisfaction with areas of daily functioning (physical health, social relationships, medication, and overall life satisfaction); rated on a 5-point Likert scale: higher scores indicate greater enjoyment and satisfaction with general life activities. Scores for items 1 to 14 are summed for a total score and converted to 0 to 100 range. Items 15 and 16 measure satisfaction with medication and overall satisfaction and are analyzed separately. Change calculated as a difference between post-baseline observation and baseline Q-LES-Q score values. (NCT00483548)
Timeframe: Baseline, Week 6
| Intervention | scores on scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Total Q-LES-Q: Week 6 (n=82, 94) | Total Q-LES-Q: ET (n=27, 17) | Medications: Week 6 (n=91, 93) | Medications: ET (n=27, 20) | Overall life satisfaction: Week 6 (n=94, 103) | Overall life satisfaction: ET (n=31, 23) | |
| Placebo | 11.6 | 1.6 | 0.3 | -0.4 | 0.5 | 0.0 |
| Ziprasidone | 15.2 | -0.1 | 0.4 | -0.3 | 0.8 | 0.1 |
SDS is a 5-item subject rated scale to measure the extent to which work and or school, social life and or leisure activities, and home life and or family responsibilities were impaired by psychiatric illness. Items 1 to 3 rated on 11-point scale ranging 0 (not at all) to 10 (extremely affected). Total score 0 to 30; higher score indicates greater impairment; items 4 and 5 report number of days in the last month (0 to 31) subject missed work or school or was unproductive and are rated separately. Change calculated as a difference between post-baseline observation and baseline SDS score values. (NCT00483548)
Timeframe: Baseline, Week 6
| Intervention | scores on scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Total SDS: Week 6 (n=58, 63) | Total SDS: ET (n=19, 14) | Work/School: Week 6 (n=58, 64) | Work/School: ET (n=19, 14) | Social life: Week 6 (n=94, 102) | Social life: ET (n=31, 23) | Family/Home: Week 6 (n=94, 102) | Family/Home: ET (n=31, 23) | |
| Placebo | -3.7 | -1.4 | -1.6 | -0.1 | -1.7 | 0.1 | -1.7 | -0.6 |
| Ziprasidone | -8.5 | 0.2 | -2.1 | 0.4 | -2.5 | -0.5 | -2.6 | 0.2 |
SDS is a 5-item subject rated scale to measure the extent to which work and or school, social life and or leisure activities, and home life and or family responsibilities were impaired by psychiatric illness. Items 1 to 3 rated on 11-point scale ranging 0 (not at all) to 10 (extremely affected). Total score 0 to 30; higher score indicates greater impairment; items 4 and 5 report number of days in the last month (0 to 31) subject missed work or school or was unproductive and are rated separately. Change calculated as a difference between post-baseline observation and baseline SDS score values. (NCT00483548)
Timeframe: Baseline, Week 6
| Intervention | days (Mean) | |||
|---|---|---|---|---|
| Days lost: Week 6 (n=85, 93) | Days lost: ET (n=29, 21) | Days unproductive: Week 6 (n=87, 89) | Days unproductive: ET (n=29, 21) | |
| Placebo | -0.7 | 0.0 | -1.3 | -0.1 |
| Ziprasidone | -1.2 | 0.5 | -1.6 | -0.2 |
SAS is a clinician rated 10-item scale to measure extrapyramidal side effects (Parkinsonism or Parkinsonian side effects induced with antipsychotics); rated on a 5-point scale with range 0 (absence of condition) to 4 (presence of condition in extreme form). Global score is sum of all scores divided by the total number of items. Change calculated as a difference between post-baseline observation and baseline SAS score values. (NCT00483548)
Timeframe: Baseline, Week 2, Week 4, Week 6
| Intervention | scores on scale (Mean) | ||
|---|---|---|---|
| Week 2 (n=136, 141) | Week 4 (n=111, 126) | Week 6 (n=100, 110) | |
| Placebo | -0.1 | 0.0 | -0.1 |
| Ziprasidone | 0.1 | 0.0 | 0.0 |
YMRS is clinician rated 11-item scale (elevated mood, increased motor activity-energy, sexual interest, sleep, irritability, speech [rate and amount], language-thought disorder, content, disruptive-aggressive behavior, appearance, and insight) used to assess the severity of manic symptoms and effect of treatment on mania severity. Seven items ranked on scale from 0 to 4; 4 items ranked 0 to 8. Higher scores indicate greater severity. Change calculated as a difference between post-baseline observation and baseline YMRS score values. Week 6 is the primary timepoint. (NCT00483548)
Timeframe: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6
| Intervention | scores on scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Week 1 (n=142, 141) | Week 2 (n=121, 139) | Week 3 (n=115, 130) | Week 4 (n=106, 122) | Week 5 (n=103, 112) | Week 6 (n=92, 108) | |
| Placebo | -0.2 | -0.2 | -0.2 | -1.1 | -1.3 | -0.9 |
| Ziprasidone | 0.7 | 0.5 | -0.0 | -0.9 | -0.9 | -1.0 |
Severity of the illness and psychopathological features will be measured by the increase in the SADS Mania Rating Scale, with higher scores representing worse mania. The range of this scale is 0-75. (NCT00183469)
Timeframe: up to 8 months
| Intervention | units on a scale (Mean) |
|---|---|
| Double-Blind Lamotrigine and Divalproex ER | 4.54 |
| Double-Blind Lamotrigine and Placebo Divalproex ER | 5.57 |
Montgomery Asberg Depression Rating Scale (MADRS) total score. Construct: Depression severity. Scores below represent mean change scores, endpoint minus baseline. Minimum total score: 0 (no depression). Maximum total score: 60 (severe depression). Lower (more negative) scores indicate a better outcome. There are no subscales. (NCT00384332)
Timeframe: 10 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Arm 1 | -15.5 |
| Arm 2 | -15.5 |
Change in weight from baseline to endpoint in kilograms. Reported as weight in Kilograms at Baseline, Weeks 1, 4, 6, and 8 (NCT00384332)
Timeframe: 10 weeks
| Intervention | kilograms (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Week 1 | Week 4 | Week 6 | Week 8 | |
| Arm 1- ODT | 76.0 | 77.4 | 77.8 | 78.9 | 79.1 |
| Arm 2- SOT | 76.1 | 77.6 | 78.3 | 79.4 | 80.1 |
A modifiable risk component for each cardiovascular risk factor not at optimal goal at the time of each encounter was calculated as the difference between total 10-year atherosclerotic cardiovascular disease risk with the patient's actual values and the goal value. Total modifiable cardiovascular risk was calculated by summing the modifiable cardiovascula risk components across cardiovascular risk factors not at optimal goal at the time of the encounter, and was calculated for each enrolled patient at the index visit and each subsequent encounter during the intervention period. Annual rate of change in modifiable cardiovascular risk was estimated from all patient encounters. A comparison of the difference in model-estimated rate of change in modifiable cardiovascular risk at 12 months post-index tested the primary efficacy hypothesis. (NCT02451670)
Timeframe: Index to 12 months post index visit
| Intervention | percentage of annual rate of change (Number) |
|---|---|
| Prioritized Clinical Decision Support | 14.2 |
| Usual Care | 20.8 |
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 3.90 |
| Gabapentin | 3.93 |
| Placebo Oral Tablet | 3.73 |
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 21.59 |
| Gabapentin | 21.69 |
| Placebo Oral Tablet | 22.25 |
156 reviews available for lamotrigine and Affective Psychosis, Bipolar
| Article | Year |
|---|---|
Genetics and antiepileptic mood stabilizer treatment response in bipolar disorder: what do we know?
Topics: Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Humans; La | 2021 |
Lamotrigine in the maintenance treatment of bipolar disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Humans; Lamotrigine; Quality of Life; Randomized Controlle | 2021 |
Lamotrigine in the maintenance treatment of bipolar disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Humans; Lamotrigine; Quality of Life; Randomized Controlle | 2021 |
Lamotrigine in the maintenance treatment of bipolar disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Humans; Lamotrigine; Quality of Life; Randomized Controlle | 2021 |
Lamotrigine in the maintenance treatment of bipolar disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Humans; Lamotrigine; Quality of Life; Randomized Controlle | 2021 |
Lamotrigine in the maintenance treatment of bipolar disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Humans; Lamotrigine; Quality of Life; Randomized Controlle | 2021 |
Lamotrigine in the maintenance treatment of bipolar disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Humans; Lamotrigine; Quality of Life; Randomized Controlle | 2021 |
Lamotrigine in the maintenance treatment of bipolar disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Humans; Lamotrigine; Quality of Life; Randomized Controlle | 2021 |
Lamotrigine in the maintenance treatment of bipolar disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Humans; Lamotrigine; Quality of Life; Randomized Controlle | 2021 |
Lamotrigine in the maintenance treatment of bipolar disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Humans; Lamotrigine; Quality of Life; Randomized Controlle | 2021 |
Lamotrigine in the maintenance treatment of bipolar disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Humans; Lamotrigine; Quality of Life; Randomized Controlle | 2021 |
Lamotrigine in the maintenance treatment of bipolar disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Humans; Lamotrigine; Quality of Life; Randomized Controlle | 2021 |
Lamotrigine in the maintenance treatment of bipolar disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Humans; Lamotrigine; Quality of Life; Randomized Controlle | 2021 |
Lamotrigine in the maintenance treatment of bipolar disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Humans; Lamotrigine; Quality of Life; Randomized Controlle | 2021 |
Lamotrigine in the maintenance treatment of bipolar disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Humans; Lamotrigine; Quality of Life; Randomized Controlle | 2021 |
Lamotrigine in the maintenance treatment of bipolar disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Humans; Lamotrigine; Quality of Life; Randomized Controlle | 2021 |
Lamotrigine in the maintenance treatment of bipolar disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Humans; Lamotrigine; Quality of Life; Randomized Controlle | 2021 |
Lamotrigine in the maintenance treatment of bipolar disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Humans; Lamotrigine; Quality of Life; Randomized Controlle | 2021 |
Lamotrigine in the maintenance treatment of bipolar disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Humans; Lamotrigine; Quality of Life; Randomized Controlle | 2021 |
Lamotrigine in the maintenance treatment of bipolar disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Humans; Lamotrigine; Quality of Life; Randomized Controlle | 2021 |
Lamotrigine in the maintenance treatment of bipolar disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Humans; Lamotrigine; Quality of Life; Randomized Controlle | 2021 |
Lamotrigine in the maintenance treatment of bipolar disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Humans; Lamotrigine; Quality of Life; Randomized Controlle | 2021 |
Lamotrigine in the maintenance treatment of bipolar disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Humans; Lamotrigine; Quality of Life; Randomized Controlle | 2021 |
Lamotrigine in the maintenance treatment of bipolar disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Humans; Lamotrigine; Quality of Life; Randomized Controlle | 2021 |
Lamotrigine in the maintenance treatment of bipolar disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Humans; Lamotrigine; Quality of Life; Randomized Controlle | 2021 |
Lamotrigine in the maintenance treatment of bipolar disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Humans; Lamotrigine; Quality of Life; Randomized Controlle | 2021 |
What not to use in bipolar disorders: A systematic review of non-recommended treatments in clinical practice guidelines.
Topics: Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Humans; Lamotrigine; Risperidone | 2022 |
Evidence-based treatment strategies for rapid cycling bipolar disorder, a systematic review.
Topics: Anticonvulsants; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Humans; Lamotrigine; Olanzapi | 2022 |
A systematic review and meta-analysis of treatments for rapid cycling bipolar disorder.
Topics: Aripiprazole; Bipolar Disorder; Citalopram; Fluoxetine; Humans; Lamotrigine; Olanzapine; Quetiapine | 2022 |
Efficacy and safety of lamotrigine in pediatric mood disorders: A systematic review.
Topics: Adolescent; Bipolar Disorder; Child; Depressive Disorder, Major; Humans; Lamotrigine; Triazines | 2023 |
Efficacy and safety profiles of mood stabilizers and antipsychotics for bipolar depression: a systematic review.
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Humans; Lamotrigine; Lithium; Lurasidone H | 2023 |
Ketogenic diet in therapy of bipolar affective disorder - case report and literature review.
Topics: Anticonvulsants; Bipolar Disorder; Diet, Ketogenic; Humans; Lamotrigine; Male; Mood Disorders; Queti | 2022 |
Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-analysis.
Topics: Adult; Bipolar Disorder; Depression; Drug-Related Side Effects and Adverse Reactions; Female; Fluoxe | 2023 |
Psychotropic drug use in perinatal women with bipolar disorder.
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Drug Elimination Routes; Fe | 2020 |
Pharmacotherapy for depression and bipolar disorder during lactation: A framework to aid decision making.
Topics: Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Decision Making; De | 2020 |
Bipolar disorders.
Topics: Adolescent; Adult; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; B | 2020 |
Common mechanisms involved in manic switch and pain relief induced by lamotrigine: A case report and a literature review.
Topics: Anticonvulsants; Bipolar Disorder; Humans; Lamotrigine; Pain; Pain Management | 2021 |
The risks associated with the use of lamotrigine during pregnancy.
Topics: Abnormalities, Drug-Induced; Bipolar Disorder; Developmental Disabilities; Excitatory Amino Acid Ant | 2018 |
Is there consensus across international evidence-based guidelines for the psychotropic drug management of bipolar disorder during the perinatal period?
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Bre | 2018 |
Short course of cyclosporin A as a treatment option for drug-induced hypersensitivity syndrome: Case reports and review of the published work.
Topics: Administration, Oral; Adult; Aged, 80 and over; Bipolar Disorder; Cyclosporine; Dose-Response Relati | 2018 |
Risks associated with lamotrigine prescription: a review and personal observations.
Topics: Antipsychotic Agents; Bipolar Disorder; Drug and Narcotic Control; Drug Prescriptions; Eosinophilia; | 2018 |
An Unusual Etiology of Vocal Tremor in a Professional Singer.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Dose-Response Relationship, Drug; Female; Humans; Lam | 2019 |
Treatment of Peripartum Bipolar Disorder.
Topics: Bipolar Disorder; Electroconvulsive Therapy; Female; Humans; Lamotrigine; Peripartum Period; Phototh | 2018 |
Lamotrigine as a mood stabilizer: insights from the pre-clinical evidence.
Topics: Animals; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Dose-Response Relationship, Drug; Drug | 2019 |
Efficacy and safety of lithium and lamotrigine for the maintenance treatment of clinically stable patients with bipolar disorder: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials with an enrichment design.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Depression; Double-Blind Method; Female; Humans; Lamo | 2019 |
Pharmacotherapies for co-occurring substance use and bipolar disorders: A systematic review.
Topics: Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Comorbidity; Humans; Lamo | 2019 |
One-carbon metabolism and bipolar disorder.
Topics: Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Brain; Folic Acid; Humans; Lamotrigine; M | 2013 |
A review of FDA-approved treatment options in bipolar depression.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzhydryl Co | 2013 |
Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; | 2014 |
Evolving Electrocardiographic Changes in Lamotrigine Overdose: A Case Report and Literature Review.
Topics: Adult; Antimanic Agents; Arrhythmias, Cardiac; Bipolar Disorder; Drug Overdose; Electrocardiography; | 2015 |
Brain biomarkers of treatment for multi-domain dysfunction: pharmacological FMRI studies in pediatric mania.
Topics: Antimanic Agents; Biomarkers; Bipolar Disorder; Brain; Child; Humans; Lamotrigine; Magnetic Resonanc | 2015 |
Current landscape, unmet needs, and future directions for treatment of bipolar depression.
Topics: Anticonvulsants; Antidepressive Agents; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Drug | 2014 |
Balancing benefits and harms of treatments for acute bipolar depression.
Topics: Acute Disease; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Diben | 2014 |
The 'disconnect' between initial judgments of lamotrigine vs. its real-world effectiveness in managing bipolar disorder. A tale with wider ramifications.
Topics: Anticonvulsants; Bipolar Disorder; Humans; Lamotrigine; Outcome Assessment, Health Care; Randomized | 2015 |
Management of adverse effects of mood stabilizers.
Topics: Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Disease Ma | 2015 |
Bipolar Disorder in Pregnancy and Postpartum: Principles of Management.
Topics: Antipsychotic Agents; Bipolar Disorder; Electroconvulsive Therapy; Female; Humans; Lactation; Lamotr | 2016 |
Topics: AC133 Antigen; Acenaphthenes; Acer; Acrosome Reaction; Adult; Agaricales; Aged; Aged, 80 and over; A | 2016 |
The effect of mood-stabilizing drugs on cytokine levels in bipolar disorder: A systematic review.
Topics: Affect; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Cytokines; Female; Humans; Lamotri | 2016 |
Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials.
Topics: Anticonvulsants; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bip | 2016 |
[Mood stabilizers--past, present and future].
Topics: Affect; Antimanic Agents; Bipolar Disorder; Calcium; Carbamazepine; Depressive Disorder; gamma-Amino | 2008 |
Clinical inquiries: what drugs are best for bipolar depression?
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Humans; Lamotrigine; | 2008 |
Lamotrigine-associated rash: to rechallenge or not to rechallenge?
Topics: Anticonvulsants; Bipolar Disorder; Databases, Bibliographic; Dose-Response Relationship, Drug; Drug | 2009 |
Fulminant hepatitis induced by lamotrigine.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Chemical and Drug Induced Liver Injury; Female; Humans; La | 2009 |
Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials.
Topics: Adult; Aged; Bipolar Disorder; Calcium Channel Blockers; Epidemiologic Methods; Female; Humans; Lamo | 2009 |
[Trichotillomania and comorbidity--lamotrigine in a new perspective].
Topics: Adolescent; Adult; Antidepressive Agents; Antimanic Agents; Anxiety; Behavior, Addictive; Bipolar Di | 2008 |
Early intervention in bipolar disorder, part II: therapeutics.
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Brain; Early Diagnosis; Humans; Lamotrigin | 2008 |
Neonatal outcomes with the use of lamotrigine for bipolar disorder in pregnancy and breastfeeding: a case series and review of the literature.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Breast Feeding; Female; Follow-Up Studies; Humans; Infant | 2009 |
Neural network dysfunction in bipolar depression: clues from the efficacy of lamotrigine.
Topics: Animals; Anticonvulsants; Bipolar Disorder; Humans; Lamotrigine; Nerve Net; Treatment Outcome; Triaz | 2009 |
Is the brain arachidonic acid cascade a common target of drugs used to manage bipolar disorder?
Topics: Animals; Anticonvulsants; Antidepressive Agents; Arachidonic Acid; Bipolar Disorder; Brain; Carbamaz | 2009 |
[Teratogenic effects of lamotrigine in women with bipolar disorder].
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Epilepsy; Fema | 2009 |
Frequency of and rationales for the combined use of electroconvulsive therapy and antiepileptic drugs in Austria and the literature.
Topics: Anticonvulsants; Austria; Bipolar Disorder; Carbamazepine; Combined Modality Therapy; Electroconvuls | 2009 |
Is anticonvulsant treatment of mania a class effect? Data from randomized clinical trials.
Topics: Amines; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Cy | 2011 |
Pharmacologic mood destabilization: case vignettes.
Topics: Adult; Affect; Anticonvulsants; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperacti | 2009 |
[Sense and sensibility: bipolar affective disorder as a battlefield of cognitions and emotions--lamotrigine therapy as a peacekeeper].
Topics: Adolescent; Adult; Affect; Aged; Antimanic Agents; Bipolar Disorder; Cerebral Cortex; Child; Clinica | 2010 |
Bipolar disorder: an update.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Benzhydryl Compounds; Benzothiazoles; | 2010 |
Treatment options for bipolar depression: a systematic review of randomized, controlled trials.
Topics: Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Di | 2010 |
Pharmacotherapy for the treatment of acute bipolar II depression: current evidence.
Topics: Acute Disease; Antidepressive Agents; Antimanic Agents; Benzhydryl Compounds; Benzothiazoles; Bipola | 2011 |
Lamotrigine: when and where does it act in affective disorders? A systematic review.
Topics: Antimanic Agents; Bipolar Disorder; Clinical Trials as Topic; Humans; Lamotrigine; Mood Disorders; T | 2011 |
Mood stabilizers in pregnancy: a systematic review.
Topics: Abnormalities, Drug-Induced; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Carbamazepin | 2010 |
Tolerance to the prophylactic effects of carbamazepine and related mood stabilizers in the treatment of bipolar disorders.
Topics: Amygdala; Animals; Anticonvulsants; Bipolar Disorder; Carbamazepine; Drug Resistance; Drug Tolerance | 2011 |
Clinical practice. Bipolar disorder--a focus on depression.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disord | 2011 |
[Treatment of bipolar disorder during pregnancy and in the postpartum period].
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Contraindications; Female; Humans; Lactati | 2011 |
Beneficial effects of mood stabilizers lithium, valproate and lamotrigine in experimental stroke models.
Topics: Animals; Antipsychotic Agents; Bipolar Disorder; Disease Models, Animal; Humans; Lamotrigine; Lithiu | 2011 |
[Evidence of treatment for depressive episodes of bipolar disorder].
Topics: Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; | 2011 |
[Lithium and anticonvulsants in bipolar depression].
Topics: Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Clinical Trials as Topic; | 2011 |
[Mood stabilizers].
Topics: Antimanic Agents; Bipolar Disorder; Carbamazepine; Humans; Lamotrigine; Lithium; Triazines; Valproic | 2012 |
[Mood stabilizer].
Topics: Antimanic Agents; Bipolar Disorder; Carbamazepine; Humans; Lamotrigine; Lithium Compounds; Triazines | 2012 |
Lamotrigine (Lamictal IR) for the treatment of bipolar disorder.
Topics: Antimanic Agents; Bipolar Disorder; Humans; Lamotrigine; Treatment Outcome; Triazines | 2012 |
Fatal progressive hepatic necrosis associated with lamotrigine treatment: a case report and literature review.
Topics: Adult; Anticonvulsants; Biopsy; Bipolar Disorder; Chemical and Drug Induced Liver Injury; Fatal Outc | 2002 |
Lamotrigine in the treatment of bipolar disorder.
Topics: Antidepressive Agents; Bipolar Disorder; Humans; Lamotrigine; Randomized Controlled Trials as Topic; | 2002 |
Long-term treatment of bipolar disorder with lamotrigine.
Topics: Anticonvulsants; Bipolar Disorder; Clinical Trials as Topic; Drug Administration Schedule; Humans; L | 2002 |
Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management.
Topics: Anticonvulsants; Antimanic Agents; Bipolar Disorder; Cross-Sectional Studies; Depressive Disorder, M | 2002 |
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression.
Topics: Antidepressive Agents; Antimanic Agents; Biological Psychiatry; Bipolar Disorder; Carbamazepine; Ele | 2002 |
New approaches in managing bipolar depression.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Clini | 2003 |
Antidepressant properties of anticonvulsant drugs for bipolar disorder.
Topics: Acetates; Affect; Amines; Anticonvulsants; Antidepressive Agents; Bipolar Disorder; Carbamazepine; C | 2003 |
Treating bipolar depression.
Topics: Acetates; Affect; Amines; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; | 2003 |
Long-term therapy of bipolar illness.
Topics: Affect; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Carbamazepine; Co | 2003 |
Selecting effective long-term treatment for bipolar patients: monotherapy and combinations.
Topics: Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Comorbidity; Drug Therapy, | 2003 |
Valproate.
Topics: Antimanic Agents; Bipolar Disorder; Drug Interactions; Humans; Lamotrigine; Lithium Compounds; Progn | 2003 |
Alternatives to lithium and divalproex in the maintenance treatment of bipolar disorder.
Topics: Acetates; Amines; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar | 2003 |
[Bipolar II disorder].
Topics: Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Clonazepam; Diagnostic and Statistical Ma | 2003 |
Latest maintenance data on lamotrigine in bipolar disorder.
Topics: Bipolar Disorder; Drug Therapy, Combination; Humans; Lamotrigine; Lithium; Randomized Controlled Tri | 2003 |
Lamotrigine: a review of its use in bipolar disorder.
Topics: Antimanic Agents; Bipolar Disorder; Clinical Trials as Topic; Drug Interactions; Humans; Lamotrigine | 2003 |
Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders.
Topics: Animals; Bipolar Disorder; Humans; Ion Channels; Lamotrigine; Signal Transduction; Triazines | 2003 |
[Treatment of acute bipolar disorder. Intriguing balancing act between mania and depression].
Topics: Acute Disease; Algorithms; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiaze | 2003 |
A re-evaluation of the role of antidepressants in the treatment of bipolar depression: data from the Stanley Foundation Bipolar Network.
Topics: Adult; Affect; Antidepressive Agents; Bipolar Disorder; Depressive Disorder; Double-Blind Method; Dr | 2003 |
Safety and tolerability of lamotrigine for bipolar disorder.
Topics: Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Clinical Trials as Topic; Drug Interactio | 2004 |
Pharmacotherapy of bipolar II disorder: a critical review of current evidence.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Dopamine Agonists; H | 2004 |
Management of bipolar disorder during pregnancy and the postpartum period.
Topics: Adolescent; Adult; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbam | 2004 |
A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Clinical Trials as Topic; Diagnostic and Statistical Manu | 2004 |
International Consensus Group on Bipolar I Depression Treatment Guidelines.
Topics: Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Clinical Trials as | 2004 |
Lamotrigine: a depression mood stabiliser.
Topics: Antidepressive Agents; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combination; Humans; Lam | 2004 |
Depression mood stabilisation: novel concepts and clinical management.
Topics: Affect; Antidepressive Agents; Bipolar Disorder; Clinical Trials as Topic; Drug Interactions; Drug T | 2004 |
An overview of primary care assessment and management of bipolar disorder.
Topics: Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Diagnostic Errors; Humans | 2004 |
Strategies for preventing the recurrence of bipolar disorder.
Topics: Anticonvulsants; Antidepressive Agents; Benzodiazepines; Bipolar Disorder; Cognitive Behavioral Ther | 2004 |
Newer anticonvulsants in the treatment of bipolar disorder.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Carbamazepine; Cyclohexanecarboxylic Acids; Dep | 2004 |
The current understanding of lamotrigine as a mood stabilizer.
Topics: Action Potentials; Affect; Bipolar Disorder; Calcium Channels; Calcium-Binding Proteins; Clinical Tr | 2004 |
Major advances in bipolar disorder.
Topics: Antimanic Agents; Benzodiazepines; Bipolar Disorder; Comorbidity; Humans; Lamotrigine; Olanzapine; S | 2004 |
Rethinking the treatment paradigm for bipolar depression: the importance of long-term management.
Topics: Amines; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Ch | 2004 |
Bipolar depression: an overview.
Topics: Acute Disease; Antidepressive Agents; Antimanic Agents; Benzodiazepines; Bipolar Disorder; Chemoprev | 2004 |
Separate and concomitant use of lamotrigine, lithium, and divalproex in bipolar disorders.
Topics: Acute Disease; Administration, Oral; Antimanic Agents; Bipolar Disorder; Drug Therapy, Combination; | 2004 |
Rapid cycling bipolar disorder: historical overview and focus on emerging treatments.
Topics: Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Cognitive Behavioral Therapy; Humans; Lamot | 2004 |
Employing pharmacologic treatment of bipolar disorder to greatest effect.
Topics: Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clinical Trials as Topic; | 2004 |
Treatment options for bipolar depression.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dep | 2005 |
Lamotrigine in psychiatry: pharmacology and therapeutics.
Topics: Antidepressive Agents; Bipolar Disorder; Controlled Clinical Trials as Topic; Drug Therapy, Combinat | 2005 |
Women are not the same as men: specific clinical issues for female patients with bipolar disorder.
Topics: Anticonvulsants; Antidepressive Agents; Benzodiazepines; Bipolar Disorder; Counseling; Dibenzothiaze | 2005 |
New data on the use of lithium, divalproate, and lamotrigine in rapid cycling bipolar disorder.
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Humans; Lamotrigine; Lithium Carbonate; Pe | 2005 |
Lamotrigine and antiepileptic drugs as mood stabilizers in bipolar disorder.
Topics: Acute Disease; Amines; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Cyclohexa | 2005 |
Lamotrigine for bipolar disorder: translating research into clinical practice.
Topics: Antidepressive Agents; Antimanic Agents; Biomedical Research; Bipolar Disorder; Clinical Trials as T | 2004 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Antipsychotic Agents; Anxiety Disorders; Benzodiaz | 2005 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Antipsychotic Agents; Anxiety Disorders; Benzodiaz | 2005 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Antipsychotic Agents; Anxiety Disorders; Benzodiaz | 2005 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Antipsychotic Agents; Anxiety Disorders; Benzodiaz | 2005 |
Antiepileptic drugs in mood-disordered patients.
Topics: Anticonvulsants; Bipolar Disorder; Carbamazepine; Depressive Disorder; Humans; Lamotrigine; Treatmen | 2005 |
Lamotrigine in the treatment of bipolar disorder.
Topics: Bipolar Disorder; Exanthema; Humans; Lamotrigine; Triazines | 2005 |
Anticonvulsant drug therapies.
Topics: Amines; Anticonvulsants; Bipolar Disorder; Carbamazepine; Cyclohexanecarboxylic Acids; Depressive Di | 2005 |
Challenges in the management of bipolar depression.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Combined Modality Therapy; Comorbidity; Female; Humans; La | 2005 |
Is the prophylactic antidepressant efficacy of lithium in bipolar I disorder dependent on study design and lithium level?
Topics: Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Double-Blind Method; Humans; Lamotrigine; | 2005 |
Newer treatment studies for bipolar depression.
Topics: Acetamides; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar D | 2005 |
[The treatment of mood stabilizers in children and adolescents suffering from bipolar affective disorder].
Topics: Adolescent; Adult; Amines; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Child; Cyclohexaneca | 2005 |
Beyond monoamines: glutamatergic function in mood disorders.
Topics: Bipolar Disorder; Brain; Clinical Trials as Topic; Depressive Disorder, Major; Excitatory Amino Acid | 2005 |
Treatment considerations for patients experiencing rapid-cycling bipolar disorder.
Topics: Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Diagnosis, Differential; Drug Administrat | 2006 |
Anticonvulsants in bipolar disorder.
Topics: Anticonvulsants; Bipolar Disorder; Carbamazepine; Humans; Lamotrigine; Triazines; Valproic Acid | 2006 |
Lamotrigine add-on therapy to venlafaxine treatment in adolescent-onset bipolar II disorder: a case report covering an 8-month observation period.
Topics: Adolescent; Age of Onset; Antidepressive Agents, Second-Generation; Antimanic Agents; Bipolar Disord | 2006 |
Maintenance treatment of bipolar disorder: Applying research to clinical practice.
Topics: Anticonvulsants; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Carbamazepin | 2006 |
The evidence for antidepressant use in bipolar depression.
Topics: Anticonvulsants; Antidepressive Agents; Bipolar Disorder; Critical Pathways; Depressive Disorder; Hu | 2006 |
[Lamotrigine in the treatment of bipolar disorder, a review].
Topics: Antimanic Agents; Bipolar Disorder; Calcium Channel Blockers; Evidence-Based Medicine; Humans; Lamot | 2007 |
Lamotrigine therapy in elderly patients with epilepsy, bipolar disorder or dementia.
Topics: Aged; Aged, 80 and over; Amines; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; | 2007 |
Differentiating bipolar disorder from depression in primary care.
Topics: Bipolar Disorder; Depression; Depressive Disorder, Major; Diagnosis, Differential; Humans; Lamotrigi | 2007 |
The role of mood stabilisers in the treatment of the depressive facet of bipolar disorders.
Topics: Affective Symptoms; Animals; Antimanic Agents; Bipolar Disorder; Carbamazepine; Depressive Disorder; | 2007 |
Antiepileptic drugs and mood stability.
Topics: Affect; Anticonvulsants; Bipolar Disorder; Carbamazepine; Clinical Trials as Topic; Humans; Lamotrig | 2007 |
[Anticonvulsants in the treatment of bipolar disorder].
Topics: Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Clinical Trials as Topic; Drug T | 2007 |
Atypical antipsychotics in bipolar disorder: systematic review of randomised trials.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Bipolar Disorder; Depressive Disorder | 2007 |
A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disor | 2007 |
Discovery and development of lamotrigine for bipolar disorder: a story of serendipity, clinical observations, risk taking, and persistence.
Topics: Adult; Aged; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Clinical Trials as | 2008 |
Special considerations: use of lithium in children, adolescents, and elderly populations.
Topics: Abnormalities, Drug-Induced; Acetates; Adolescent; Adult; Age Factors; Aged; Amines; Anticonvulsants | 1998 |
Anticonvulsants and antipsychotics in the treatment of bipolar disorder.
Topics: Acetates; Amines; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Clinical T | 1998 |
Cellular and molecular actions of lamotrigine: Possible mechanisms of efficacy in bipolar disorder.
Topics: Acetates; Action Potentials; Amines; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Bipol | 1998 |
Lamotrigine and gabapentin. Alternative in the treatment of bipolar disorder.
Topics: Acetates; Amines; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Clinic | 1998 |
Clinical studies on the use of lamotrigine in bipolar disorder.
Topics: Anticonvulsants; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Clinical Trials as Topic | 1998 |
Anticonvulsant therapy and suicide risk in affective disorders.
Topics: Amitriptyline; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Female; Follow | 1999 |
Controlled trials in bipolar I depression: focus on switch rates and efficacy.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Antimanic Agents; Bipolar Disorder; Control | 1999 |
Lamotrigine in the treatment of bipolar depression.
Topics: Acetates; Affect; Amines; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Cross-Over Stud | 1999 |
Lamotrigine and the treatment of mania in bipolar disorder.
Topics: Adult; Affect; Antimanic Agents; Bipolar Disorder; Drug Therapy, Combination; Humans; Lamotrigine; L | 1999 |
Gabapentin and lamotrigine in bipolar disorder.
Topics: Acetates; Adult; Amines; Anticonvulsants; Bipolar Disorder; Clinical Trials as Topic; Cyclohexanecar | 1999 |
Treating bipolar illness: focus on treatment algorithms and management of the sleep-wake cycle.
Topics: Adult; Algorithms; Anticonvulsants; Antidepressive Agents; Bipolar Disorder; Circadian Rhythm; Drug | 1999 |
Lamotrigine for the treatment of bipolar disorder.
Topics: Antimanic Agents; Bipolar Disorder; Humans; Lamotrigine; Triazines | 2000 |
Mood stabilizers during breastfeeding: a review.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Breast Feeding; Carbamazepine; Cyclohexanecarbo | 2000 |
New treatments of bipolar disorder.
Topics: Acetates; Amines; Anticonvulsants; Antimanic Agents; Benzodiazepines; Bipolar Disorder; Clinical Tri | 1999 |
An ever-increasing pharmacopoeia for the management of patients with bipolar disorder.
Topics: Acetates; Amines; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Carbamaz | 2000 |
Novel treatments for bipolar disorder.
Topics: Acetates; Amines; Bipolar Disorder; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Therapy, Combin | 2001 |
Lamotrigine: a review of clinical studies in bipolar disorders.
Topics: Antimanic Agents; Bipolar Disorder; Clinical Trials as Topic; Double-Blind Method; Humans; Lamotrigi | 2001 |
Cognitive side effects of anticonvulsants.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Carbamazepine; Cognition Disorders; Cyclohexane | 2001 |
Bipolar rapid cycling: focus on depression as its hallmark.
Topics: Anticonvulsants; Antidepressive Agents, Tricyclic; Bipolar Disorder; Comorbidity; Controlled Clinica | 2001 |
Developments in mood stabilisers.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Elect | 2001 |
Current research on rapid cycling bipolar disorder and its treatment.
Topics: Acute Disease; Antimanic Agents; Bipolar Disorder; Carbamazepine; Drug Administration Schedule; Drug | 2001 |
Stabilization of mood from below versus above baseline in bipolar disorder: a new nomenclature.
Topics: Affect; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Clinical Trial | 2002 |
Bipolar disorders and the effectiveness of novel anticonvulsants.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Fructose; Gabapent | 2002 |
The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder.
Topics: Acetates; Acute Disease; Amines; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; | 2001 |
Lamotrigine update and its use in mood disorders.
Topics: Acetates; Aggression; Amines; Antidepressive Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; | 2002 |
Third generation anticonvulsants in bipolar disorder: a review of efficacy and summary of clinical recommendations.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Double-Blind Metho | 2002 |
Bipolar disorder: current treatments and new strategies.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Fructose; Gabapent | 1998 |
Newer antiepileptic drugs in bipolar disorder: rationale for use and role in therapy.
Topics: Acetates; Amines; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Clinical Trials as Topic; Cyc | 2002 |
92 trials available for lamotrigine and Affective Psychosis, Bipolar
| Article | Year |
|---|---|
Sequential Multiple Assignment Randomized Treatment (SMART) for Bipolar Disorder at Any Phase of Illness and at least Mild Symptom Severity.
Topics: Antipsychotic Agents; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combination; Humans; Lamo | 2020 |
Correlation between the Efficacy of Lamotrigine and the Serum Lamotrigine Level during the Remission Phase of Acute Bipolar II Depression: A Naturalistic and Unblinded Prospective Pilot Study.
Topics: Adult; Aged; Antidepressive Agents; Bipolar Disorder; Drug Therapy, Combination; Female; Humans; Lam | 2017 |
Biochemical and genetic predictors and correlates of response to lamotrigine and folic acid in bipolar depression: Analysis of the CEQUEL clinical trial.
Topics: Adult; Bipolar Disorder; Brief Psychiatric Rating Scale; Catechol O-Methyltransferase; Double-Blind | 2017 |
Melancholic Symptoms in Bipolar II Depression and Responsiveness to Lamotrigine in an Exploratory Pilot Study.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Double-Blind Method; Female; Hum | 2018 |
Comparative economic evaluation of quetiapine plus lamotrigine combination vs quetiapine monotherapy (and folic acid vs placebo) in patients with bipolar depression (CEQUEL).
Topics: Antipsychotic Agents; Bipolar Disorder; Cost-Benefit Analysis; Depression; Double-Blind Method; Drug | 2018 |
Effect of lamotrigine on cognitive function and serum inflammatory factors in patients with depression of recurrent bipolar disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Cognition; Female; Humans; Inflammation Mediators; Interle | 2018 |
Driving ability according to German guidelines in stabilized bipolar I and II outpatients receiving lithium or lamotrigine.
Topics: Adult; Antimanic Agents; Automobile Driving; Bipolar Disorder; Female; Germany; Guidelines as Topic; | 2013 |
A factor analytic study in bipolar depression, and response to lamotrigine.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Depressive Disorder; Double-Blind Method; Drug Admin | 2013 |
Olanzapine is superior to lamotrigine in the prevention of bipolar depression: a naturalistic observational study.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Depressive Di | 2014 |
[Treatment of bipolar disorder with lamotrigine -- relapse rate and suicidal behaviour during 6 month follow-up].
Topics: Adult; Ambulatory Care; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Bipolar Disord | 2015 |
Adjunctive Maintenance Lamotrigine for Pediatric Bipolar I Disorder: A Placebo-Controlled, Randomized Withdrawal Study.
Topics: Adolescent; Antimanic Agents; Bipolar Disorder; Child; Double-Blind Method; Female; Humans; Kaplan-M | 2015 |
Comparative evaluation of quetiapine plus lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in bipolar depression (CEQUEL): a 2 × 2 factorial randomised trial.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combination; Femal | 2016 |
Prediction of an Optimal Dose of Lamotrigine for Augmentation Therapy in Treatment-Resistant Depressive Disorder From Plasma Lamotrigine Concentration at Week 2.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Chromatograp | 2016 |
Methylene blue treatment for residual symptoms of bipolar disorder: randomised crossover study.
Topics: Adult; Anxiety; Bipolar Disorder; Cognitive Dysfunction; Cross-Over Studies; Depression; Double-Blin | 2017 |
Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression.
Topics: Adolescent; Adult; Benzodiazepines; Bipolar Disorder; Calcium Channel Blockers; Dose-Response Relati | 2009 |
A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Area Under Curve; Aripiprazole; Bipolar Disorder; Dose | 2009 |
Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Depressive Disorder, Major; Dose-Respons | 2009 |
Rash in adult patients receiving lamotrigine to treat bipolar I disorder in Korea: a multicenter, prospective, naturalistic, open-label trial.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Exanthema; Female; Humans; Incidence; Korea; Lamotrigine; | 2009 |
Genetic association study of treatment response with olanzapine/fluoxetine combination or lamotrigine in bipolar I depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Benzodiazepines; Bipolar Disorder; Dopamine beta-Hy | 2010 |
Adjunctive lamotrigine therapy for patients with bipolar II depression partially responsive to mood stabilizers.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Anticonvulsants; Antimanic Agents; Bipolar Disorder; | 2010 |
Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6).
Topics: Adult; Antimanic Agents; Bipolar Disorder; Confidence Intervals; Female; Humans; Lamotrigine; Lithiu | 2010 |
Enhanced prefrontal function with pharmacotherapy on a response inhibition task in adolescent bipolar disorder.
Topics: Adolescent; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Brain; Humans; Lamotrigine; Ma | 2010 |
Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression.
Topics: Antidepressive Agents, Second-Generation; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benz | 2011 |
Lamotrigine adjunctive therapy to lithium and divalproex in depressed patients with rapid cycling bipolar disorder and a recent substance use disorder: a 12-week, double-blind, placebo-controlled pilot study.
Topics: Adult; Analysis of Variance; Antimanic Agents; Bipolar Disorder; Chi-Square Distribution; Depression | 2010 |
Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design.
Topics: Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Antimanic Agents; Bipolar Disorder | 2011 |
Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Antimanic Agents; Bipolar Disorder; Depressive Disorder, Maj | 2011 |
Multisite, open-label, prospective trial of lamotrigine for geriatric bipolar depression: a preliminary report.
Topics: Aged; Aged, 80 and over; Antimanic Agents; Bipolar Disorder; Disability Evaluation; Female; Humans; | 2011 |
Aripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double-blind study (CN138-392).
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Double-Blind Method; | 2012 |
Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trial.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Depression; Dopamine Agents; Doubl | 2012 |
Correlates of treatment response in depressed older adults with bipolar disorder.
Topics: Aged; Aged, 80 and over; Antimanic Agents; Bipolar Disorder; Cholesterol; Depressive Disorder; Execu | 2012 |
A randomized, double-blind, placebo-controlled, trial of lamotrigine therapy in bipolar disorder, depressed or mixed phase and cocaine dependence.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Calcium Channel Blockers; Cocaine-Related Disorders; Depr | 2012 |
Lamotrigine vs. lamotrigine plus divalproex in randomized, placebo-controlled maintenance treatment for bipolar depression.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combination; Female; H | 2012 |
Bayesian model of Hamilton Depression Rating Score (HDRS) with memantine augmentation in bipolar depression.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Bayes Theorem; Bipolar Disorder; Dopamine Agents; Double-B | 2013 |
Lamotrigine as add-on treatment to lithium and divalproex: lessons learned from a double-blind, placebo-controlled trial in rapid-cycling bipolar disorder.
Topics: Adolescent; Adult; Aged; Antimanic Agents; Bipolar Disorder; Double-Blind Method; Drug Therapy, Comb | 2012 |
Relative effectiveness of adjunctive risperidone on manic and depressive symptoms in mixed mania.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Depressive Disorder; Diagnostic an | 2013 |
Investigation into the long-term metabolic effects of aripiprazole adjunctive to lithium, valproate, or lamotrigine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Weight; Double-Blind Method; Drug | 2013 |
Lamotrigine as an augmentation agent in treatment-resistant depression.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety Disorders; Bipolar Disorder; Chronic Disease | 2002 |
Lamotrigine in patients with bipolar disorder and cocaine dependence.
Topics: Adult; Anticonvulsants; Behavior, Addictive; Bipolar Disorder; Cocaine-Related Disorders; Drug Thera | 2003 |
Phenotypic spectra of bipolar disorder in responders to lithium versus lamotrigine.
Topics: Adolescent; Adult; Aged; Antimanic Agents; Bipolar Disorder; Diagnostic and Statistical Manual of Me | 2003 |
A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Depressive Disorder; Double-Blind Method; Drug Administrat | 2003 |
Lamotrigine in adolescent mood disorders.
Topics: Adolescent; Anticonvulsants; Bipolar Disorder; Child; Delayed-Action Preparations; Drug Therapy, Com | 2003 |
A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Depressive Disorder; Dose-Response | 2003 |
A 52-week, open-label continuation study of lamotrigine in the treatment of bipolar depression.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Depressive Disorder, Major; Dose-Response Relationship, Dr | 2004 |
Lamotrigine treatment of bipolar disorder: data from the first 500 patients in STEP-BD.
Topics: Adolescent; Adult; Antimanic Agents; Bipolar Disorder; Female; Humans; Lamotrigine; Male; Severity o | 2004 |
A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Clinical Trials as Topic; Diagnostic and Statistical Manu | 2004 |
Quality of life in patients with bipolar I depression: data from 920 patients.
Topics: Acute Disease; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Double-Blind Meth | 2004 |
Effect of lamotrigine on cognitive complaints in patients with bipolar I disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Cognition Disorders; Diagnostic and Statistical Manual of | 2004 |
Maintenance treatment outcomes in older patients with bipolar I disorder.
Topics: Adult; Antipsychotic Agents; Back Pain; Bipolar Disorder; Dose-Response Relationship, Drug; Double-B | 2005 |
Dermatology precautions and slower titration yield low incidence of lamotrigine treatment-emergent rash.
Topics: Adult; Ambulatory Care; Anticonvulsants; Bipolar Disorder; Cohort Studies; Drug Administration Sched | 2005 |
Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Depressive Di | 2006 |
An open-label study of lamotrigine adjunct or monotherapy for the treatment of adolescents with bipolar depression.
Topics: Adolescent; Antimanic Agents; Anxiety Disorders; Attention Deficit and Disruptive Behavior Disorders | 2006 |
Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Body Weight; Double-Blind Method; Female; Humans; Inc | 2006 |
Cognitive functioning in bipolar patients receiving lamotrigine: preliminary results.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Carbamazepine; Cognition; Female; Humans; Lamotrigine; Mal | 2006 |
The effect of dermatologic precautions on the incidence of rash with addition of lamotrigine in the treatment of bipolar I disorder: a randomized trial.
Topics: Adolescent; Adult; Ambulatory Care; Antipsychotic Agents; Bipolar Disorder; Cohort Studies; Comorbid | 2006 |
Recurrence in bipolar I disorder: a post hoc analysis excluding relapses in two double-blind maintenance studies.
Topics: Antimanic Agents; Bipolar Disorder; Double-Blind Method; Humans; Lamotrigine; Lithium; Patient Selec | 2006 |
Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar I disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Body Weight; Comorbidity; Double-Blind Method; Humans; Lam | 2006 |
Randomized, double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression.
Topics: Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Antimanic Agents; Bipolar Disorder | 2006 |
A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Depressive Disorder | 2006 |
Adjunctive treatment for mood stabilization of patients with bipolar I disorder treated with lamotrigine.
Topics: Adult; Affect; Anti-Anxiety Agents; Antimanic Agents; Benzodiazepines; Bipolar Disorder; Double-Blin | 2006 |
Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clozapine; Drug Interactions; Female | 2006 |
Tranylcypromine vs. lamotrigine in the treatment of refractory bipolar depression: a failed but clinically useful study.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Bias; Bipolar Disorder; Female; Humans; Lamotrigine; | 2007 |
Six-month prospective life charting of mood symptoms with lamotrigine monotherapy versus placebo in rapid cycling bipolar disorder.
Topics: Adult; Analysis of Variance; Anticonvulsants; Bipolar Disorder; Chi-Square Distribution; Double-Blin | 2008 |
Treatment adherence in individuals with rapid cycling bipolar disorder: results from a clinical-trial setting.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Double-Blind Method; Female; Humans; Lamotrigine; Lithium | 2007 |
Effect of open-label lamotrigine as monotherapy and adjunctive therapy on the self-assessed cognitive function scores of patients with bipolar I disorder.
Topics: Adult; Aged; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Cognit | 2007 |
Effectiveness and weight effects of open-label lamotrigine with and without concomitant psychotropic medications in patients with bipolar I disorder.
Topics: Analgesics; Bipolar Disorder; Body Weight; Drug Therapy, Combination; Female; Humans; Lamotrigine; M | 2007 |
Simultaneous high-performance liquid chromatographic determination of olanzapine and lamotrigine in plasma of bipolar patients.
Topics: Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Chromatography, High Pres | 2007 |
Open-label, concomitant use of lamotrigine and other medications for bipolar disorder.
Topics: Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Double-Blind Method; Drug | 2008 |
Rapid-cycling bipolar I disorder: course and treatment outcome of a large sample across Europe.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Europe; Female; Humans; Lamotrigine | 2008 |
Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Double-Blind Method; Drug Administration Schedule; Fe | 2008 |
Olanzapine or lamotrigine addition to lithium in remitted bipolar disorder patients with anxiety disorder comorbidity: a randomized, single-blind, pilot study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Anxiety Disorders; Benzodiazepines; Bipolar Disorder; | 2008 |
Pilot investigation of the changes in cortical activation during facial affect recognition with lamotrigine monotherapy in bipolar disorder.
Topics: Adolescent; Adult; Affect; Antimanic Agents; Bipolar Disorder; Brain Mapping; Cerebral Cortex; Facia | 2008 |
Aripiprazole therapy in 20 older adults with bipolar disorder: a 12-week, open-label trial.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Bipolar Disorde | 2008 |
A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression.
Topics: Acute Disease; Adolescent; Adult; Aged; Ambulatory Care; Anticonvulsants; Bipolar Disorder; Diagnost | 2008 |
A preliminary functional magnetic resonance imaging study of prefrontal-amygdalar activation changes in adolescents with bipolar depression treated with lamotrigine.
Topics: Adolescent; Amygdala; Antimanic Agents; Bipolar Disorder; Female; Humans; Image Processing, Computer | 2008 |
Lamotrigine in bipolar disorder: efficacy during pregnancy.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Fe | 2008 |
Effectiveness of lamotrigine in bipolar disorder in a clinical setting.
Topics: Adult; Ambulatory Care; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Clinical Protocols; Coh | 2008 |
The effect of lamotrigine on platelet monoamine oxidase type B activity in patients with bipolar depression.
Topics: Adult; Analysis of Variance; Antimanic Agents; Bipolar Disorder; Female; Humans; Lamotrigine; Middle | 2008 |
The anticonvulsant lamotrigine in treatment-resistant manic-depressive illness.
Topics: Adult; Anticonvulsants; Anxiety; Bipolar Disorder; Drug Resistance; Female; Humans; Lamotrigine; Mal | 1997 |
Lamotrigine treatment of refractory bipolar disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Drug Therapy, Combination; Female; Humans; Lamotrigine; Ma | 1997 |
Lamotrigine in rapid-cycling bipolar disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Drug Administration Schedule; Drug Therapy, Combination; F | 1997 |
Anticonvulsant therapy and suicide risk in affective disorders.
Topics: Amitriptyline; Anticonvulsants; Bipolar Disorder; Carbamazepine; Double-Blind Method; Female; Follow | 1999 |
A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group.
Topics: Adult; Aged; Ambulatory Care; Anticonvulsants; Bipolar Disorder; Depressive Disorder; Dose-Response | 1999 |
Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Borderline Pe | 1998 |
Lamotrigine for the treatment of bipolar disorder: a clinical case series.
Topics: Adolescent; Adult; Antimanic Agents; Bipolar Disorder; Dose-Response Relationship, Drug; Female; Hum | 1999 |
The efficacy of lamotrigine in rapid cycling and non-rapid cycling patients with bipolar disorder.
Topics: Activity Cycles; Adolescent; Adult; Antimanic Agents; Bipolar Disorder; Dose-Response Relationship, | 1999 |
Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder.
Topics: Adult; Aged; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Drug Eruptions; Drug Therapy, Comb | 1999 |
Lamotrigine in the treatment of bipolar depression.
Topics: Acetates; Affect; Amines; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Cross-Over Stud | 1999 |
Lamotrigine compared with lithium in mania: a double-blind randomized controlled trial.
Topics: Acute Disease; Adolescent; Adult; Antimanic Agents; Bipolar Disorder; Double-Blind Method; Female; H | 2000 |
A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Antidepressive Agents; Bipolar Disorder; Cohort Studies; D | 2000 |
An open longitudinal study of patients with bipolar rapid cycling treated with lithium or lamotrigine for mood stabilization.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Female; Follow-Up Studies; Humans; Lamotrigine; Lithium C | 2000 |
The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder.
Topics: Acetates; Acute Disease; Amines; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; | 2001 |
Third generation anticonvulsants in bipolar disorder: a review of efficacy and summary of clinical recommendations.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Double-Blind Metho | 2002 |
241 other studies available for lamotrigine and Affective Psychosis, Bipolar
| Article | Year |
|---|---|
Lamotrigine may Increase Risk of Arrythmias.
Topics: Anticonvulsants; Arrhythmias, Cardiac; Bipolar Disorder; Epilepsy; Humans; Lamotrigine; Treatment Ou | 2021 |
Undetermined predominant polarity in a cohort of bipolar disorder patients: Prevalent, severe, and overlooked.
Topics: Bipolar Disorder; Cohort Studies; Humans; Lamotrigine; Recurrence | 2022 |
Association of Lithium Treatment With the Risk of Osteoporosis in Patients With Bipolar Disorder.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Female; Humans; Lamotrigine; Lithiu | 2022 |
Common effects of bipolar disorder medications on expression quantitative trait loci genes.
Topics: Bipolar Disorder; Genome-Wide Association Study; Humans; Lamotrigine; Protein Serine-Threonine Kinas | 2022 |
Response to lithium and anticonvulsants among patients with bipolar disorder with and without comorbid epilepsy - A nation-wide population-based longitudinal study.
Topics: Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Comorbidity; Epilepsy; Humans; Lamotrigine; | 2022 |
What's Going on with Lamotrigine (Lamictal)? An Updated Look at the Popular Medication for Bipolar Disorder.
Topics: Antimanic Agents; Bipolar Disorder; Humans; Lamotrigine | 2022 |
Lithium produces bi-directionally regulation of mood disturbance, acts synergistically with anti-depressive/-manic agents, and did not deteriorate the cognitive impairment in murine model of bipolar disorder.
Topics: Animals; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Cognitive Dysfu | 2022 |
Prescribing changes for bipolar patients discharged from two public psychiatric hospitals in Taiwan, 2006-2019.
Topics: Anticonvulsants; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bip | 2022 |
Lamotrigine in the Maintenance Treatment of Bipolar Disorder.
Topics: Anticonvulsants; Antimanic Agents; Bipolar Disorder; Humans; Lamotrigine | 2022 |
Analysis of adverse drug events in patients with bipolar disorders using the Japanese Adverse Drug Event Report database.
Topics: Adverse Drug Reaction Reporting Systems; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Drug | 2022 |
Pharmacological treatment of bipolar disorder and risk of diabetes mellitus: A nationwide study of 30,451 patients.
Topics: Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Diabetes Mellitus; Humans | 2023 |
Clinical correlates associated with the long-term response of bipolar disorder patients to lithium, valproate or lamotrigine: A retrospective study.
Topics: Adult; Alcoholism; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Comorbidity; Female; Fo | 2020 |
Mood-Stabilizing Antiepileptic Treatment Response in Bipolar Disorder: A Genome-Wide Association Study.
Topics: Adult; Affect; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Female; Gastrointestinal Absorpt | 2020 |
Changes in ratio of ineligible use of lamotrigine in Japan based on data from the relief system of the Pharmaceuticals and Medical Devices Agency.
Topics: Bipolar Disorder; Compensation and Redress; Drug and Narcotic Control; Drug-Related Side Effects and | 2021 |
The utility of daily mood ratings in clinical trials of patients with bipolar II disorder.
Topics: Affect; Bipolar Disorder; Humans; Lamotrigine; Lithium; Mania | 2021 |
Lamotrigine for acute bipolar depression: An exploratory item-level analysis.
Topics: Adult; Bipolar Disorder; Depression; Double-Blind Method; Humans; Lamotrigine; Psychiatric Status Ra | 2021 |
Duration of untreated illness and bipolar disorder: time for a new definition? Results from a cross-sectional study.
Topics: Bipolar Disorder; Cross-Sectional Studies; Humans; Lamotrigine; Retrospective Studies; Valproic Acid | 2021 |
Risk of postpartum episodes in women with bipolar disorder after lamotrigine or lithium use during pregnancy: A population-based cohort study.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Cohort Studies; Depression, Postpartum; Female; Humans; L | 2017 |
Lithium Use in Pregnancy and the Risk of Cardiac Malformations.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Cohort Studies; F | 2017 |
Lamotrigine induced dress syndrome in bipolar disorder.
Topics: Adult; Bipolar Disorder; Drug Hypersensitivity Syndrome; Humans; Lamotrigine; Male; Triazines; Volta | 2017 |
Associations between use of mood stabilizers and risk of cataract: A population-based nested case-control study.
Topics: Adult; Aged; Antimanic Agents; Bipolar Disorder; Carbamazepine; Case-Control Studies; Cataract; Data | 2018 |
Mood-Stabilizing Anticonvulsants, Spina Bifida, and Folate Supplementation: Commentary.
Topics: Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Dietary Supplements; Female; Fol | 2018 |
Both Serum Brain-Derived Neurotrophic Factor and Interleukin-6 Levels Are Not Associated with Therapeutic Response to Lamotrigine Augmentation Therapy in Treatment-Resistant Depressive Disorder.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Brain-Derived Neurotrophic Factor; Depressive Disord | 2017 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
Topics: Adolescent; Aged; Algorithms; Antipsychotic Agents; Bipolar Disorder; Bupropion; Child; Evidence-Bas | 2018 |
A Standard Intervention Practice to Promote Appropriate Lamotrigine Therapy by Pharmacists.
Topics: Adolescent; Anticonvulsants; Bipolar Disorder; Drug Administration Schedule; Epilepsy; Humans; Inapp | 2018 |
Lamotrigine Rechallenge in Treatment-Resistant Bipolar Disorder.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antimanic Agents; Bipolar Disorder; Che | 2018 |
Refractory ventricular fibrillation in patient taking Lamictal.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Electrocardiography; Female; Heart Conduction System; | 2018 |
Changes in amygdala, cerebellum, and nucleus accumbens volumes in bipolar patients treated with lamotrigine.
Topics: Adult; Amygdala; Antidepressive Agents; Bayes Theorem; Bipolar Disorder; Brain; Cerebellum; Emotions | 2018 |
The use of a gene expression signature and connectivity map to repurpose drugs for bipolar disorder.
Topics: Animals; Bipolar Disorder; Drug Repositioning; Lamotrigine; Pharmaceutical Preparations; Quetiapine | 2020 |
Lamotrigine-induced pancytopenia in bipolar disorder.
Topics: Antipsychotic Agents; Bipolar Disorder; Female; Humans; Lamotrigine; Middle Aged; Pancytopenia | 2018 |
Lamotrigine-induced obsessive-compulsive disorder in patients with bipolar disorder.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders | 2019 |
[Prediction of response to lamotrigine treatment in bipolar outpatients: a multicentric, 6-month, prospective, observational study].
Topics: Anticonvulsants; Bipolar Disorder; Humans; Lamotrigine; Prospective Studies | 2018 |
Mood stabilisers and risk of stroke in bipolar disorder.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Cross-O | 2019 |
Commentary on Simon et al. 2018: "Comparative economic evaluation of quetiapine plus lamotrigine combination vs quetiapine monotherapy (and folic acid vs placebo) in patients with bipolar depression (CEQUEL)".
Topics: Antipsychotic Agents; Bipolar Disorder; Cost-Benefit Analysis; Folic Acid; Humans; Lamotrigine; Quet | 2019 |
Changes in brain Glx in depressed bipolar patients treated with lamotrigine: A proton MRS study.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Brain; Female; Glutamic Acid; Humans; Lamotrigine; Ma | 2019 |
Comparative economic evaluation of quetiapine plus lamotrigine combination vs quetiapine monotherapy(and folic acid vs placebo) in patients with bipolar depression (CEQUEL).
Topics: Antipsychotic Agents; Bipolar Disorder; Cost-Benefit Analysis; Folic Acid; Humans; Lamotrigine; Quet | 2019 |
Case of drug eruption during treatment with lithium and lamotrigine implicating a possible role of additives in the lithium tablet.
Topics: Acneiform Eruptions; Aged; Bipolar Disorder; Drug Therapy, Combination; Female; Humans; Lamotrigine; | 2019 |
Lamotrigine Therapy and Biomarkers of Cerebral Energy Metabolism in Older Age Bipolar Depression.
Topics: Aged; Aging; Antipsychotic Agents; Aspartic Acid; Biomarkers; Bipolar Disorder; Cerebral Cortex; Cre | 2019 |
Management of lamotrigine overdose using hemodialysis.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Drug Overdose; Female; Humans; Lamotrigine; Renal Dialysis | 2019 |
The interaction between rifampicin and lamotrigine: A case report.
Topics: Anti-Bacterial Agents; Antipsychotic Agents; Bipolar Disorder; Drug Interactions; Fracture Fixation, | 2019 |
A man in his 40s with repeated seizures.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Diagnosis, Differential; Humans; Lamotrigine; Male; Middle | 2013 |
Valproate as a risk factor for lamotrigine discontinuation.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Bipolar Disorder; Drug Therapy, Combination; Female; | 2013 |
Observational study to evaluate the clinical benefit of lamotrigine add-on therapy in bipolar patients in a naturalistic treatment setting.
Topics: Adult; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Drug Synergism; Fe | 2014 |
Lamotrigine-induced facial tic in a pediatric bipolar disorder patient.
Topics: Adolescent; Anticonvulsants; Bipolar Disorder; Humans; Lamotrigine; Male; Tics; Triazines | 2013 |
Lamotrigine dosing for pregnant patients with bipolar disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Breast Feeding; Female; Humans; Infant, Newborn; Lamotrigi | 2013 |
Lamotrigine dosing for pregnant patients with bipolar disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Breast Feeding; Female; Humans; Infant, Newborn; Lamotrigi | 2013 |
Lamotrigine dosing for pregnant patients with bipolar disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Breast Feeding; Female; Humans; Infant, Newborn; Lamotrigi | 2013 |
Lamotrigine dosing for pregnant patients with bipolar disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Breast Feeding; Female; Humans; Infant, Newborn; Lamotrigi | 2013 |
The impact of being newly diagnosed with a bipolar disorder and the short-term outcome of disorder-specific management.
Topics: Adolescent; Adult; Aged; Awareness; Bipolar Disorder; Excitatory Amino Acid Antagonists; Female; Fol | 2014 |
Trends in pharmacotherapy in patients referred to a bipolar specialty clinic, 2000-2011.
Topics: Academic Medical Centers; Adult; Ambulatory Care Facilities; Antimanic Agents; Antipsychotic Agents; | 2014 |
Rapid development of severe skin rash after adding valproic acid in a case of bipolar depression treated with low-dose lamotrigine.
Topics: Antimanic Agents; Bipolar Disorder; Drug Eruptions; Drug Interactions; Drug Therapy, Combination; Fe | 2014 |
Elevated concentrations of neurofilament light chain in the cerebrospinal fluid of bipolar disorder patients.
Topics: Adult; Age Factors; Antipsychotic Agents; Axons; Biomarkers; Bipolar Disorder; Brain; Fatty Acid Bin | 2014 |
Lamotrigine treatment of adolescents with unipolar and bipolar depression: a retrospective chart review.
Topics: Adolescent; Anticonvulsants; Bipolar Disorder; Depressive Disorder, Major; Dose-Response Relationshi | 2014 |
International prescribing patterns for mood illness: the International Mood Network (IMN).
Topics: Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Asia; Bipolar Disorder; Carbamazepine | 2014 |
The effect of cognitive functioning on treatment attendance and adherence in comorbid bipolar disorder and cocaine dependence.
Topics: Adult; Bipolar Disorder; Cocaine-Related Disorders; Cognition Disorders; Diagnosis, Dual (Psychiatry | 2015 |
Effects of mood-stabilizing drugs on dendritic outgrowth and synaptic protein levels in primary hippocampal neurons.
Topics: Animals; Antimanic Agents; Bipolar Disorder; Brain-Derived Neurotrophic Factor; Cell Adhesion Molecu | 2015 |
Predominant polarity in bipolar disorder and validation of the polarity index in a German sample.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antidepressive Agents; Antipsychotic Agents; Bipolar | 2014 |
Lamotrigine-induced tactile hallucination.
Topics: Adult; Bipolar Disorder; Excitatory Amino Acid Antagonists; Hallucinations; Humans; Lamotrigine; Mal | 2014 |
N-acetylaspartate normalization in bipolar depression after lamotrigine treatment.
Topics: Adult; Aged; Aspartic Acid; Biomarkers; Bipolar Disorder; Brain; Dipeptides; Female; Gyrus Cinguli; | 2015 |
[Changes in prescription patterns to patients with bipolar syndromes. Increased use of lamotrigine and decreased use of lithium].
Topics: Adult; Age Factors; Aged; Anticonvulsants; Bipolar Disorder; Drug Prescriptions; Drug Utilization; F | 2014 |
Gender differences in the treatment of patients with bipolar disorder: a study of 7354 patients.
Topics: Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Drug Pr | 2015 |
Lamotrigine and GABAA receptor modulators interact with menstrual cycle phase and oral contraceptives to regulate mood in women with bipolar disorder.
Topics: Adult; Affect; Bipolar Disorder; Contraceptives, Oral; Drug Synergism; Excitatory Amino Acid Antagon | 2015 |
Poor neonatal adaptation following in-utero exposure to quetiapine and lamotrigine.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Female; Humans; Hypothyroidism; Infant, Newborn; Infa | 2015 |
Multi-state outcome analysis of treatments (MOAT): application of a new approach to evaluate outcomes in longitudinal studies of bipolar disorder.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Female; Humans | 2016 |
Retrospective analysis of therapeutic drug monitoring data for treatment of bipolar disorder with lamotrigine.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Bipolar Disorder; Databases, Pharmaceutical; Dose-R | 2015 |
Hoarding Symptoms Respond to Treatment for Rapid Cycling Bipolar II Disorder.
Topics: Bipolar Disorder; Calcium Channel Blockers; Depressive Disorder; Dopamine Uptake Inhibitors; Hoardin | 2016 |
The comparative short-term outcome of bipolar II disorder patients variably meeting or not meeting DSM-5 duration criteria following lamotrigine treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bipolar Disorder; Diagnostic and Statistical Manual of M | 2016 |
Clinical correlates of sustained response to individual drugs used in naturalistic treatment of patients with bipolar disorder.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disor | 2016 |
[Changes in quality of life and work function during phase prophylactic lamotrigine treatment in bipolar patients: 6 month, prospective, observational study].
Topics: Bipolar Disorder; Calcium Channel Blockers; Humans; Lamotrigine; Prospective Studies; Quality of Lif | 2016 |
[Psychogenic non-epileptic seizures: issues of comorbidity in the diagnosis and treatment].
Topics: Adult; Anticonvulsants; Bipolar Disorder; Brain; Comorbidity; Electroencephalography; Epilepsy; Huma | 2016 |
Cataplexy Possibly Associated With Lamotrigine.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Cataplexy; Female; Humans; Lamotrigine; Triazines | 2016 |
Does folic acid interfere with lamotrigine?
Topics: Antipsychotic Agents; Bipolar Disorder; Folic Acid; Humans; Lamotrigine; Quetiapine Fumarate; Triazi | 2016 |
Maternal and Fetal Outcomes After Lamotrigine Use in Pregnancy: A Retrospective Analysis from an Urban Maternal Mental Health Centre in New Zealand.
Topics: Bipolar Disorder; Calcium Channel Blockers; Female; Humans; Infant; Lamotrigine; Mental Health; New | 2016 |
Fetal exposure to lamotrigine and quetiapine in two consecutive pregnancies.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Female; Humans; Infant, Newborn; La | 2017 |
Pharmacokinetic Drug-Drug Interactions of Mood Stabilizers and Risperidone in Patients Under Combined Treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; | 2016 |
Brugada Pattern Caused by a Flecainide Overdose.
Topics: Atrial Fibrillation; Bipolar Disorder; Brugada Syndrome; Consciousness Disorders; Drug Overdose; Ele | 2017 |
Lamotrigine in the Prevention of Bipolar II Postpartum Depression.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Depression, Postpartum; Female; Humans; Lamotrigine; Post | 2016 |
Clinical pharmacokinetic interactions between lamotrigine and hormonal contraceptives in bipolar I disorder.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Contraceptives, Oral, Hormonal; Drug Interactions; Dysmen | 2017 |
Attrition factors in clinical trials of comorbid bipolar and substance-related disorders.
Topics: Adult; Alcohol-Related Disorders; Amphetamine-Related Disorders; Anticonvulsants; Antipsychotic Agen | 2009 |
Lamotrigine-induced toxic epidermal necrolysis treated with intravenous immunoglobulin and amniotic membranes.
Topics: Adult; Anticonvulsants; Biological Dressings; Bipolar Disorder; Female; Follow-Up Studies; Humans; I | 2008 |
Lamotrigine-induced obsessional symptoms in a patient with bipolar II disorder: a case report.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Female; Humans; Lamotrigine; Obsessive Behavior; Triazines | 2009 |
Lamotrigine in bipolar disorder: results of a mirror-image evaluation using the NIMH Lifechart-Methodology.
Topics: Adult; Affect; Anticonvulsants; Bipolar Disorder; Dose-Response Relationship, Drug; Female; Germany; | 2009 |
Lamotrigine in the treatment of comorbid bipolar spectrum and bulimic disorders: case series.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Bulimia; Female; Humans; Lamotrigine; Triazines; Young Adu | 2008 |
Publication bias and the pharmaceutical industry: the case of lamotrigine in bipolar disorder.
Topics: Antimanic Agents; Bipolar Disorder; Clinical Trials as Topic; Drug Industry; Guidelines as Topic; Hu | 2008 |
Improvement of obsessive-compulsive disorder with divalproex and lamotrigine in two patients with bipolar II disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Female; Humans; Lamotrigine; Male; Obsessive-Compulsive Di | 2009 |
Effects of neuronal Kv7 potassium channel activators on hyperactivity in a rodent model of mania.
Topics: Amphetamine; Animals; Anticonvulsants; Antimanic Agents; Benzamides; Bipolar Disorder; Carbamates; C | 2009 |
Combination therapy of levosulpiride and lamotrigine associated with tardive dyskinesia.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Dr | 2009 |
Depressive relapse during lithium treatment associated with increased serum thyroid-stimulating hormone: results from two placebo-controlled bipolar I maintenance studies.
Topics: Adult; Affect; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Double-Blind Method; Humans; Lam | 2009 |
The use of lithium, valproate or lamotrigine for psychiatric conditions in children and adolescents in Norway 2004-2007 - a prescription database study.
Topics: Adolescent; Age Factors; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Antipsychotic Age | 2009 |
Feasibility of a slower lamotrigine titration schedule for bipolar depression: a naturalistic study.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Dr | 2009 |
International Consensus Group on the evidence-based pharmacologic treatment of bipolar I and II depression.
Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Central Nervous Syst | 2008 |
Effectiveness of lamotrigine in maintaining symptom control in pediatric bipolar disorder.
Topics: Adolescent; Antimanic Agents; Bipolar Disorder; Child; Depressive Disorder; Female; Humans; Lamotrig | 2009 |
Lamotrigine-induced aseptic meningitis: a case report.
Topics: Antimanic Agents; Bipolar Disorder; Blood Cell Count; Female; Humans; Lamotrigine; Magnetic Resonanc | 2009 |
[Anticonvulsant hypersensitivity syndrome and lamotrigine-associated anticonvulsant hypersensitivity syndrome].
Topics: Adult; Aged; Anticonvulsants; Bipolar Disorder; Drug Eruptions; Drug Hypersensitivity; Eosinophilia; | 2009 |
Maintenance treatment received by patients with bipolar I and II disorders--a naturalistic prospective study.
Topics: Adult; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipol | 2010 |
Clinical and neurocognitive predictors of functional outcome in bipolar euthymic patients: a long-term, follow-up study.
Topics: Adult; Affect; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Cognition Disorders; Female; Fol | 2010 |
Treatment-emergent mania/hypomania during antidepressant monotherapy in patients with rapid cycling bipolar disorder.
Topics: Adult; Affect; Anticonvulsants; Antidepressive Agents, Second-Generation; Antimanic Agents; Bipolar | 2008 |
The failure to know what isn't known: negative publication bias with lamotrigine and a glimpse inside peer review.
Topics: Antimanic Agents; Bipolar Disorder; Humans; Lamotrigine; Peer Review, Research; Publication Bias; Tr | 2009 |
End-of-dose emergent psychopathology in ambulatory patients with epilepsy on stable-dose lamotrigine monotherapy: a case series of six patients.
Topics: Adult; Affective Symptoms; Agoraphobia; Anticonvulsants; Bipolar Disorder; Depression; Epilepsy; Fem | 2009 |
Mood stabilization and destabilization during acute and continuation phase treatment for bipolar I disorder with lamotrigine or placebo.
Topics: Adult; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Depressive Disorder; Female; Humans; Iat | 2009 |
Possible lamotrigine-induced mania in a child with autism spectrum disorder and epilepsy.
Topics: Bipolar Disorder; Child; Child Development Disorders, Pervasive; Epilepsy; Humans; Lamotrigine; Male | 2009 |
Rash and lamotrigine in bipolar patients.
Topics: Antimanic Agents; Bipolar Disorder; Exanthema; Humans; Lamotrigine; Randomized Controlled Trials as | 2010 |
Lamotrigine and bipolar disorder: new indication. Only after lithium, like other antiepileptics. Preventive effects in only one aspect of bipolar disorder, but with a risk of Lyell syndrome.
Topics: Anticonvulsants; Antimanic Agents; Bipolar Disorder; Depressive Disorder; Europe; Humans; Lamotrigin | 2009 |
Clozapine intoxication in a patient with lamotrigine-induced rash.
Topics: Analgesics; Antipsychotic Agents; Bipolar Disorder; Clozapine; Exanthema; Humans; Lamotrigine; Male; | 2010 |
Brugada syndrome unmasked by lithium.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Brugada Syndrome; Cardiopulmonary Resuscitation; Drug The | 2009 |
Lamotrigine: an unusual etiology for aseptic meningitis.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Female; Humans; Hypothyroidism; Lamotrigine; Meningitis, | 2010 |
The long-term effectiveness of clozapine and lamotrigine in a patient with treatment-resistant rapid-cycling bipolar disorder.
Topics: Antipsychotic Agents; Bipolar Disorder; Calcium Channel Blockers; Clozapine; Drug Therapy, Combinati | 2010 |
The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression.
Topics: Adolescent; Adult; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; C | 2010 |
Use of the D2/D3 receptor agonist pramipexole in treatment of rapid-cycling bipolar disorder in an elderly patient.
Topics: Aged; Anticonvulsants; Antidepressive Agents, Second-Generation; Benzothiazoles; Bipolar Disorder; B | 2010 |
Infection or idiosyncratic reaction to antiepileptic drugs?
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Clozapine; Diagnosis, Differential; | 2010 |
Statins can produce ataxia in bipolar disorder: two case reports.
Topics: Antimanic Agents; Ataxia; Bipolar Disorder; Comorbidity; Female; Follow-Up Studies; Humans; Hydroxym | 2010 |
Advancing bipolar disorder: key lessons from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).
Topics: Anticonvulsants; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety Disorders; | 2010 |
Enhanced working and verbal memory after lamotrigine treatment in pediatric bipolar disorder.
Topics: Adolescent; Attention; Bipolar Disorder; Calcium Channel Blockers; Case-Control Studies; Child; Cogn | 2010 |
A prospective open-label trial of lamotrigine monotherapy in children and adolescents with bipolar disorder.
Topics: Adolescent; Anticonvulsants; Bipolar Disorder; Child; Drug Administration Schedule; Evaluation Studi | 2010 |
Cost effectiveness of adjunctive quetiapine fumarate extended-release tablets with mood stabilizers in the maintenance treatment of bipolar I disorder.
Topics: Absenteeism; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder | 2010 |
Lamotrigine and hemodialysis in bipolar disorder: case analysis of dosing strategy with literature review.
Topics: Antimanic Agents; Bipolar Disorder; Drug Administration Schedule; Drug Monitoring; Humans; Kidney Fa | 2010 |
[Application of lamotrigine in bipolar disorder--3T MR spectroscopy follow up (part 1)].
Topics: Antimanic Agents; Aspartic Acid; Bipolar Disorder; Choline; Creatine; Excitatory Amino Acid Antagoni | 2010 |
A pharmacological functional magnetic resonance imaging study probing the interface of cognitive and emotional brain systems in pediatric bipolar disorder.
Topics: Adolescent; Affect; Antipsychotic Agents; Attention; Bipolar Disorder; Brain; Case-Control Studies; | 2010 |
Use of mood stabilizers for hospitalized psychotic and bipolar disorder patients.
Topics: Anticonvulsants; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Dr | 2011 |
Lamotrigine plus quetiapine combination therapy in treatment-resistant bipolar depression.
Topics: Adult; Affect; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Diagnostic and Statistical | 2011 |
Fronto-limbic dysfunction in mania pre-treatment and persistent amygdala over-activity post-treatment in pediatric bipolar disorder.
Topics: Adolescent; Amygdala; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Case-Control Studies | 2011 |
Successful treatment of ultradian or ultra-ultra-rapid cycling: a case report.
Topics: Affect; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Dibenzothiazepines; Female; H | 2011 |
Possible acute myocardial infarction in a hypothermic patient.
Topics: Acute Disease; Anticonvulsants; Antimanic Agents; Benzodiazepines; Bipolar Disorder; Drug Overdose; | 2011 |
An observational nationwide register based cohort study on lamotrigine versus lithium in bipolar disorder.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Cohort Studie | 2012 |
Antiepileptic drugs for bipolar disorder and the risk of suicidal behavior: a 30-year observational study.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Carbamazepine; Female; Humans; Lamotrigine; Lithium Compou | 2012 |
Tourette syndrome with comorbid bipolar disorder and migraine: can lamotrigine monotherapy help?
Topics: Adult; Bipolar Disorder; Brain; Comorbidity; Compulsive Behavior; Female; Follow-Up Studies; Halluci | 2012 |
Effectiveness of quetiapine plus lamotrigine maintenance therapy in challenging bipolar disorder patients.
Topics: Adult; Bipolar Disorder; Dibenzothiazepines; Drug Therapy, Combination; Female; Humans; Lamotrigine; | 2012 |
Lamotrigine and aseptic meningitis.
Topics: Adolescent; Adult; Aged; Algorithms; Animals; Anticonvulsants; Antidepressive Agents; Bipolar Disord | 2012 |
Lack of interaction between sertraline and lamotrigine in psychiatric patients: a retrospective study.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Bipolar Disorder; Drug Interactions; Female; Humans; | 2012 |
Amygdala functional connectivity predicts pharmacotherapy outcome in pediatric bipolar disorder.
Topics: Adolescent; Age Factors; Amygdala; Bipolar Disorder; Child; Female; Humans; Lamotrigine; Male; Nerve | 2011 |
Lamotrigine-induced neuroleptic malignant syndrome under risperidone treatment: a case report.
Topics: Aged; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Drug Interactions; Drug Therapy | 2012 |
Clinical factors leading to lamotrigine prescription in bipolar outpatients: subanalysis of the SIN-DEPRES study.
Topics: Adult; Aged; Antimanic Agents; Bipolar Disorder; Depressive Disorder; Female; Guideline Adherence; H | 2012 |
Use of carbamazepine and lamotrigine in a Taiwanese diabetic patient with bipolar disorder.
Topics: Antimanic Agents; Bipolar Disorder; Carbamazepine; Diabetes Complications; Drug Therapy, Combination | 2012 |
Neural correlates of treatment response in depressed bipolar adolescents during emotion processing.
Topics: Adolescent; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Bipolar Diso | 2013 |
Updated treatment guidelines for bipolar disorder: key medications.
Topics: Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Delayed-Action Preparations; Humans; Lamo | 2002 |
Lamotrigine use in geriatric patients with bipolar depression.
Topics: Aged; Aged, 80 and over; Antimanic Agents; Bipolar Disorder; Depressive Disorder; Dose-Response Rela | 2002 |
Lamotrigine and rash: scratching beneath the surface.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Anticonvulsants; Antimanic Agents; Bipolar Disorder; | 2002 |
Outcome measures in treatment trials in bipolar disorder.
Topics: Antidepressive Agents; Bipolar Disorder; Controlled Clinical Trials as Topic; Humans; Lamotrigine; P | 2002 |
Hypomania induced by adjunctive lamotrigine.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Bupropion; Depressive Disorder, Major; Dose-Response | 2003 |
This life.
Topics: Affective Symptoms; Antidepressive Agents; Bipolar Disorder; Body Weight; Humans; Lamotrigine; Patie | 2003 |
Case report: Successful riluzole augmentation therapy in treatment-resistant bipolar depression following the development of rash with lamotrigine.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Drug Synergism; Exanthema; Excitatory Amino Acid Ant | 2004 |
Spotlight on lamotrigine in bipolar disorder.
Topics: Antidepressive Agents; Bipolar Disorder; Clinical Trials as Topic; Dose-Response Relationship, Drug; | 2004 |
How to treat bipolar II depression and bipolar II mixed depression?
Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder; Humans; Lamotrigine; Triazines | 2004 |
Borderline personality disorder in patients with bipolar disorder and response to lamotrigine.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Borderline Personality Disorder; Comorbidity; Female | 2004 |
Drug dreams in outpatients with bipolar disorder and cocaine dependence.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antimanic Agents; Bipolar Disorder; Cocaine-Related Disord | 2004 |
Successful rechallenge with slowly titrated lamotrigine after rash.
Topics: Antimanic Agents; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Dose-Resp | 2004 |
Anticonvulsants as mood stabilizers and adjuncts to antipsychotics: valproate, lamotrigine, carbamazepine, and oxcarbazepine and actions at voltage-gated sodium channels.
Topics: Affect; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Drug Therapy, Combin | 2004 |
Lamotrigine therapy in treatment-resistant menstrually-related rapid cycling bipolar disorder: a case report.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Chronobiology Phenomena; Cyclohexanols; Drug Resistance; | 2004 |
Drug combinations for bipolar spectrum disorders: evidence-based prescribing or prescribing-based evidence?
Topics: Anticonvulsants; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Dr | 2004 |
Two cases of acneiform eruption associated with lamotrigine.
Topics: Acne Vulgaris; Adult; Anticonvulsants; Bipolar Disorder; Drug Eruptions; Humans; Lamotrigine; Male; | 2004 |
The economic value of lamotrigine as a mood stabilizer: a U.S. managed care perspective.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Cost-Benefit Analysis; Evidence-Based Medicine; Fema | 2004 |
Evaluation of the effects of lamotrigine, valproate and carbamazepine in a rodent model of mania.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Bipolar Disorder; Carbamazepine; Central Nervous Syst | 2005 |
A different depression: clinical distinctions between bipolar and unipolar depression.
Topics: Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Depressive Disorder; Diagnosis, Different | 2005 |
Sustained remission with lamotrigine augmentation or monotherapy in female resistant depressives with mixed cyclothymic-dysthymic temperament.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Cyclothymic Disorder; Depressive Disorder, Major; Di | 2005 |
Lamotrigine for the treatment of bipolar spectrum disorder: a chart review.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Female; Follow-Up Studies; Humans; Lamotrigine; Male; Mid | 2005 |
Anticonvulsant hypersensitivity syndrome from addition of lamotrigine to divalproex.
Topics: Anticonvulsants; Bipolar Disorder; Drug Hypersensitivity; Drug Therapy, Combination; Exanthema; Fema | 2005 |
Lamotrigine-induced neutropenia.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Female; Fructose; Humans; Lamotrigine; Neuroprotecti | 2005 |
Potential risks associated with high-dose valproate in pregnancy in psychiatric patients.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Depressive Disorder, Major; Dose-Response Relationship, D | 2005 |
Lamotrigine add-on to valproate therapy for paediatric bipolar affective disorder.
Topics: Antimanic Agents; Bipolar Disorder; Child; Drug Therapy, Combination; Humans; Lamotrigine; Male; Tri | 2005 |
Outcome measurement, outcome management and monitoring.
Topics: Anticonvulsants; Antipsychotic Agents; Australia; Benzodiazepines; Bipolar Disorder; Carbamazepine; | 2005 |
What is the best way to treat bipolar depression?
Topics: Adult; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Humans; Lamotrigine; Lithium; Male | 2005 |
About lamotrigine and its hepatic effects.
Topics: Anticonvulsants; Bipolar Disorder; Humans; Lamotrigine; Triazines | 2005 |
Current management of bipolar affective disorder: is it reflective of the BAP guidelines?
Topics: Adolescent; Adult; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Female; Guidelines as | 2006 |
Toxic epidermal necrolysis with combination lamotrigine and valproate in bipolar disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Drug Therapy, Combination; Female; Humans; Lamotrigine; St | 2006 |
Adjunctive lamotrigine as a possible mania inducer in bipolar patients.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Dibenzothiazepines; Drug Thera | 2006 |
Tourette's symptoms provoked by lamotrigine in a bipolar patient.
Topics: Anticonvulsants; Bipolar Disorder; Dose-Response Relationship, Drug; Female; Humans; Lamotrigine; Mi | 2006 |
Lamotrigine-associated anticonvulsant hypersensitivity syndrome in bipolar disorder.
Topics: Anticonvulsants; Bipolar Disorder; Drug Hypersensitivity; Female; Humans; Lamotrigine; Middle Aged; | 2006 |
Lamotrigine for bipolar disorder and comorbid cocaine dependence: a replication and extension study.
Topics: Adult; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Brief Psychiatric Rating Scale; Cocaine; | 2006 |
PHARMAC and treatment of bipolar depression--the limits of utilitarianism.
Topics: Antidepressive Agents; Bipolar Disorder; Drug and Narcotic Control; Drug Costs; Drug Evaluation; Hum | 2006 |
Hallucinations during lamotrigine treatment of bipolar disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Dose-Response Relationship, Drug; Dreams; Female; Hallucin | 2006 |
Safety and tolerability of mood-stabilising anticonvulsants in the elderly.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Drug In | 2006 |
Efficacy and safety of lamotrigine for adults with bipolar disorder in a private practice setting.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Bipolar Disorder; Female; Humans; Lamotrigine; Male; | 2006 |
Clinical and therapeutic implications of predominant polarity in bipolar disorder.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Cross-Sectio | 2006 |
Successful treatment with lamotrigine in bipolar depression: a study from Turkey.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Fe | 2006 |
Effects of lamotrigine in patients with bipolar disorder and alcohol dependence.
Topics: Adolescent; Adult; Aged; Alcoholism; Antipsychotic Agents; Bipolar Disorder; Diagnosis, Dual (Psychi | 2006 |
Lamotrigine-induced toxic epidermal necrolysis in three patients treated for bipolar disorder.
Topics: Adolescent; Adult; Anticonvulsants; Bipolar Disorder; Burn Units; Female; Humans; Lamotrigine; Skin; | 2006 |
A retrospective analysis of changing from alternative agents to carbamazepine extended-release capsules in bipolar disorder.
Topics: Adolescent; Adult; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Capsul | 2006 |
Adjunctive lamotrigine treatment for adolescents with bipolar disorder: retrospective report of five cases.
Topics: Adolescent; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Female; Humans; Lamotrigine; M | 2006 |
The cost-effectiveness of lamotrigine in the maintenance treatment of adults with bipolar I disorder.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disor | 2006 |
Combined use of lamotrigine and electroconvulsive therapy in bipolar depression: a case series.
Topics: Adult; Aged; Antidepressive Agents; Bipolar Disorder; Combined Modality Therapy; Electroconvulsive T | 2006 |
Lamotrigine-induced severe manic switch.
Topics: Adolescent; Affective Disorders, Psychotic; Anticonvulsants; Benzodiazepines; Bipolar Disorder; Dose | 2006 |
Hair loss as a side effect of lamotrigine treatment.
Topics: Alopecia; Anticonvulsants; Bipolar Disorder; Female; Humans; Lamotrigine; Middle Aged; Triazines | 2006 |
Atypical antipsychotics related metabolic syndrome in bipolar patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Body Mass Index; Carbama | 2007 |
Long-term lamotrigine plus lithium for bipolar disorder: One year outcome.
Topics: Adult; Aged; Antipsychotic Agents; Bipolar Disorder; Depression; Drug Therapy, Combination; Female; | 2006 |
Lamotrigine combined with divalproex or lithium for bipolar disorder: a case series.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Drug Therapy, Combinat | 2006 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007.
Topics: Acute Disease; Antidepressive Agents; Antipsychotic Agents; Anxiety Disorders; Benzodiazepines; Bipo | 2006 |
Incidence and time course of subsyndromal symptoms in patients with bipolar I disorder: an evaluation of 2 placebo-controlled maintenance trials.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Comorbidity; Depression; Humans; Incidence; Lamotrigine; | 2006 |
Lamotrigine added to valproate successfully treated a case of ultra-rapid cycling bipolar disorder.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Calcium Channel Blockers; Drug Therapy, Combination; Huma | 2007 |
[Vigency of lithium treatment].
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Controlled Clinical Trials as Topic; Depres | 2007 |
An association of intrusive, repetitive phrases with lamotrigine treatment in bipolar II disorder.
Topics: Anticonvulsants; Bipolar Disorder; Delusions; Dose-Response Relationship, Drug; Drug Therapy, Combin | 2007 |
Case report of 3 patients with severe mental illness and chronic hepatitis C virus infection treated with interferon-alpha.
Topics: Adult; Alcoholics Anonymous; Alcoholism; Anticonvulsants; Antidepressive Agents, Second-Generation; | 2006 |
Increased anterior cingulate/medial prefrontal cortical glutamate and creatine in bipolar depression.
Topics: Adult; Analysis of Variance; Antidepressive Agents; Bipolar Disorder; Creatine; Evaluation Studies a | 2007 |
Two case reports of oral ulcers with lamotrigine several weeks after oxcarbazepine withdrawal.
Topics: Adult; Bipolar Disorder; Carbamazepine; Drug Administration Schedule; Drug Synergism; Female; Humans | 2007 |
Under-recruitment of patients for clinical trials: an illustrative example of a failed study.
Topics: Anticonvulsants; Antidepressive Agents; Bias; Bipolar Disorder; Lamotrigine; Patient Selection; Rand | 2007 |
The effect of lamotrigine on electroconvulsive therapy outcomes.
Topics: Adult; Aged; Antidepressive Agents; Bipolar Disorder; Combined Modality Therapy; Electroconvulsive T | 2007 |
Prophylactic treatment response in bipolar disorder: results of a naturalistic observation study.
Topics: Adult; Aged; Aged, 80 and over; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Dis | 2007 |
Lamotrigine-associated Stevens-Johnson syndrome after discontinuation of interferon, ribavirin, and filgrastim: a case report.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Calcium Channel Blockers; Filgrastim; Granulocyte Colony- | 2007 |
Lamotrigine-induced manic switches have already been reported.
Topics: Antimanic Agents; Bipolar Disorder; Depressive Disorder, Major; Humans; Lamotrigine; Triazines | 2007 |
Chronic lamotrigine does not alter the turnover of arachidonic acid within brain phospholipids of the unanesthetized rat: implications for the treatment of bipolar disorder.
Topics: Acyl Coenzyme A; Animals; Antimanic Agents; Arachidonic Acid; Bipolar Disorder; Brain; Disease Model | 2007 |
Lack of mania prophylaxis associated with lamotrigine monotherapy in manic-predominant bipolar I disorder.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Female; Humans; Lamotrigine; Male; Triazines | 2007 |
Changes in brain activation during working memory and facial recognition tasks in patients with bipolar disorder with Lamotrigine monotherapy.
Topics: Adolescent; Adult; Affect; Anger; Antimanic Agents; Bipolar Disorder; Brain; Emotions; Face; Female; | 2008 |
Addition of lamotrigine to valproic acid: a successful outcome in a case of rapid-cycling bipolar affective disorder.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Depressive Disorder, Major; Female; Humans; Lamotrigine; | 2007 |
The empirical redefinition of the psychometric criteria for remission in bipolar disorder.
Topics: Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Double-Blind Method; Drug | 2008 |
Psychosis, delirium, or manic switch due to lamotrigine?
Topics: Anticonvulsants; Bipolar Disorder; Delirium; Humans; Lamotrigine; Mental Disorders; Triazines | 2007 |
Quetiapine for the continuation treatment of bipolar depression: naturalistic prospective case series from the Stanley Bipolar Treatment Network.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Databases, Factual; Depression; Dib | 2007 |
Lamotrigine-induced mania in adolescents.
Topics: Adolescent; Age Factors; Anticonvulsants; Bipolar Disorder; Dose-Response Relationship, Drug; Female | 2007 |
Comments on "Addition of lamotrigine to valproic acid: a successful outcome in a case of rapid-cycling bipolar affective disorder".
Topics: Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Drug Therapy, Combination; Humans; Lamotrig | 2008 |
Effect of the new antiepileptic drug retigabine in a rodent model of mania.
Topics: Amphetamine; Animals; Anticonvulsants; Behavior, Animal; Bipolar Disorder; Carbamates; Chlordiazepox | 2008 |
Treatment of bipolar disorder, restless legs syndrome and parkinsonian symptoms using lamotrigine: a report of seven patients.
Topics: Adult; Bipolar Disorder; Calcium Channel Blockers; Female; Humans; Lamotrigine; Male; Middle Aged; P | 2007 |
The effect of lamotrigine on platelet serotonin concentration in patients with bipolar depression.
Topics: Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Bipolar Diso | 2008 |
Choreiform dyskinesia following isolated lamotrigine overdose.
Topics: Adult; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Chorea; Drug Overdose; Dyskinesia, Drug- | 2008 |
Role of lamotrigine in the management of treatment-resistant bipolar II depression: a chart review.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Drug Resista | 2008 |
Quetiapine and classical mood stabilizers in the long-term treatment of Bipolar Disorder: a 4-year follow-up naturalistic study.
Topics: Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Dibenzothiazepines; Drug | 2008 |
Myoclonus provoked by lamotrigine in a bipolar patient.
Topics: Anticonvulsants; Bipolar Disorder; Female; Humans; Lamotrigine; Middle Aged; Myoclonus; Triazines | 2008 |
[Secondary delirium due to the use of lamotrigine with abrupt increase valproic acid's dose].
Topics: Adult; Anticonvulsants; Bipolar Disorder; Delirium; Drug Interactions; Drug Therapy, Combination; Hu | 2008 |
Antidepressant-like effect of lamotrigine is reversed by veratrine: a possible role of sodium channels in bipolar depression.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal; Bipolar Disorder; Disease Mo | 2008 |
Antidepressant effects of lamotrigine in rapid cycling bipolar disorder.
Topics: Anticonvulsants; Bipolar Disorder; Depressive Disorder; Humans; Lamotrigine; Lithium; Male; Middle A | 1996 |
Addition of lamotrigine to valproate may enhance efficacy in the treatment of bipolar affective disorder.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Drug Therapy, Combination; Humans; Lamotrigine; Male; Tria | 1996 |
Lamotrigine treatment of rapid cycling bipolar disorder.
Topics: Adult; Aged; Anticonvulsants; Bipolar Disorder; Drug Administration Schedule; Drug Eruptions; Drug T | 1997 |
Lamotrigine for treatment-refractory bipolar disorder.
Topics: Anticonvulsants; Bipolar Disorder; Drug Therapy, Combination; Humans; Lamotrigine; Male; Middle Aged | 1997 |
An open study of lamotrigine in refractory bipolar depression.
Topics: Adolescent; Adult; Anticonvulsants; Antidepressive Agents; Bipolar Disorder; Cohort Studies; Depress | 1997 |
Recurrence of lamotrigine-associated rash with rechallenge.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Drug Eruptions; Humans; Lamotrigine; Male; Obsessive-Compu | 1998 |
Is lamotrigine effective for treatment-refractory mania?
Topics: Bipolar Disorder; Calcium Channel Blockers; Drug Resistance; Humans; Lamotrigine; Triazines | 1998 |
Advances in mood stabilizing medications.
Topics: Acetates; Amines; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Calcium Channel Blockers; Cyc | 1998 |
New perspectives in the treatment of acute mania: a single case report.
Topics: Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Female; Humans; Infusions | 1998 |
Mood stabilizer combinations for bipolar disorder.
Topics: Acetates; Adolescent; Age Factors; Amines; Antimanic Agents; Bipolar Disorder; Child; Cyclohexanecar | 1999 |
Lamotrigine and the treatment of bipolar disorder. Introduction.
Topics: Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Humans; Lamotrigine; Triazines | 1999 |
Lamotrigine as prophylaxis against steroid-induced mania.
Topics: Adult; Anti-Inflammatory Agents; Antimanic Agents; Bipolar Disorder; Contraindications; Female; Huma | 1999 |
Pramipexole treatment for cocaine cravings.
Topics: Adult; Antidepressive Agents; Behavior, Addictive; Benzothiazoles; Bipolar Disorder; Cocaine-Related | 1999 |
Lamotrigine-induced rash after sun exposure.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Drug Eruptions; Drug Therapy, Combination; Female; Haloper | 1999 |
The efficacy of lamotrigine in rapid cycling and non-rapid cycling patients with bipolar disorder.
Topics: Antimanic Agents; Bipolar Disorder; Clinical Trials as Topic; Confounding Factors, Epidemiologic; Hu | 1999 |
Lamotrigine and clozapine for bipolar disorder.
Topics: Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Clozapine; Drug Therapy, Combination; | 2000 |
Agranulocytosis associated with lamotrigine.
Topics: Adult; Agranulocytosis; Antidepressive Agents; Bipolar Disorder; Drug Administration Schedule; Drug | 2000 |
Use of lamotrigine in a patient with bipolar disorder and psychiatric comorbidity.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Diagnosis, Dual (Psychiatry); Humans | 2000 |
Acute granulomatous interstitial nephritis and colitis in anticonvulsant hypersensitivity syndrome associated with lamotrigine treatment.
Topics: Adolescent; Anti-Inflammatory Agents; Antidepressive Agents; Bipolar Disorder; Female; Granuloma; Hu | 2000 |
Lamotrigine-associated neutropenia in a geriatric patient.
Topics: Antimanic Agents; Bipolar Disorder; Drug Interactions; Female; Humans; Lamotrigine; Middle Aged; Neu | 2000 |
Maintenance ECT replaced with lamotrigine.
Topics: Age Factors; Aged; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Drug Administration Sche | 2000 |
Valproate and other anticonvulsants for psychiatric disorders.
Topics: Abnormalities, Drug-Induced; Acetates; Adult; Amines; Anti-Anxiety Agents; Anticonvulsants; Bipolar | 2000 |
Evaluating the tolerability of the newer mood stabilizers.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Central Nervous System Diseases; Cyclohexanecar | 2001 |
[Lamotrigine in the treatment of mental disorders].
Topics: Adolescent; Adult; Aged; Anticonvulsants; Antidepressive Agents; Bipolar Disorder; Depression; Femal | 2001 |
Introduction: the role of anticonvulsants as mood stabilizers.
Topics: Anticonvulsants; Bipolar Disorder; Depressive Disorder; Humans; Lamotrigine; Lithium; Terminology as | 2001 |
[A casuistic report on Lamotrigine].
Topics: Anticonvulsants; Bipolar Disorder; Drug Costs; Humans; Lamotrigine; Triazines | 2001 |
[Lamotrigine in neuropsychiatric diseases].
Topics: Anticonvulsants; Bipolar Disorder; Humans; Lamotrigine; Triazines | 2001 |
Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited.
Topics: Anticonvulsants; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Female; Fructose; Humans; La | 2002 |